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(presented by the Commission) EXPLANATORY MEMORANDUM 
1.  In the context of a  people's Europe, the Commission attaches great importance to simplifying and clarifying Community 
law so as to make it clearer and more accessible to the ordinary citizen, thus giving him new opportunities and the chance 
. to make use of  the specific rights it gives him. 
This  aim  cannot  be achieved  so  long  as  numerous  provisions  that  have  been  amended  several  times,  often  quite 
substantially, remain scattered, so that they must be sought partly in the original instrument and partly in  later amending 
ones. Considcmble research work, comparing many; different instruments, is thus needed to identify the current rules. 
For this reason a codification of  rules that have frequently been amended is also essential if Community law is to be clear 
and transparent. 
2.  On  I April  1987 the Commission therefore decided to  instruct its stall" that all legislative measures should be  codified 
after  no  more  than  ten  amendments,  stressing  that  this  was  a  minimum  requirement  and  that  departments  should 
endeavour to condify at even shorter intervals the texts for which they were responsible, to ensure that the Community 
rules were clear and readily understandable.  · 
3.  The Conclusions of the Presidency of the Edinburgh European Council (December 1992) confirmed this,  stressing the 
importance of  legislative codification as it offers certainty as to the law applicable to a given matter at a given time. 
It  must be undertaken in full compliance with the normal Community legislative procedure. 
Given that no changes of  substance may be made to the instruments affected by  legislative codification, Parliament, the 
Council  and  the  Commission  have  agreed,  by  an  interinstitutional  agreement  dated  20  December  1994,  that  an 
accelemted procedure may be used for the fast-track adoption of  codification instruments. 
4.  The purpose of this proposal I for legislative codification of Council  Dir~ctives 65/65/EEC of 26  January  1965 on the 
approximation  of provisions  laid  down  by  law,  regulation  or  administrative  action  relating  to  medicinal  products; 
75/318/EEC of 20  May  1975  on the  approximation of the  laws  of Member States  relating  to  analytical,  pharmaco-
toxicological and clinical standards and protocols in respect of  the testing of proprietary medicinal products; 75/319/EEC 
of 20 May  1975  on the approximation of provisions laid  down by  law, regulation or administrative action relating to 
proprietary  medicinal  products;  89/342/EEC  of 3  May  1989  extending  the  scope  of Directives  65/65/EEC  and 
75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins 
or serums and allergens; 89/343/EEC of  3 May 1989 extending the scope of Directives 65/65/EEC and 75/319/EEC and 
laying  down  additional  provisions  for  radiopharmaceuticals;  89/381/EEC  of 14  June  1989  extending  the  scope  of 
Directives  65/65/EEC  and  75/319/EEC  on  the  approximation  of provisions  laid  down  by  law,  regulation  or 
administrative  action  relating  to  medicinal  products  and  laying  down  special  provisions  for  proprietary  medicinal 
products derived from  human blood or human plasma; 92/25/EEC of 31  March  1992 on the wholesale distribution of 
medicinal  products  for  human  use;  92/26/EEC  of 31  March  1992  concerning  the  classification  for  the  supply  of 
medicinal products for human use; 92/27/EEC of  31  March  1992 on the labelling of medicinal products for human use 
and on package leaflets; 92/28/EEC of 31  March  1992  on  the advertising of medicinal  products for human  usc;  and 
92173/EEC of  22 September 1992 widening the scope of  Directives 65/65/EEC and 75/319/EEC on the approximation of 
provisions  laid  down  by  law,  regulation  or  administrative  action  relating  to  medicinal  products  and  laying  down 
additional  provisions  on. homeopathic  medicinal  products,  prepared  b.y  the  Legal  Service  in  cdlljunction  with  the 
Directorate-Geneml III,  is  to  undertake official codification of this type.  The new directive will supersede the various 
directives  incorporated  in  it2,  their content is  fully  preserved,  and  they are  brought together  with  only  such  formal 
amendments as are required by the codification exercise itself. 
4a In order to point out the satisfactory application of the codification of the Directive mentioned above, in  order to  take 
into account the fact that since the last Directive cited in point 4, the European Agency for the Evaluation of Medicinal 
Products has been established by Council Regulation (EEC) 2309/9~ of22 July 1993. 
I 
2 
In the same manner, in  order to point out that this codification proposal concerning medicinal products for human usc 
was created in parallel with the codification proposal for Directives relating to veterinary medicinal products. 
Entered in the legislative programme for 1998. 
See Annex II, Part A of  this Proposal. 
2 5.  This  legislative  codification  proposal  was  drawn  up  on  the  basis  of a  preliminary  consolidation,  in  all  the  official 
languages.  The  instruments  amending  it,  carried  out  by  the  Office  for  Official  Publications  of the  European 
Communities, by means of  the data-processing system referred to in the conclusions of  the European Council meeting at 
Edinburgh. Although the articles have been given new numbers, the old numbering has been retained in the margin for 
ease of reference;  the correlation between the old  and  new  numbers  is  shown  in  a table set out in  Annex  III  of the 
consolidated Directive. 
3 Proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL DIRECTIVE ...  /  ..  ./EC 
on the Community code relating to medicinal products for human use 
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN 
UNION, 
Having regard to the Treaty establishing the European Community, and in 
particular Article 95 thereof, 
Having regard to the proposal from the Commission; 
Having regard to the opinion of  the Economic and Social Committee1 
Acting in accordance with the procedure laid down in Article 251 of  the Treaty2, 
(I)  Whereas  Council  Directive  65/65/EEC  of  26  January  1965  on  the 
approximation of provisions laid down  by  law,  regulation or administrative 
action  relating  to  medicinal  products3,  Council  Directive  75/318/EEC  of 
20 May  1975  on  the approximation of the  laws  of Member States  relating 
to  analytical,  pharmaco-toxicological  and  clinical  standards  and  protocols 
in  respect  of  the  testing  of  proprietary  medicinal  products4, 
Council Directive  75/319/EEC  of 20  May  1975  on  the  approximation  of 
provisions  laid  down  by  law,  regulation  or administrative  action  relating 
to  proprietary  medicinal  products5,  Council  Directive  89/342/EEC  of 
3 May 1989 extending the scope of Directives 65/65/EEC and  75/319/EEC 
and  laying  down  additional  provisions  for  immunological  medicinal 
products  consisting  of  vaccines,  toxins  or  serums  and  allergens6, 
Council Directive  89/343/EEC  of 3  May  1989  extending  the  scope  of 
Directives 65/65/EEC and 
2 
3 
4 
5 
6 
OJC 
OJ 22, 9.2.1965, p. 369/65. Directive as last amended by Directive 93/39/EEC (OJ L 214, 24.8.1993, p. 22). 
OJ L 147, 9.6.1975, p. I. Directive as last amended by Directive 93/39/EEC. 
OJ L, 147, 9.6.1975, p. 13. Directive as last amended by Directive 93/39/EEC. 
OJ L 142, 25.5.1989, p. 14. 
4 75/319/EEC  and  laying  down  additional  provisions  for 
radiophannaceuticals',  Council  Directive  89/381/EEC  of  14  June  1989 
extending  the  scope  of Directives  65/6:;/EEC  and  75/319/EEC  on  the 
approximation of provisions laid down by law, regulation or administrative 
action relating to medicinal products and laying down special provisions for 
proprietary medicinal products derived from human blood or human plasma2, 
Council  Directive  92125/EEC  of  31  March  1992  on  the 
wholesale  distribution  of  medicinal  products  for  human  use3, 
Council Directive  92/26/EEC  of  31  March  1992  concerning  the 
classification for  the  supply  of  medicinal  products  for  human  usc4, 
Council  Directive  92127/EEC  of  31  March  1992  on  the  labelling  of 
medicinal  products  for  human  use  and  on  package  leafletsS, 
Council Directive  92/28/EEC  of 31\  March  1992  on  the  advertising  of 
medicinal  products  for  human  use6,  Council  Directive  92173/EEC  of 
22 September  1992  widening  the  scope  of  Directives  65/65/EEC  and 
75/319/EEC on the approximation of  provisions laid down by law, regulation 
or administrative  action  relating  to  medi,;:inal  products  and  laying  down 
additional  provisions  on  homeopathic  medicinal  products  7  have  been 
frequently and substantially amended; whereas, in the interests of  clarity and 
rationality,  the said Directives should therefore  be  codified  by assembling 
them in a single text; 
(2)  Whereas the essential aim of  any rules govt:rning the production, distribution 
and use of  medicinal products must be to safeguard public health; 
(3)  Whereas, however, this objective must be attained by means which will not 
hinder the development of  the pharmaceutical industry or trade in medicinal 
products within the Community; 
2 
3 
4 
5 
6 
7 
OJ L 142, 2S.S.J989, p. 16. 
OJ L 181, 28.6.1989, p. 44. 
OJ L 113, 30.4.1992, p. I. 
OJ L 113, 30.4.1992, p. S. 
OJ L 113, 30.4.1992, p. 8. 
OJ L 113, 30.4.1992, p. 13. 
OJL297,13.JO.J992,p.8. 
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I.  89/341/EEC 
2.  65/65/EEC (4)  Whereas trade in medicinal products within the Community is  hindered by 
disparities  between  certain  ~ational  provisions,  in  particular  between 
provisions  relating  to  medicinal  products  (excluding  substances  or 
combinations of substances which are foods,  animal feeding-stuffs or toilet 
preparations); and whereas such disparities directly affect the functioning of 
the internal market; 
(5)  Whereas such hindrances must accordingly be removed; whereas this entails 
approximation of  the relevant provisions; 
(6)  Whereas in order to reduce the disparities which remain, rules should be laid 
down on the control of  medicinal products and the duties incumbent upon the 
Member States' competent authorities should  be specified  with  a  view  to 
ensuring compliance with legal requirements; 
(7)  Whereas the concepts of harmfulness and therapeutic efficacy can only be 
examined  in  relation  to  each  other and have only ·a relative  significance 
depending on the progress of  scientific knowledge and the use for which the 
medicinal product is intended; whereas the particulars and documents which 
. must accompany an application for marketing authorization for a medicinal 
product demonstrate that potential risks are outweighed by the therapeutic 
efficacy of  the product; 
(8)  Whereas standards and protocols for the performance of tests and trials on 
medicinal products are an effective means of control of these products and 
hence of protecting public health and can facilitate the movement of these 
products  by laying down uniform  rules applicable  to tests  and  trials,  the 
compilation of  dossiers and the examination of  applications; 
(9)  Whereas experience has shown that it is advisable to stipulate more precisely 
the cases in which the results of toxicological and pharmacological tests or 
clinical  trials  do  not  have  to  be  provided  with  a  view  to  obtaining 
authorization  for  a  medicinal  product  which  is  essentially  similar  to  an 
authorized product, while ensuring that innovative firms are not placed at a 
disadvantage;  · 
6 
3. 
4. 
2. 
7. 
3. 
65/65/EEC 
(adapted) 
65/65/EEC 
75/319/EEC 
(adapted) 
75/318/EEC 
(adapted) 
75/318/EEC 
(adapted) 
2. ·  87121/EEC 
(adapted) {lO)Whereas,  however,  there  are  reasons  of public  policy  for  not conducting 
repetitive tests on humans or animals without over-riding cause; 
{ll)Whereas the adoption of  the same standards and protocols by all the Member 
States will enable the competent authoritit:s to arrive at their decisions on the 
basis of uniform tests and by reference to uniform criteria and will therefore 
help to avoid differences in evaluation; 
{l2)Whereas, with the exception of  those medicinal products which are subject to 
the centralized Community authorization  procedure established by Council 
Regulation  (EEC)  No 2309/93  of 22  July  1993  laying  down  Community 
procedures for  the  authorization and supervision of medicinal  products  for 
human  and  veterinary  use  and  establishing  a  European  Agency  for  the 
Evaluation of Medicinal Products1 a marketing authorization for a medicinal 
product granted by a competent authority  in  one Member State ought to be 
recognized by the  competent authorities of the other Member States unless 
there  are  serious  grounds  for  supposing  that  the  authorization  of the 
medicinal product concerned may present a risk to public health; whereas, in 
the event of a disagreement between  Member States  about the  quality,  the 
safety or the efficacy of a medicinal product, a scientific evaluation of the 
matter should be undertaken according to a Community standard, leading to a 
single decision on the  area of disagreement binding on  the Member States 
concerned;  whereas this  decision  should  be  adopted  by  a rapid  procedure 
ensuring close cooperation between the Commission and the. Member States; 
(13)Whereas, for this purpose, a Committee for Proprietary Medicinal Products 
should  be  set up  attached  to  the  European  Agency  for  the  Evaluation  of 
Medicinal  Products  established  in  the  abovementioned  Regulation  (EEC) 
No 2309/93; 
(14)Whereas this Directive represents an important step towards achievement of 
the objective of the free movement of medicinal products; whereas further 
measures  may  abolish  any  remaining  barriers  to  the  free  movement  of 
proprietary medicinal products will  be  necessary  in  the  light of experience 
gained,  particularly  in  the  abovementioned  Committee  for  Proprietary 
Medicinal Products; 
(15)Whereas in  order better to  protect public health and avoid any unnecessary 
duplication of effort during the examination of application for a marketing 
authorization for  medicinal products, Member States should systematically 
prepare  assessment reports  in  respect of each  medicinal  product  which  is 
authorized  by  them,  and  exchange  the  reports  upon  request;  whereas, 
furthermore, a Member State should be able to suspend the examination of  an 
application  for  authorization to  place  a  medicinal  product on the  market 
which is currently under active considerati,on in another Member State with a 
view to recognizing the decision reached by the latter Member State; 
4. 
4. 
4. 
4. 
5. 
5. 
OJ L 214, 24.8.1993, p. I; Regulation as amended by Commission Regulation (EC) No 649/98 (OJ L 88, 24.3.1998, p. 7). 
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87/21/EEC 
75/318/EEC 
93/39/EEC 
(adapted) 
75/319/EEC 
(adapted) 
75/319/EEC 
(adapted) 
93/39/EEC 
(adapted) (16)Whereas following the establishment of  the internal market, specific controls 
to guarantee the quality of  medicinal products imported from third countries 
can  be  waived  only if appropriate  arrangements  have  been  made  by  the 
Community  to  ensure that  the  necessary  controls  are  carried  out  in  the 
exporting country; 
(17)Whereas  it  is  necessary  to  adopt  specific  prov1s1ons  for  immunological 
medicinal products, homeopathic medicinal products, radiopharmaceuticals, 
and medicinal products based on human blood or human plasma; 
(18}Whereas  any rules  governing radiopharmaceuticals  must  take  into  account 
the  provisions of Council  Directive  84/466/Euratom  of 3  September  1984 
laying  down  basic  measures  for  the  radiation  protection  of  persons 
undergoing medical examination or treatment1; whereas account should also 
be taken of  Council Directive 80/836/Euratom of 15 July 1980 amending the 
Directives laying down the basic safety standards for the health protection of 
the general public and workers against the dangers of ionizing radiation2, the 
objective  of which  is  to  prevent  the  exposure  of workers  or patients  to 
excessive or unnecessarily high levels of  ionizing radiation, and in particular 
of Article 5c thereof, which requires prior authorization for the addition of 
radioactive substances to medicinal products as well as for the importation of 
such medicinal products; 
(I9)Whereas  the  Community  entirely  supports  the  efforts  of the  Council  of 
Europe to  promote  voluntary unpaid  blood and  plasma donation  to  attain 
self-sufficiency throughout the Community in the supply of  bl~od products, 
and to ensure respect for ethical principles in trade in therapeutic substances 
of  human origin; 
(20)Whereas the rules designed to guarantee the quality, safety and efficacy of 
medicinal  products  derived  from  human  blood or human  plasma must  be 
applied in the same manner to both public and private establishments, and to 
blood and plasma imported from third countries; 
(2l)Whereas, having regard to the particular characteristics of  these homeopathic 
medicinal  products,  such  as  the  very  low  level  of active  principles  they 
contain  and  the  difficulty of applying  to  them  the  conventional  statistical 
methods  relating  to  clinical  trials,  it  is  desirable  to  provide  a  special, 
simplified registration procedure for those homeopathic medicinal  products 
which  are  placed  on  the  market  witliout  therapeutic  indications  in  a 
pharmaceutical form and dosage which do not present a risk for the patient; 
(22)Whereas  the  anthroposophic  medicinal  products  described  in  an  official 
pharmacopoeia and prepared by a homeopathic method are to be treated, as 
regards  registration  and  marketing  authorization,  in  the  same  way  as 
homeopathic medicinal products; 
6. 
8. 
7. 
5. 
10. 
4. 
93/39/EEC 
75/319/EEC 
(adapted) 
89/343/EEC 
(adapted) 
89/381/EEC 
89/381/EEC 
92173/EEC 
(adapted) 
92173/EEC 
I 
2 
OJ L 26S, S.IO.l984, p.  I; Directive repealed with effect from  13 May 2000 by  Di~"e~:tivc 97/43/Euratom (OJ L 180, 9.7.1997, p. 22). 
OJ L 246,  17.9.1980, p.  I~ Di~"e~:tivc as amended by Directive 84/467/Euratom (OJ L ~6S, S.  10.  1984, p. 4); repealed with effect from  13 May 2000 by 
Directive 96129/Euratom (OJ L 314, 4.12.1996, p. 20). 
8 (23)Whereas  it  is  desirable  in  the  first  instance  to  provide  users  of these 
homeopathic  medicinal  products  with  a  very  clear  indication  of their 
homeopathic  character and  with  sufficient guarantees  of their quality  and 
safety; 
(24)Whereas  the  rules  relating  to  the  manufacture,  control  and  inspection  of 
homeopathic  medicinal  products  must  be  ·hannonized  to  permit  the 
circulation throughout the Community of medicinal products which are safe 
and of  good quality; 
(25)Whereas  the  usual  rules  governing  the  authorization  to  market  medicinal 
products should be applied to homeopathic medicinal products placed on the 
market with therapeutic  indications  or in  a.  form  which  may  present  risks 
which must be balanced  against the desired therapeutic effect; whereas,  in 
particular, those Member States which have .  a homeopathic tradition should 
be able to apply particular rules for the evaluation of the results of tests and 
trials intended to establish the safety and efficacy of  these medicinal products 
provided that they notify them to the Commission, 
(26)Whereas  in  order to  facilitate  the  movement of medicinal  products and to 
prevent the controls carried out in one Member State from  being repeated in 
another,  minimum requirements should  be  laid  down  for  manufacture and 
imports coming from  third countries and for the grant of the authorization 
relating thereto; 
(27)Whereas it should be ensured that, in the Member States, the supervision and 
control of the manufacture of medicinal pwducts is carried out by a person 
who fulfils minimum conditions of  qualification; 
(28)Whereas,  before  an  authorization  to  market  an  immunological  medicinal 
·  product or derived from human blood or human plasma can be granted, the 
manufacturer  must  demonstrate  his  ability  to  attain  batch-to-batch 
consistency; whereas before and authorization to market a medicinal product 
derived  from  human  blood  or  human  plasma  can  be  granted,  the 
manufacturer  must  also  demonstrate  the  absence  of  specific  viral 
contamination, to the extent that the state of  technology permits; 
9• 
8.  - 92173/EEC 
9.  ·  92173/EEC 
1'1.  92/73/EEC 
6.  75/319/EEC 
(adapted) 
7.  75/319/EEC 
(adapted) 
5.  89/342/EEC 
(adapted) 
+ 
7.  89/381/EEC 
(adapted) (29)Whereas the conditions governing the supply of medicinal  products to  the 
public should be harmonized; 
(30)Whereas in  this connection persons moving around within  the Community 
have the right to carry a reasonable quantity of medicinal products lawfully 
obtained for their personal use; whereas it must also be possible for a person 
'  established  in  one Member State to  receive  from  another Member State a 
reasonable quantity of  medicinal products intended for his personal use; 
(,3l)Whereas,  in  addition,  by  virtue  of Regulation  (EC)  No  2309/93,  certain 
medicinal products are the subject of a Community marketing authorization; 
whereas,  in  this  context,  the  classification  for  the  supply  of medicinal 
products  covered  by  a  Community  marketing  authorization  needs  to  be 
established; whereas it is therefore important to set the criteria on the basis of 
which Community decisions will be taken; 
(32)Whereas it is therefore appropriate, as an initial step, to harmonize the basic 
principles applicable to the classification for the supply of  medicinal products 
_ in  the  Community  or in  the  Member  State  concerned,  while  taking  as  a 
starting point the principles already established on this subject by the Council 
of Europe  as  well  as  the  work  of harmonization  completed  within  the 
framework  of the  United  Nations,  concerning  narcotic -and  psychotropic 
substances; 
(33)Whereas the provisions dealing with the classification of medicin11I  products 
for-the  purpose  of supply  do  not  infringe  the  national  social  security 
arrangements  for  reimbursell)ent  or  payment  for  medicinal  products  on 
prescription; 
(34)Whereas many operations involving the wholesale distribution of medicinal 
products for human use may cover several Member States simultaneously; 
(35)Whereas  it  is  necessary  to  exercise  control  over  the  entire  chain  of 
distribution of  medicinal products, from their manufacture or import into the 
Community through to  supply to  the  public,  so  a5  to  guarantee  that  such 
products are stored, transported and handled in suitable conditions; whereas 
the requirements which must be adopted for this purpose will considerably 
facilitate  the  withdrawal  of defective products  from  the  market  and  allow 
more effective efforts against counterfeit products; 
10 
3. 
4. 
5. 
6. 
7. 
2. 
3. 
92/26/EEC 
(adapted) 
92/26/EEC 
(adapted) 
92/26/EEC 
(adapted) 
92/26/EEC 
92/26/EEC 
(adapted) 
92/25/EEC 
(adapted) 
92/25/EEC (36)Whereas  any  person  involved  in  the  wholesale  distribution  of medicinal 
products  should  be  in  possession  of a  special  authorization;  whereas 
pharmacists  and  persons  authorized  to  supply  medicinal  products  to  the 
public, and who confine themselves to this activity, should be  exempt from 
obtaining  this  authorization;  whereas  it  is  however necessary,  in  order to 
control  the  complete  chain  of distribution  of medicinal  products,  that 
pharmacists  and  persons  authorized  to  supply  medicinal  products  to  the 
public keep records showing transactions in products received; 
(37)Whereas authorization must be subject to 1;ertain essential conditions and it is 
the  responsibility  of the  Member  Statt:  concerned  to  ensure  that  such 
conditions  are  met;  whereas  each  Member  State  must  recognize 
authorizations granted by other Member States; 
(38)Whereas certain Member States impose on wholesalers who supply medicinal 
products  to  pharmacists  and  on  persons  authorized  to  supply  medicinal 
products  to  the  public  cert~in  public  service  obligations;  whereas  those 
Member  States  must  be  able  to  continue  to  impose  those  obligations  on 
wholesalers established within their territory; whereas they must also be able 
to impose them on wholesalers in other Member States on condition that they 
do not impose any obligation more stringent than those which they impose on 
their own wholesalers and provided that such obligations may be regarded as 
warranted on grounds of public health  protection  and  are  proportionate in 
relation to the objective of  such protection; 
(39)Whereas  rules. should  be  laid  down  as  to  how  the  labelling  and  package 
leaflets are to be presented; 
(40)Whereas the provisions governing the  information supplied to users should 
provide  a  high  degree  of consumer  protection,  in  order  that  medicinal 
products  may  be  used  correctly  on  the  basis  of full  and  comprehensible 
information; 
(41)Whereas the marketing of medicinal products whose  labelling and package 
leaflets comply with this  Directive should not be prohibited or impeded on 
grounds connected with the labelling or package leaflet; 
(42)Whereas this Directive  is  without prejudice to  the  application of measures 
adopted pursuant to  Council  Directive  84/450/EEC of 10  September  1984 
relating  to  the  approximation  of the  laws,  regulations  and  administrative 
provisions of  the Member States concerning misleading advertising1; 
OJ L 2SO, 19.9.1984, p. 17. Direc:tive as amended by Directive 97/SS/EC (OJ L 290,23. 10. 1997, p. 18). 
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4. 
5. 
6. 
2. 
+ 
3. 
5. 
6. 
1. 
92/25/EEC 
(adapted) 
92/25/EEC 
92/25/EEC 
92/27/EEC 
(adapted) 
92/27/EEC 
92/27/EEC 
92/28/EEC 
(adapted) (43)Whereas  all  Member  States  have  adopted  further  specific  measures 
concerning  the  advet:(:ising  of  medicinal  products;  whereas  there  are 
disparities between these measures;  whereas these  disparities  are  likely  to 
have an impact on the functioning of the internal market, since advertising 
disseminated  in  one  Member  State  is  likely  to  have  effects  in  other 
Member States; 
(44)Whereas  Council  Directive  89/552/EEC  of  3  October  1989  on  the 
coordination  of  certain  provisions  laid  down  by  law,  regulation  or 
administrative action in Member States concerning the pursuit of television 
broadcasting  activities•  prohibits  the  television  advertising  of medicinal 
products  which  are  available  only  on  medical  prescription  in  the 
Member State within whose jurisdiction the television broadcaster is located; 
whereas this principle should be made of general application by extending it 
to other media; 
(45)Whereas  advertising  to  the  general  public,  even  of  non-prescription 
medicinal products, could affect public health, were it to be excessive and ill-
considered; whereas advertising of medicinal products to the general public, 
where  it  is  permitted,  ought  therefore  to  satisfy  certain  essential  criteria 
which ought to be defined; 
(46)Whereas, furthermore,  distribution of samples free  of charge to  the general 
public for promotional ends must be prohibited; 
(47)Whereas  the  advertising  of medicinal  products  to  persons  qualified  to 
prescribe or supply  them  contributes  to  the  information  available  to  such 
persons;  whereas,  nevertheless,  this  advertising  should  be  subject to  strict 
conditions  and  effective  monitoring,  referring  in  particular  to  the  work 
carried out within the framework of  the Council of  Europe; 
(48)Whereas advertising of medicinal  products  should  be  subject to  effective, 
adequate monitoring; whereas reference in this regard should be made to the 
monitoring mechanisms set up by Directive 84/450/EEC; 
(49)Whereas  medical  sales  representatives  have  an  important  role  in  the 
promotion  of medicinal  products;  whereas,  therefore,  certain  obligations 
should  be  imposed  upon  them,  in  particular  the  obligation  to  supply  the 
person visited with a summary of  product characteristics; 
(50)Whereas persons qualified to prescribe medicinal products must be  able to 
carry out these functions  objectively without being  influenced by direct or 
indirect financial inducements; 
(5l)Whereas it should be possible within certain restrictive conditions to provide 
samples of  medicinal products free of  charge to persons qualified to prescribe 
'or supply them so that they can familiarize themselves with new products and 
acquire experience in dealing with them; 
OJ L 298, 17.10.1989, p. 23; Directive as amended by Directive 97/36/EC (OJ L 202, 30. 7.  1997, p. 60). 
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2. 
3. 
4. 
5. 
6. 
!I. 
7. 
8. 
9. 
92/28/EEC 
(adapted) 
92/28/EEC 
92/28/EEC 
92/28/EEC 
92/28/EEC 
92/28/EEC 
92/28/EEC 
92/28/EEC 
92/28/EEC (52)Whereas persons qualified  to  prescribe or supply medicinal  products  must 
have  access  to  a  neutral,  objective  source  of information  about  products 
available on the market; whereas it is nevertheless for the Member States to 
take all measures necessary to this end,  1in  the  light of their own particular 
situation; 
(53)Whereas  each  undertaking  which  manufactures  or  imports  medicinal 
products should set up a mechanism to ensure that all information supplied 
about a medicinal product conforms with the approved conditions of  use; 
(54) Whereas it is desirable to regulate and improve the cooperation and exchange 
of  information  between  Member  States  relating  to  the  supervision  of 
medicinal  products  and  in  particular  the  monitoring  of adverse  reactions 
under  practical  conditions  of use  through  the  national  pharmacovigilance 
systems; 
(55)Whereas  the  Commission  should  be  empowered  to  adopt  any  necessary 
changes  to  Anriex  I  in  order to  take  into  account scientific  and  technical 
progress; 
(56)Whereas  this  Directive  is  without  prejudice  to  the  obligations  of the 
Member States concerning the deadlines for transposition set out in Annex II, 
Part B. 
HAVE ADOPTED THIS DIRECTIVE: 
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10. 
12. 
7. 
8. 
+ 
6. 
+ 
6. 
+ 
8. 
92/28/EEC 
'  92/28/EEC 
93/39/EEC 
{adapted) 
75/318/EEC 
(~dapted) 
89/342/EEC 
(adapted) 
89/343/EEC 
{adapted) 
89/381/EEC 
(adapted) TITLE I 
DEFINITIONS 
Article 1 
For  the  purposes . of this  Directive,  the  following  terms  shall  bear  the  following  65/65/EEC 
meanings:  Art.  l ( l) to (3) 
(adapted) 
1.  Proprietary medicinal product: 
Any ready-prepared medicinal product placed on  the  market under a special  name 
and in a special pack. 
2.  Medicinal product: 
Any substance or combination of substances presented  for  treating  or preventing 
disease in human beings. 
Any substance or combination of substances which may be administered to human 
beings  with  a  view  to making a  medical diagnosis  or to  restoring,  correcting  or 
modifying  physiological  functions  in  human  beings  is  likewise  considered  a 
medicinal product. 
3.  Substance: 
Any matter irrespective of  origin which may be: 
human, e.g  •. 
human blood and human blood products; 
animal, e.g. 
micro-organisms,  whole  animals,  parts  of organs,  animaJ  secretions,  toxins, 
extracts, blood products; 
vegetable, e.g. 
micro-organisms, plants, parts of  plants, vegetable secretions, extracts; 
chemical, e.g. 
elements,  naturally  occurring  chemical  materials  and  chemical  products 
obtained by chemical change or synthesis. · 
14 4.  Immunological medicinal product: 
Any medicinal product consisting of  vaccines, toxins, serums or allergen products: 
(a)  vaccines, toxins and serums shall cover in particular: 
(i)  agents used to produce active  immunity,  such  as  cholera vaccine,  BCG, 
polio vaccines, smallpox vaccine:; 
(ii)  agents  used  to  diagnose  the  state  of immunity,  including  in  particular 
tuberculin  and  tuberculin  PPD,  toxins  for  the  Schick  and  Dick  Tests, 
brucellin; 
(iii)  agents  used  to  produce  passive  immunity,  such  as  diphtheria antitoxin, 
anti-smallpox globulin, antilymphocytic globulin. 
(b) "allergen  product"  shall  mean  any  medicinal  product  which  is  intended  to 
identify or induce a specific acquired alteration in the immunological response 
to an allergizing agent. 
5.  Homeopathic medicinal product: 
Any medicinal product prepared from  products, substances or·compositions called 
homeopathic  stocks  in  accordance  with  a  homeopathic  manufacturing  procedure 
described  by  the  European  Pharmacopoeia  or,  in  absence  thereof,  by  the 
pharmacopoeias currently used officially in the Member States. 
A homeopathic medicinal product may also contain a number of  principles. 
89/342/EEC 
Art. I (I) 
(adapted) 
89/342/EEC 
Art. I (2), 2nd indent 
+ 
75/3I9/EEC 
Annex. 
89/342/EEC 
Art.  I (2), I st indent 
(adapted) 
92/73/EEC 
Art. I 
(adapted) 
6.  Radiopharmaceutical:  89/343/EEC 
Art. I (2) 
Any  medicinal  product  which,  when  rt!ady  for  use,  contains  one  or  more  (adapted) 
radionuclides (radioactive isotopes) included for a medicinal purpose. 
7.  Radionuclide generator: 
Any system  incorporating a  fixed  parent radionuclide  from  which  is  produced  a 
daughter radionuclide which is to be obtained by elution or by any other method and 
used in a radiopharmaceutical. 
8.  Radionuclide kit: 
Any preparation to  be  reconsitituted or combined with  radionuclides  in  the  final 
radiopharmaceutical, usually prior to its administration. 
9.  Radionuclide precursor: 
Any other radionuclide produced for the radio-labelling of another substance prior 
to administration. 
15 10.  Medicinal products derived  from human blood or human plasma:  89/3 81/EEC 
Art. 1 (1) 
Medicinal products based on blood constitutents which are prepared industrially by  (adapted) 
public or private establishments, such medicinal products including,  in  particular, 
albumin, coagulating factors and immunoglobulins of  human origin. 
"11.  Adverse reaction:.  75/319/EEC 
Art. 29b 
A reaction which is harmful and unintended and which occurs at doses normally  (as amended by 
used  in  man  for  the  prophylaxis,  diagnosis  or  treatment. of  disease  or  the  93/39/EEC Art. 3 (3)) 
modification of  physiological function. 
I 
12.  Serious adverse reaction: 
An adverse  reaction which  is  fatal,  life-threatening,  disabling,  incapacitating,  or 
which results in or prolongs hospitalization. 
13.  Unexpected adverse reaction: 
An  adverse  reaction  which  is  not  mentioned  in  the  summary  of  product 
characteristics. 
14.  Serious unexpected adverse reaction: 
An adverse reaction which is both serious and unexpected. 
15.  Wholesale distribution of  medicinal products: 
All  activities  consisting of procuring,  holding,  supplying  or  exporting medicinal 
products, apart from supplying medicinal products to the public; such activities are 
carried out with  manufacturers  or their  depositories,  importers, . other wholesale 
distributors or with pharmacists and persons authorized to supply medicinal products' 
to the public in the Member State concerned. 
16.  Public service obligation: 
The obligation placed on wholesalers to guarantee permanently an adequate range of 
medicinal products to meet the requirements of a specific geographical area and to 
deliver the supplies requested within a very short time over the whole of the area in 
question. 
92/25/EEC 
Art. 1 (2) 
17.  Medicinal Prescription:  92/26/EEC 
Art. 1 (2), 2nd sentence 
Any medicinal prescription issued by a professional person qualified to. make such a  (adapted) 
prescription. 
16 18.  Name of  the medicinal product: 
The name given to a medicinal product, which may be either an  invented name or a 
common  or  scientific  name,  together  with  a  trade  mark  or  the  name  of the 
manufacturer; the invented name shall not be liable to confusion with the common 
name. 
19.  Common name: 
The international name recommended by the World Health Organization, or, if one 
does not exist, the usual common name  . 
.  20.  Strength of  the medicinal product: 
92127/EEC 
Art. I (2) 
The content of the active substances expressed quantitatively per dosage unit,  per  (adapted) 
unit of volume or weight according to th.e dosage form. 
21 . Immediate packaging: 
The container or other form of packaging immediately in contact with the medicinal 
product. 
22.  Outer packaging: 
The packaging into which is placed the immediate packaging. 
23.  Labelling: 
Information on the immediate or outer packaging. 
24.  Package leaflet: 
A  leaflet  containing  information  for  the  user  which  accompanies  the  medicinal 
product. 
25. Agency: 
The  European  Agency  for  the  Evaluation  of Medicinal  Products  established  by 
Regulation (EEC) No 2309/93. 
26.  Risk to public health: 
AIJ risks w!th regard to the quality, safety and efficacy of  the medicinal product. 
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75/3I9/EEC 
Art. 8 (I) 
(as amended by 
93/39/EEC Art. 3 (I)) 
(adapted) 
75/319/EEC 
Art. 10 (I) 
(as amended by 
93/39/EEC Art. 3 (I)) 
(adapted) TITLE II 
SCOPE 
Article l 
•  The. provisions  of this  Directive  shall  apply  to  medicinal  products  for  human  use 
intended to be placed on the market in Member States. 
Article 3 
This Directive shall not apply to: 
I.  Any  medicinal  product  prepared  in  a  pharmacy  in  accordance  with  a  medical 
prescription for an individual patient (commonly known as the magistral formula); 
2.  Any medicinal  product which is  prepared in a pharmacy in  accordance with the 
prescriptions of a  pharmacopoeia and  is  intended to  be  supplied  directly  to the 
patients  s~rved by the  pharmacy  in  question  (commonly  known  as  the  official 
formula);  . 
3.  Medicinal products intended for research and development trials; 
4.  Intermediate  products  intended  for  further  processing  by  an  authorized 
manufacturer; 
5.  Any radionuclides in the form of  sealed sources; 
6.  Whole blood, plasma or blood cells of  human origin. 
Article 4 
65/65/EEC 
Art. 2 (1) 
(as amended by 
89/34I/EEC Art. I (3)) 
(adapted) 
65/65/EEC 
Art. 1 (4) and (5) and 
Art. 2 (3},  Ist indent 
(as amended by 
89/341/EEC Art. I (2) 
and (3)) 
(adapted) 
65/65/EEC 
Art. 2 (3), 2nd and 3rd 
indents 
(as amended by 
89/341/EEC Art. 1 (3}) 
(adapted) 
89/343/EEC 
I 
Art. 1 (1)  ' 
(adapted) 
1
89/381/EEC 
Art. I (2) 
1. Nothing in this Directive shall in any way derogate from the Community rules for the  89/343/EEC 
radiation protection of persons undergoing medical examination or treatment, or from  Art. 1 (3} 
the Community rules laying down the basic safety standards for the health protection of 
the general public and ~orkers  against the dangers of  ionizing radiation. 
18 2. This Directive shall be without prejudice to Councii.Decision 86/346/EEC1• 
'3.  The provisions of this Directive shall not affect the powers of  the Member States' 
authorities either as regards the setting of  prices for medicinal products or their inclusion 
in the scope of  national health insurance schc:mes, on the basis of  health, economic and 
social conditions. 
4. This Directive shall not affect the application of national legislation prohibiting or 
restricting  the  sale,  supply  or  use  of  medicinal  products  as  contraceptives  or 
abortifacients. The Member States shall communicate the national legislation concerned 
to the Commission. 
ArticleS 
A Member State may, in accordance with legi:slation in force and to fulfil special needs, 
exclude from the provisions of  this Directive medicinal products supplied in response to 
a  bona fide unsolicited order, formulated  in  accordance with the specifi"ations of an 
authorized health care professional and for use by his individual patients on his direct 
personal responsibility; 
OJ L 207, 30.7.1986, p.  I. 
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1
89/381/EEC 
Art. I (3) 
65/65/EEC 
Art. 3, 2nd subparagraph 
(as amended by 
93/39/EEC Art. I (I)) 
65/65/EEC 
Art. 6 
(as amended by 
93/39/EEC Art. I (5)) 
65/65/EEC 
Art. 2 (4) 
(as amended by 
89/341/EEC Art.  I (3)) 
(adapted) TITLE III 
PLACING ON THE MARKET 
Chapter 1 
Marketi~g  authorization 
Article 6 
No medicinal product product may be placed on the market of a Member State unless a 
marketing authorization has been issued by the competent authorities of that Member 
States  in  accordance  with  this  Directive  or  an  authorization  has  been  granted  in 
accordance with Regulation (EEC) No 2309/93. 
Article 7 
65/65/EEC 
Art. 3 (1) 
(as amended by 
93/39/EEC Art. 1 (I)) 
(adapted) 
A marketing authorization shall not be required for a radiopharmaceutical prepared at  89/343/EEC 
the time of use by a  person or by an  establishment authorized, according to  national  Art. 2, 2nd sentence 
legislation, to use such medicinal products  in  an  approved health  care establishment  (adapted) 
exclusively from authorized radionuclide generators, radionuclide kits or radionuclide 
precursors in accordance with the manufacturer's instructions. 
Article 8 
1.  In  order to  obtain  an  authorization  to  place  a  medicinal  product  on  the  market 
regardless of  the procedure established by Regulation (EEC) No 2309/93, an application 
shall be made to the competent authority of  the Member State concerned. 
2. A  marketing authorization may only be granted to an applicant established in  the 
Community. 
20 
65/65/EEC 
Art. 4 (1) 
(adapted) 
65/65/EEC 
Art. 4 (2) 
(as amended by 
93/39/EEC Art. 1 (2)) 
(adapted) 3. The application shall be accompanied by the. following particulars and documents, 
submitted in accordance with Annex 1: 
(a)  Name  or corporate  name  and  permane,nt  address  of the  applicant  and,  where 
applicable, of  the manufacturer. 
(b)  Name of  the medicinal product. 
(c)  Qualitative  and  quantitative  particulars  of all  the  constituents  of the  medicinal 
product  in  usual  terminology,  but  excluding  empirical  chemical  formulae,  with 
mention of  the international name recommended by the World Health Organization 
where such name exists. 
(d)  Description of  the manufacturing method. 
(e) ·Therapeutic indications, contra-indicatiom: and adverse reactions. 
65/65/EEC 
Art. 4, 3rd paragraph, 
points 1 to 5 
(as amended by 
89/341/EEC Art. I ( 1)) 
(adapted) 
+ 
75/318/EEC 
Art. i, 1st paragraph 
(adapted) 
(f)  Posology, pharmaceutical form,  method ;md  route of administration and expected  65/65/EEC 
shelf  life.  Art. 4, 3rd paragraph, 
point 6 
(g)  If  applicable, reasons for any precautionary and safety measures to be taken for the  (as amended by 
storage of  the medicinal product, its administration to patients and for the disposal of  93/39/EEC Art. I (3)) 
waste products, together with an  indication of any potential risks presented by the 
medicinal product for the environment. 
(h)  Description of the control methods employed by the manufacturer (qualitative and 
quantitative analysis of the constituents and of the finished  product, special  tests~ 
e.g.  sterility tests, tests for the presence of pyrogenic su.bstances,  the presence of 
heavy metals, stability tests, biological and toxicity tests, controls carried out at an 
intermediat~ stage of  the manufacturing process): 
(i)  Results of: . 
physico-chemical, biological or microbiological tests, 
toxicological and pharmacological tests, 
clinical trials. 
2I 
65/65/EEC 
Art. 4, 3rd paragraph, 
point 7 
(as amended by 
75/3I9/EEC Art. 35) 
(adapted) 
65/65/EEC 
Art. 4, 3rd paragraph, 
point 8.I  · 
·cas amended by 
87/2I/EEC Art. I (I)) (j)  A summary, in  accordance with Article  11, of the product characteristics, one or 
more specimens or mock-ups of the sales presentation of the  medicinal  product, 
together with a package leaflet. 
65/65/EEC 
Art. 4, 3rd paragraph, 
point 9 
(as amended by  · 
83/570/EEC Art. 1 (1) 
(c) and 89/341/EEC 
Art. 1 (1)) 
(adapted) 
(k)  A  document showing that the  manufacturer  is  authorised  in  his own country to  65/65/EEC 
produce medicinal.products. ·  Art. 4, 3rd paragraph, 
point 10 
(as amended by 
89/341/EEC Art.  I (1}) 
(I)  Copies of  any authorisation obtained in another Member State or in a third country  65/65/EEC 
to place the medicinal product on the market, together with a list of  those Member  Art. 4, 3rd paragraph, 
States in  which an application for authorisation submitted in accordance ·with this  point 11 
Directive is under e?Camination. Copies of  the summary of  the product characteristics  (as amended by 
proposed  by  the  applicant  in  accordance  with  Article  11  or approved  by  the  93/39/EEC Art. 1 (3)) 
competent authorities of  the Member State in accordance with Article 21. Copies of  (adapted) 
the  package  leaflet proposed. in  accordance  with  Article  59  or approved  by the 
competent authorities of  the Member State in accor®nce with Article 61. Details of 
any  decision  to  refuse  authorization,  whether  in  the  Community  or in  a  third 
country, and the reasons for such a decision.  · 
This information shall be updated on a regular basis. 
Article 9 
In addition  to  the  requirements  set out  in  Articles  8  and  10  (1),  an  application  for  89/343/EEC 
authorization  to  market  a  radionuclide  generator  shall  also  contain  the  following  Art. 3 
information and particulars:  (adapted) 
a  general  description  of the  system  together  with  a  detailed  description  of the 
.components  of the  system  which  may  affect  the  composition  or quality  of the 
daughter nucleid preparation,  · 
qualitative and quantitative particulars of  the eluate or the sublimate. 
22 Article 10 
1.  In  derogation of Article 8 (3) (i),  and  without prejudice to  the  law  relating to the 
protection of  industrial and commercial property: 
(a)  The  applicant  shall  not  be  required  to  provide  the  results  of toxicological  and 
pharmacological tests or the results of  clinical trials if  he can demonstrate: 
(i)  either that the medicinal product is  el>Sentially  similar to a medicinal  product 
authorized in the country concerned by the application and that the marketing 
authorization  holder has consented  to  the toxicological,  pharmacological  and 
clinical references contained in the file  on the original medicinal product being 
used for the purpose of  examining the application in question; 
(ii)  or that the  constituent or constituents  of the  medicinal  product  have  a  well 
established medicinal use, with recognized efficacy and an acceptable level of 
safety, with a detailed scientific bibliography; 
(iii) or that the proprietary medicinal prodtJct  is  essentially similar to a  medicinal 
product which has been authorized within the Community, in accordance with 
Community provisions in force,  for not less than six years and is marketed in 
the  Member  State  for  which  the  application  is  made;  this  period  shall  be 
extended  to  I  0  years  in  the  case  of high-technology  medicinal  products 
having  been authorised according to th<: procedure laid down in Article 2 (5) of 
Council Directive 87/22/EEC1 ; furthermore, a Member State may also extend 
this period to  I  0 years by a single Decision covering all the medicinal products 
marketed  on  its  territory  where  it con:,iders  this  necessary  in  the  interest of 
public health.  Member States  are  at  liberty not  to  apply the  six-year period 
beyond the date of  expiry of  a patent protecting the original medicinal product. 
However, where the medicinal product is intended for a different therapeutic use 
from that of the other medicinal products marketed or is to be administered by 
different routes or in different doses, the results of  appropriate toxicological and 
pharmacological tests and of  appropriate clinical trials must be provided. 
I  OJ LIS, 17.1.1987, p. 38; Directive repealed by Directive 93/41/EEC (OJ L 214, 24.8.1993, p. 40). 
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65/65/EEC 
Art. 4, 3rd paragraph, 
point 8, 2nd 
subparagraph 
(as amended by 
87/21/EEC Art. 1 (I) and 
89/341/EEC Art. 1 (I)) 
(adapted) (b)  In  the case of new medicinal products containing known constituents not hitherto 
used  in  combination  for  therapeutic  purposes,  the  results  of toxicological  and 
phannacological tests  and of clinical  trials  relating  to that combination  must  be 
I 
provided,  but  it  shall  not .  be·. necessary  to  provide  references  relating  to  each 
individual constituent. 
65/65/EEC 
Art. 4, 3rd paragraph, 
point 8, 2nd 
subparagraph 
(as amended by 
87/21/EEC Art. I ( 1) and 
89/34I/EEC Art. I (I)) 
(adapted) 
2.  Annex I  shall apply  by  analogy where,  pursuant to point (ii) of paragraph  1,  (a),  75/318/EEC 
bibliographic references to published data are submitted.  Art. 1, 2nd paragraph 
(adapted) 
Article 11 
The summary of  the product characteristics shall contain the following information:  65/65/EEC 
Art. 4a, points 1 to 5.4, 
·1.  Name of  the medicinal product.  (as amended by 
83/570/EEC Art.  1 (2) 
2.  Qualitative  and  quantitative  composition  in  terms  of the  active  substances  and  and 89/34I/EEC 
constituents  of  the  excipient,  knowledge  of  which  is  essential  for  proper  Art. 1 (1)) 
administration  of the  medicinal  product;  the  usual  common· name  or chemical  (adapted) 
description shall be used. 
3.  Phannaceutical form. 
4.  Phannacological properties and, in so far as this information is useful for therapeutic 
purposes, phannacokinetic particulars. 
5.  Clinical particulars: 
5.1. 
5.2. 
5.3. 
5.4. 
5.5. 
5.6. 
5.7. 
5.8~ 
5.9. 
5.10. 
·therapeut~c indications, 
contra-indications, 
adverse reactions (frequency and seriousness), 
special precautions for  use  and,  in  the  case of immunological medicinal 
products,  any  special  precautions  to  be  taken  by  persons  handling such 
products and administering them to patients, together with any precautions 
to be taken by the patient,  ·  · 
use during pregnancy and lactation, 
interaction with other medicaments and other forms of  interaction, 
posology and method of  administration for adults and, where necessary, for 
children, 
overdose (symptoms, emergency procedures, antidotes), 
special warnings, 
effects on ability to drive and to use machines. 
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S9/342/EEC 
Art. 3 
(adapted) 
65/65/EEC 
Art. 4a, points 5.5 to 6.4 
(as amended by 
83/570/EEC, Art.  I(2) 
and 89/341/EEC, 
Art. I(l) 
(adapted) 6.  Phannaceuticalparticulars: 
6.1. major incompatibi~ities, 
6.2. shelf life, when necessary after reconstitution of  the medicinal product or when 
the immediate packaging is opened for the first time, 
6.3. special precautions for storage, 
6.4. nature and contents of  the immediate packaging, 
65/65/EEC 
Art. 4a (I} to (6), 
point 6.4 
(as amended by 
83/570/EEC Art. I (2) 
and 89/341/EEC 
Art. 1 (1}) 
(adapted) 
6.5  special precautions for disposal of  unused medicinal products or waste materials  65/65/EEC 
derived from such medicinal products, if  appropriate;  Art. 4a (6), point 6.6 
(as amended by 
89/341/EEC Art. 1 (  4)) 
(adapted) 
7.  Name  or corporate  name  and  permanent address  of the  marketing  authorization 
holder; 
8.  For radiophannaceuticals, full details of  internal radiation dosimetry; 
9.  For  radiopharinaceuticals,  additional  detailed  instructions  for  extemporaneous 
preparation  and  quality  control  of such  preparation  and,  where  appropriate, 
maximum storage time during which any intermediate preparation such as an eluate 
or the ready-to-use phannaceutical will conform with its specifications. 
25 
65/65/EEC 
Art. 4a (6), point 6.5 
(as amended by 
83/570/EEC Art. I (2)) 
(adapted) 
89/343/EEC 
Art. 4 
(adapted) Article 12 
1.  Member States shall take all appropriate measures to ensure that the documents and  75/319/EEC 
particulars listed ifi Article 8 (3) (h) and (i), and Article 10 ( 1) are drawn up by experts  Art. 1 
with the necessary technical or professional qualifications before they are submitted to  (adapted) 
the  competent  authorities.  These  documents  and ·particulars  shall  be  signed  by  the 
experts. 
2. The duties of  the experts according to their respective qualifications shall be:  75/319/EEC 
Art. 2 
(a)  to perfoim tasks falling within their respective disciplines (analysis, pharmacology.  (adapted) 
and similar experimental  sciences,  clinical  trials)  and to  describe  objectively  the 
results obtained (qualitatively and quantitatively); 
(b)  to describe their observations in accordance with Annex I, and to state, in particular: 
in the case of the analyst, whether the medicinal product is consistent with the 
declared  composition,  giving  any  substantiation  of  the  control  methods 
employed by the manufacturer; 
· in the· case of the  pharmacologist or the- specialist with  similar experimental 
competence,  the  toxicity  of the  medicinal  product  and  the  pharmacological 
properties observed;  ·  · 
in the case of the clinician, whether he has  been able to ascertain effects on 
persons treated with the medicinal product which correspond to the particulars 
given by the applicant in accordance with Articles 8 and 10, whether the patient 
tolerates the medicinal product well, the posology the clinician advises and any 
contra-indications and adverse reactions;  . 
(c)  where  applicable, .to state  the  grounds  for  using  the  bibliography  mentioned  in 
point (a)(ii) of  Article 10 (1). 
3.  Detailed reports by the experts shall form  part of the particulars accompanying the 
application which the applicant submits to the competent authorities. 
26 Chapter2 
Specific provisions applicable to 
homeopathic medicinal products 
Article 13 
I. Member States shall ensure that homeopathic medicinal products manufactured and  92/73/EEC 
placed on the market within the Community are registered or authorized in accordance  Art. 6 (I) and (2) 
with Articles  14,  15  and  16. Each Member State shall take due account of registrations  (adapted) 
and authorizations previously granted by another Member State. 
2.  A  Member  State  may  refrain  from  establishing  a  special,  simplified  registration 
procedure for the homeopathic medicinal products referred to  in Article 14. A Member 
State  shall  inform  the  Commission  accord4tgly.  The  Member  State  concerned  shall 
allow the  use  in  its  territory of homeopathic  medicinal  products  registered  by  other 
Member States in accordance with Articles 14 and 15. 
Article 14 
I. Only homeopathic medicinal products which  satisfy all of the following  conditions  92/73/EEC 
may be subject to a special, simplified registration procedure:  Art. 7 (I) and (4) 
(adapted) 
they are administered orally or externally, 
:- no specific therapeutic indication appears on the labelling of the medicinal product 
or in any information relating thereto, 
there  is  a  sufficient  degree  of dilution  to  guarantee  the  safety  of the  medicinal 
product; in particular, the medicinal product may  not contain either more than one 
part per 10 000 of  the mother tincture or more than 1/IOOth of  the smallest dose used 
in  allopathy  with  regard  to  active  substances  whose  presence  in  an  allopathic 
medicinal product results in the obligation to submit a doctor's prescription. 
At the  time  of registration,  Member States  shall  determine  the  classification  for  the 
dispensing of  the medicinal product. 
2.  The criteria and rules of procedure provided for in  Articles 4 (4),  17,  18,22 to 26, 
I 12, 116 and 127 shall apply by analogy to the special, simplified registration procedure 
for  homeopathic  medicinal  products,  with  th1~ exception  of the  proof of therapeutic 
efficacy. 
27 3.  The proof of therapeutic efficacy shall  not be required for  homeopathic medicinal  92173/EEC 
products registered in accordance with paragraph 1 of  this Article, or, where appropriate,  Art. 4, 2nd paragraph 
admitted in accordance with Article 13 (2).  (adapted) 
Article IS 
An  application  for  special,  simplified  registration  may  cover  a  series  of medicinal  92/73/EEC 
products derived from the same homeopathic stock or stocks, The following documents  Art. 8 
shall  be  included  with  the  application  in  order  to  demonstrate,  in  particular,  the  (adapted) 
pharmaceutical quality and the batch-to-batch homogeneity of  the products concerned: 
scientific name or other name given in a pharmacopoeia of  the homeopathic stock or 
stocks,  together  with  a  statement  of  the  various  routes  of  administration, 
pharmaceutical forms and degree of  dilution to be registered, 
dossier  describing  how  the  homeopathic  stock  or  stocks  is/are  obtained  and 
controlled, and justifying its/their homeopathic nature, on the basis of an  adequate 
bibliography, 
manufacturing and control file for each pharmaceutical form and a description of  the 
method of  dilution and potentization, 
manufacturing authorization for the medicinal product concerned, 
copies of  any registrations or authorizations obtained for the same medicinal product 
in other Member States, 
one  or more  specimens  or mock-ups  of the  sales  presentation  of the  medicinal 
products to be registered, 
data concerning the stability of  the medicinal product. 
28 Article 16 
I. Homeopathic medicinal products other than those referred ~o in Article 14 (1) shall be  92173/EEC 
authoriied in accordance with Articles 8,  I 0 (l) and II.  Art. 9 
(adapted) 
2.  A  Member  State  may  introduce  or  retain  in  its  territory  specific  rules  for  the 
toxicological  and  phannacological  tests  and  clinical  trials of homeopathic  medicinal 
products other than those referred to in Article  I4 (I) in accordance with the principles 
arid characteristics of  homeopathy as practised in that Member State. 
In  this case, the Member State concerned shall notify the  Commission of the  specific 
rules in force.  · 
29 Chapter3 
Procedures relevant to the 
marketing authorization 
Article 17 
1.  Member States shall take all appropriate measures to ensure that the procedure for 
granting an authorization to place a medicinal product on the market is completed within 
210 days ofthe submission of  a valid application. 
2. Where a  Member State notes that an applicatioQ  for authorization is  already under 
active examination in another Member State in  respect of that medicinal product, the 
Member  State  concerned  may  decide  to  suspend  the  detailed  examination of the 
application in order to await the assessment report prepared by the other Member State 
in accordance with Article 21 (4). 
The Member State concerned shall inform the other Member State and the applicant of 
its decision to suspend detailed examination of  the application in question. As soon as it 
has completed the examination of the application  and  reached  a  decision,  the  other 
Member  State  shall  forward  a  copy  of its  assessment  report  to  the  Member  State 
concerned. 
Article 18 
Where a  Member State is  informed in  accordance with Article  8 (3) (I) that another 
Member State has authorized a medicinal pr~duct which is the subject of an application 
for  authorization  in  the Member State  concerned,  that  Member State shall  forthwith 
request the  authorities  of the  Member State  which  has granted  the  authorization  to 
forward to it the assessment report referred to in Article 21  (4). 
Within 90 days of  the receipt of  the assessment report, the Member State concerned shall 
either recognize the decision of  the first Member State and the summary of the product 
characteristics as approved by it or, if it considers that there are grounds for supposing 
that the authorization of the medicinal product concerned may present a risk to public 
health, it shall apply the procedures set out in Articles 29 to 34. 
30 
65/65/EEC 
Art. 7 
(as amended by 
93/39/EEC Art. 1 (6)) 
(adapted). 
65/65/EEC 
Art. 7a 
(as amended by 
93/39/EEC Art. 1 (7)) 
(adapted) Article 19 
In order to examine the application submitted in  accordance with Articles 8 and  I 0 (I), 
the competent authority of  the Member State: 
I.  must verify whether the particulars submitted in support of the application comply 
with the said Articles 8 and 10 (1) and examine whether the conditions for issuing 
an  authorization  to  place  medicinal  products  on  the  market  (marketing 
authorization) are complied with; 
2 .. may submit the medicinal product for testing by a State laboratory or by a laboratory 
designated for that purpose in order to ensure that the control methods employed by 
the manufacturer and described in the particulars accompanying the application in 
accordance with Article 8 (3) (h) are satisfactory; 
3.  may,  where  appropriate,  require  the  applicant  to  supplement  the  particulars 
accompanying the application in respect of  the items listed in the Articles 8 (3) and 
I 0 (I). Where the competent authority avails itself of  this option, the time limits laid 
down  in  Article  17  shall  be  suspended  until  such  time  as  the  supplementary 
information  required  has  been  provided.  Likewise,  these  time  limits  shall  be 
suspended for the time allowed the applicant, where appropriate, for giving oral or 
written explanation. 
' 
31 
75/319/EEC 
Art. 4 (a) 
(adapted) 
75/319/EEC 
Art. 4 (b) 
(as amended by 
89/341/EEC Art. 3 (I)) 
75/319/EEC 
Art. 4 (c) 
(adapted) Article 20 
Member States shall take all appropriate measures to ensure that:  75/319/EEC 
Art. 5 
(a)  the  competent authorities  verify  that  manufacturers  and  importers  of medicinal  (adapted) 
products  coming  from  third  countries  are  able  to  carry  out  manufacture  in 
compliance. with the particulars supplied pursuant to Article 8 (3) (d), and/or to carry 
out controls according to the methods described in the particulars accompanying the 
application in accordance with Article 8 {3) (h); 
(b) the  competent. authorities  may  allow  manufacturers  and  importers  of medicinal 
products coming from third countries, in  exceptional and justifiable cases, to  have 
certain stages of  manufacture and/or certain of  the controls referred to in (a) carried 
out by third parties; in such cases,  the  verifications by  the competent authorities 
shall also be made in the establishment designated. 
Article 21 
1.  When the marketing authorization  is  issued,  the  holder shall  be  informed,  by the  65/65/EEC 
competent authorities of the Member State concerned, of the summary of the product  Art. 4b 
characteristics as approved by it.  (as amended by 
93/39/EEC Art.  1 (4)} 
2.  The  competent  authorities  shall  take  all  necessary  measures  to  ensure  that  the  (adapted) 
information  given  in  the  summary  is  in  conformity  with  that  accepted  when  the 
marketing authorization is issued or subsequently. 
3.  The  competent  authorities  shall  forward  to  the  Agency  a  notification  of the 
authorization, or a copy of  this, together with the summary of  the product characteristics. 
4. The competent authorities shall draw up an assessment report and comments on the 
~ossier as regards the results of the analytical and pharmacotoxicological tests and the 
clinical  trials  of the  medicinal  product  concerned.  The  assessment  report  shall  be 
updated whenever new information becomes available which is of importance for the 
evaluation of  the quality, safety or efficacy of  the medicinal product concerned. 
32 Article 22 
In  exceptional  circumstances,  and  following  c;onsultation  with  the  applicant,  an 
authorization may be granted subject to certain specific obligations, including: 
the carrying out of  further studies following the granting of  authorization, 
the notification of  adverse reactions to the medicinal product. 
These exceptional decisions may be adopted only for objective and verifiable reasons 
and shall be based on one of  the causes referred to in Part 4 (G) of  Annex I. 
Article 23 
After an authorization has been issued, the authorization holder must, in respect of the 
methods of manufacture and control  provided  for  in  Article  8  (3) (d) and (h),  take 
account of scientific  and technical  progress  and  introduce  any  changes  that may be 
required to enable the medicinal product to be manufactured and checked by means of 
. generally accepted scientific methods. 
These changes shall be subject to the approval of  the competent authority of  the Member 
State concerned. 
Article 24 
65/65/EEC 
Art. 10 (2) 
(as amended by 
93/39/EEC Art. 1 (9)) 
65/65/EEC 
Art. 9a 
(as amended by 
93/39/EEC Art. I (8)) 
(adapted) 
Authorization shall be valid for five years and shaH be renewable for five-year periods,  65/65/EEC 
on application  by the holder at least  three  months  before  the  expiry  date  and after  Art. IO (I) 
consideration by the competent authority of a dossier containing in particular details of  (as amended by 
the data on pharmacovigilance and other information relevant to the monitoring of the  93/39/EEC.Art. I (9)) 
medicinal product. 
Article 25 
Authorization shall not affect the civil and .criminal liability of the manufacturer and;  65/65/EEC 
where applicable, of  the marketing authorization holder.  Art. 9 
(adapted) 
33 (3) 
Article26 
The marketing authorisation shall be refused if, after verification of the particulars and  65/65/EEC 
documents listed in Articles 8 and 10 (1), it proves that:  Art. 5 
(a)  the medicinal product is harmful in: the normal conditions of  use, or 
(b)  thai its  therapeutic  efficacy. is  lacking  or  is  insufficiently  substantiated  by  the 
applicant, or 
(c)  that its qualitative and quantitative composition is not as declared. 
Authorisation shall  likewise be  refused  if the particulars and docume.nts  submitted  in 
support of  the application do not comply with Articles 8 and 10 (1). 
34 
(as amended by 
89/341/EEC Art. 1 ( 1)) 
(adapted) Chaptcr4 
Mutual recognition of  authorizations 
Article 27 
I.  In· order to facilitate  the  adoption of common decisions by Member States on  the  75/319/EEC 
authorization of medicinal  products  on the  basis  of the  scientific  criteria of quality,  Art. 8 
safety and efficacy, and to achieve thereby the free movement of  medicinal products  (as amended by 
within  the  Community,  a  Committee  for  Proprietary  Medicinal  Products,  hereinafter.  93/39/EEC Art. 3 (l)) 
referred to as "the Committee", is  hereby set up.  The Committee shall  be  part of the  (adapted) 
Agency. 
2.  In  addition  to  the  other responsibilities  conferred upon  it  by  Community  law,  the 
Committee shall examine any question relating to the granting, variation, suspension or . 
withdrawal of marketing authorization which  is submitted to it in accordance with this 
Directive. 
3. The Committee shall draw up its own Rules of  Prodecure. 
Article 28 
1.  Before submitting the application for recognition of a marketing authorization, the  75/319/EEC 
holder  of  the  authorization  shall  inform  the  Member  State  which . granted  the  Art. 9 (3) 
~uthorization on which the application is based (hereinafter "referential Member State"),  (as amended by 
that an application is to be made in accordanct! with this Directive and shall notify it of  93/39/EEC Art. 3 (1)) 
any additions to  the original dossier;  that Member State may require  the applicant to  (adapted) 
provide it with all the particulars and documents necessary to enable it to check that the 
dossiers filed are identical. 
In addition the holder of  the authorization shall request the referential Member State to 
prepare  an  assessment  report  in  respect  of the  medicinal  product  concerned,  or,  if 
necessary, to update any existing assessment re]port. That Member State shall prepare the 
assessment report, or update it, within 90 days of  the receipt of  the request. 
At the same time as  the application is  submitted in  accordance with paragraph 2, the 
referential Member State shall  forward the as:>essment  report to  the Member State or 
Member States concerned by the application. 
2.  In  order to  obtain  the  recognition  according  to  the  procedures  laid  down  in  this  75/319/EEC 
Chapter in  one or more of the Member States of a marketing authorization issued by a  Art. 9 (I) 
Member  State,  the  holder  of the  authorization  shall  submit  an  application  to  the  (as amended by 
competent authorities of the Member State or Member States concerned, together with  93/39/EEC Art. 3 (l)) 
the information and particulars referred to in Articles 8, 10 (I) and  11. He shaH  testify  (adapted) 
that the dossier is identical to that accepted by the .  referential Member S~ate, or shall 
identify any additions or amendments it may contain. In the latter case, he shall certify 
that the summary of the product characteristics proposed  by him  in  accordance with 
Article  II is  identical to that accepted by the referential Member State in  accordance 
with  Article 2I. Moreover,  he shall  certify  that  all  the  dossiers  filed  as  part  of the 
procedure are identical. 
35 3.  The holder of the marketing authorization shall communicate the application to the 
Agency, inform it of  the Member States concerned and of the dates of submission of  the 
application and send it a copy of the authorization granted by the referential  Member 
State. He shall also send the Agency copies of any such authorization which may have 
been g~ted  by the other Member States in respect of  the medicinal product concerned, 
and  shall  indicate  whether  any  application  for  authorization  is  currently  under 
consideration in any Member State. 
4.  Save in the exceptional case provided for in Article 29(1), each Member State shall 
recognize the .marketing authorization granted by the referential Member State within 90 
days of  receipt of  the application and the assessment report. It shall inform the referential 
Member  State  which  granted ·the  initial  authorization,  the  other  Member  States 
concerned by the application, the Agency, and the marketing authorization holder 
Article 29 
75/319/EEC 
Art. 9 (2) 
(as amended by 
93/39/EEC Art. 3 (1)) 
(adapted) 
75/319/EEC 
Art. 9 (4) 
(as amended by 
93/39/EEC Art. 3 (I)) 
(adapted) 
t.  Where  a  Member  State  considers  that  there  are  grounds  for  supposing  that  the  75/3 19/EEC 
~keting  authorization of  the medicinal product concerned may present a risk to public  Art. 10 
health,  it  shall  forthwith  inform  the  applicant,  the  referential  Member  State  which  (as amended by 
granted the initial authorization, any other Member States concerned by the application  93/39/EEC Art. 3 (1)) 
and the Agency. The Member State shall  s~ate its  reasons  in  detc1il  and shall  indicate  (adapted) 
what action may be necessary to correct any defect in the application. 
2. All the Member States concerned shall use their best endeavours to reach agreement 
on the action to be taken in respect of the application. They shall provide the applicant 
with the opportunity to make his point of view known orally or in writing. However,  if 
the  Member  States  have  not  reached  agreement  within  the  time  limit  referred  to  in 
Article 28 (4) they shall forthwith  refer the matter to the Agency with  regard to  the 
Committee's reference for the application of  the procedure laid down in Article 32. 
3.  Within the time limit referred to in Article 28(4), the Member States concerned shall 
provide the Committee with a detailed statement of  the matters on which they have been 
unable to reach agreement and the reasons for their disagreement. The applicant shall be 
provided with a copy of  this information. 
4.  As soon as he  is  informed that the matter has  been referred to the Committee, the 
applicant  shall  forthwith  forward  to  the  Committee  a  copy  of the  information  and 
particulars referred to in Article 28 (2). 
36 ·Article30 
If several applications submitted  in  aCcordance  with Articles  8,  10 (1) and  Article  II 
have  been  made  for  marketing ·authorization  for  a particular medicinal  product,  and 
Member States have  adopted  divergent decisions  concerning  the  authorization  of the 
medicinal product or its suspension or withdrawal. a Member State, or the Commission, 
or the  marketing  authorisation  holder  may  refer  the  matter  to  the  Committee  for 
application of  the procedure laid down in Article 32. 
The Member State concerned, the marketing authorization  holder or the Commission 
shall clearly identify the question which is referred to the Committee for consideration 
and, where appropriate, shall inform the holder. 
The  Member  State  and  the  marketing  authorization  holder  shall  forward  to  the 
Committee all available information relating to the matter in question. 
Article 31 
75/319/EEC 
Art. II 
(as amended by. 
93/39/EEC Art. 3 (I)) 
(adapted) 
• 
The  Member  States or the  Commission  or the  applicant  or holder of the  marketing  75/319/EEC 
authorization may, in specific cases where the  interests of the Community are involved,  Art. 12 
refer the  matter to  the  Committee for  the  application of the· procedure  laid  down  in  (as amended by 
Article 32 before reaching a decision on !l request for a marketing authorization or on the  93/39/EEC Art. 3 (I)) 
suspension or withdrawal of  an authorization, or on any other variation to the terms of  a  (adapted) 
marketing authorization which appears necessary,  in  particular to  take account of the 
. information collected in accordance with Title IX. 
The  Member  State  concerned or the Commission  shall  clearly  identify  the  question 
which  is  referred to the Committee for consideration and shall  inform the  marketing 
authorization holder. 
The  Member  States  and  the  marketing  authorization  holder  shall  forward  to  the 
Committee all available information relating to the matter in question. 
37 Artide32 
· ·1.  When reference is made to the procedure described in this Article, the Committee  75/319/EEC 
shall consider the matter concerned and issue a reasoned opinion within 90 days of  the  Art. 13 
date on which the matter was referred to it.  .  ·  (as amended by 
93/39/EECArt. 3 (J)) 
However, in cases submitted to the Committee in accordance with Articles 30 and 31,  (adapted)  · 
this Period may be extended by 90 days. 
In case of urgency, on a  proposal from its Chairman, the Committee may·agree to a 
shorter deadline. 
2. In order to consider the matter, the Committee may appoint one of its members to act 
as  rapporteur.  The  Committee  may  also  appoint  individual  experts  to advise  it  on 
specific questions. When appointing experts, the Committee shall define their tasks and 
specify the time-limit for the completion of  these tasks. 
3.  In  the  cases  referred  to  in  Articles  29  and  30,  before  issuing  its  opinion,  the 
Committee shall provide the marketing  authorization  holder with  an opportunity to 
present written or oral explanations. 
In the case referred to in Article 31, the marketing authorization holder may be asked to 
explain himself orally or in writing. 
If it considers it appropriate, the Committee may  invite  any  other person to provide 
information relating to the matter before it. 
The Committee may suspend the time limit referred to in paragraph 1 .in order to allow 
the marketing authorization holder to prepare explanations.  · 
38 4.  The Agency shall. forthwith  inform  the  marketing  authorization  holder  where  the  75/319/EEC 
opinion ofthe Committee is that:  Art.  13 
the application does not satisfy the criteria for authorization, or 
the summary of  the product characteristics proposed by the applicant in accordance 
with Article II  should be amended, or 
the authorization should be granted subject to conditions,. with regard to conditions 
considered essential for the safe and effective use of  the medicinal product including 
pharmacovigilance, or 
a marketing authorization should be suspended, varied or withdrawn, 
Within  15  days of the receipt of the opinion, the marketing authorization holder may 
notify the Agency in writing of  his intention to appeal. In that case, he shall forward the 
detailed grounds for appeal  to the  Agency within  60 days  of receipt of the  opinion. 
Within  60  days  of receipt  of the  grounds  for  appeal,  the  Committee  shall  consider 
whether its opinion should be revised, and the conclusions reached on the appeal shall be 
annexed to the assessment report referred to in paragraph 5. 
5.  Within  30 days of its  adoption,  the Agency shall  forward  the  final  opinion of the 
Committee to the  Member  States,  the  Commission  and  the  marketing  authorization 
holder together with  a report describing the assessment of the  medicinal  product and 
stating the reasons for its conclusions. 
In the event of  an opinion in favour of  granting or maintaining an authorization to place 
the  medicinal  product  concerned  on  the  market,  the  following  documents  shall  be 
annexed to the opinion. 
(a)  a draft summary of  the product characteristics, as referred to in Article 1  I; 
(b)  any conditions affecting the authorization within the meaning of  paragraph 4. 
39 
(as amended by 
93/39/EEC Art. 3 (I)) 
(adapted) Article 33 
Within 30 days of  the receipt of  the opinion, the Commission shall prepare a draft of  the 
decision to be taken in respect of  the application, taking into account Community law. 
In the event of  a draft decision which envisages the granting of  marketing authorization, 
the documents referred to in Article 34 (5) (a) and (b) shall be annexed. 
Where,  exceptionally, the draft decision is  not in accordance with the  opinion of the 
Agency, the Commission shall also annex a detailed explanation of the reasons for the 
differences. 
The draft decision shall be forwarded to the Member States and the applicant. 
Article 34 
1. A final decision on the application shall be adopted in accordance with the procedure 
laid down in Article 124. 
2. The rules of  procedure of  the Standing Committee establishedby Article 120 shall be 
adjusted to take account of  the tasks incumbent upon it in accordance with this Chapter. 
These adjustments shall involve the following: 
except in cases referred to in the third paragraph of Article 33, the opinion of the 
Standing Committee shall be obtained in writing, 
each Member State is allowed at least 28 days to forward written observations on the 
draft decision to the Commission, 
each Member State is  able to require in writing that the draft decision be discussed 
by the Standing Committee, giving its reasons in detail. 
Where, in the opinion of the Commission, the written observations of a Member State 
raise important new questions of a scientific or technical nature which have not been 
addressed in the opinion of the Agency, the Chairman shall suspend the procedure and 
refer the application back to the Agency for further consideration. 
The provisions necessary for the implementation of this paragraph shall be adopted by 
the Commission in accordance with the procedure laid down in Article 122. 
3.  A decision  as  referred to in  paragraph  1 shall  be  iiddressed to the Member States 
concerned  by  the  matter  and  reported  to  the  marketing  authorization  holder.  The 
Member States shall either grant or withdraw marketing authorization, or vary the terms 
of a marketing authorization as necessary to comply with the decision within 30 days of 
its notification. They shall inform the Commission and the Agency thereof. 
40 
75/319/EEC 
Art. 14 (1) 
(as amended by 
93/39/EEC Art. 3 (1)) 
(adapted) 
75/319/EEC 
Art. 14 (2) 
(as amended by 
93/39/EEC Art. 3 (1 )) 
75/319/EEC 
Art. 14 (3) 
(as amended by 
93/39/EEC Art. 3 (1)) 
(adapted) 
75/319/EEC 
Art. 14 (4) 
(as amended by 
93/39/EEC Art. 3 (1)) 
(adapted) Article 35 
I.  Any  application  by  the  marketing  ·authorization  holder  to  vary  a  marketing  75/319/EEC 
authorization which has been granted in accordance with the provisions of  this Chapter  Art. 15 
· shall  be  submitted to all  the  Member States  which  have  previously authorized  the  (as amended by 
medicinal product concerned.  93/39/EEC Art. 3 (1)) 
The Commission shall, in consultation with the Agency, adopt ·appropriate arrangements 
for the examination of  variations to the terms of  a marketing authorization. 
These  arrangements  shall  include  a  notification system  or administration  procedures 
concerning minor variations and define precisely the concept of"a minor variation". 
These arrangements shall be adopted by the Commission in the form of  an implementing 
Regulation in accordance with the procedure laid down in Article 122.  .  . 
2.  The procedure  laid  down  in  Articles  32,  33  and  34  shall . apply  by  analogy  to 
variations made to marketing authorizations for products. 
Artide36 
I. Where a Member State considers that the variation of  a marketing authorization which 
has been granted in accordance with the provisions of this Chapter or its suspension or 
withdrawal is necessary for the protection of  public health, the Member State concerned 
shall forthwith refer the matter to the Agency for the application of the products laid 
down in Articles 32,33 and 34. 
2. Without prejudice to the provisions of  Article 31, in exceptional cases, where urgent 
action  is  essential  to  protect  public  health,  until  a  definitive  decision  is  adopted  a 
Member  State  may  suspend  the  marketing  and  the  use  of the  medicinal  product 
concerned on its territory. It shall inform the Commission and the other Member States 
no later th~  the following working day of  the reasons for its action. 
41 
(adapted) 
75/319/EEC 
Art. 15a 
(as amended by 
93/39/EEC Art. 3 (I)) 
(adapted) Article 37 
Articles 35 and 36 shall apply by analogy to medicinal products authorized by Member  75/319/EEC 
States following an opinion of the Committee given  in  accordance  with  Article 4  of  Art. 15b 
Directive 87122/EEC before l January 1995.  (as amended by  . 
93/39/EEC Art. 3 (1)) 
Article 38 
1. The Agency shall publish an annual report on the operation of the procedures laid  75/319/EEC 
down in this Chapter and shall forward that report to the European Parliament and the  Art.15c 
Council for information.  (as amended by 
93/39/EEC Art. 3 {I)) 
2. By I January 2001, the Commission shall publish a detailed review of  the operation of 
the procedures laid down in this Chapter and shall propose any amendments which may 
be necessary to improve these procedures. 
_The  Council  shall  decide,  under  the  conditions  provided  for  in  the  Treaty,  on  the 
Commission proposal within one year of  its submission. 
Article 39 
The  provisions  referred  to  in  Articles  27  to  34  shall  not  apply .to  the  homeopathic 
medicinal products referred to in Article 16 (2). 
42 
75/319/EEC 
Art. 14 (5) 
(as amended by 
93/39/EEC Art. 3 {I)) 
(adapted) TITLE IV 
MANUFACTURE AND IMPORTATION 
Article 40 
I. Member States shall take all appropriate measures to ensure that the manufacture of 
the medicinal products within their territory is subject to the holding of  an authorization. 
·This manufacturing authorization shall be required nothwithstanding that the medicinal 
products manufactured are intended for export. 
2. The authorization referred to in paragraph I shall be required for both total and partial 
manufacture, and for the various processes of  dividing up, packaging or presentation.  . 
However, such authorization shall not be required for preparation, dividing up, changes 
in  packaging  or presentation  where  these  procc~sses are  carried  out,  solely  for  retail 
supply, by pharmaci::;ts in dispensing pharmacies or by persons legally authorized in the 
Member States to carry out such processes. 
3. Authorization referred to in  paragraph  1 shaH  also be  required for imports coming 
from  third  countries  into  a  Member State;  this  Title  and Article  118  (I)  shall  have 
corresponding application to such imports as they have to manufacture. 
Article41 
In order to obtain the manufacturing authorization, the applicant shall meet at least the 
following requirements: 
(a)  specify  the  medicinal  products  and  pharmaceutical  forms  which  are  to  be 
manufactured or imported and also  the  pla,:e  where  they are  to  be  manufactured 
and/or controlled;  -
(b)  have  at  his  disposal,  for  the  manufacture  or  import  of the  above,  suitable  and 
sufficient premises, technical equipment and control facilities ·complying with the 
legal requirements which the  Member State  concerned lays down as  regards both 
manufacture and control and the storage of medicinal products, in  accordance with 
Article 20; 
(c)  have at his disposal the services of at least one qualified person within the meaning 
of  Article 48. 
The appli~ant shall provide particulars in support of  the above in his application. 
43 
75/319/EEC 
Art. 16 (l) 
(as amended by 
89/341/EEC Art. 3 (3)) 
(adapted) 
75/319/EEC 
Art. 16 (2) and (3) 
(adapted) 
75/319/EEC 
Art. 17 
(adapted) Article 42 
l.  The  competent  authority  of the  Member  State  shall  issue  the  manufacturing 
authorization only after having. made sure of the accuracy of the  particulars supplied 
pursuant to Article 41, by means of  an inquiry carried out by its agents. 
2. In order to ensure that the requirements referred to  in  Article 41  are complied with, 
authorization  may  be  made  conditional  on  the  carrying  out  of certain  obligations 
imposed either when authorization is granted or at a later date. 
3. The authorization shall apply only to the premises specified in the application and to 
the medicinal products and pharmaceutical forms specified in that same application. 
Article 43 
75/319/EEC 
Art.  18 
(adapted) 
The Member States shall take all appropriate measures to ensure that the time taken for  7  5/319/EEC 
the  procedure for  granting the  manufacturing authorization does  not exceed  90  days  Art. 20 (I) 
from the day on which the competent authority receives the application. 
Article 44 
If the  holder  of the  manufacturing  authorization  requests  a  change  in  any  of the  75/319/EEC 
particulars  referred  to  in  the  first  paragraph  of Article  41,  the  time  taken  for  the  Art. 20 (2) 
procedure relating to this request shall not exceed 30 days.  In exceptional  cases  this  (adapted) 
period of  time may be extended to 90 days. 
Article 45 
The competent authority of the Member State may require  from  the applicant further  75/319/EEC 
information concerning the particulars supplied pursuant to Article 41  and concerning  Art. 20 (3) 
the qualified persOn referred to in Article 48; where the competent authority concerned  (adapted) 
exercises this right, application of  the time-limits referred to in Article 43 and 44 shall be 
suspended until the additional data required have been supplied. 
44 Article 46 
The holder of  a manufacturing authorization shaii at least be obliged:  75/319/EEC 
Art. 19 (a) to (e) 
(a)  to have at his disposal the services of staff who comply with the legal requirements  (adapted) 
existing in the Member State concerned both as regards manufacture and controls; 
(b)  to  dispose  of the  authorized  medicinal  products  only  in  accordance  with  the 
legislation of  the Member States concerned; 
(c)  to give prior notice to the competent authority of  any changes he may wish to make 
to  any of the  particulars supplied pursuant to Article 41;  the  competent authority 
shall,  in  any event,  be  immediately informed if the  qualified person referred to in 
Article 48 is replaced unexpectedly; 
(d)  to allow the agents of  the competent authority of  the Member State concerned access 
to his premises at any time; 
(e)  to enable the qualified person referred to  in  Article 48  to  carry out his duties,  for 
example by placing at his' disposal all the necessary facilities; 
(f)  to  comply with  the  principles and  guidelines  of good  manufacturing practice  for 
medicinal products as laid down by Community law. 
Article 47 
75/319/EEC 
Art. 19 (f) 
(as amended by 
89/341/EEC Art. 3 (4)) 
The principles and guidelines of good manufacturing practices  fo~ medicinal products  75/319/EEC 
referred to in  Article 46  (f) shall be adopted in  the form  of a directive,  in  accordance  Art.  19a 
with the procedure laid down in Article 122.  (as amended by 
89/341/EEC Art. 3 (5)) 
Detailed guidelines in  line with those principles will be published by  the Commission  (adapted) 
and revised as necessary to take account of  technical and scientific progress. 
45 Article48 
I. Member States shall take all  appropriate  measures to  ensure that the  holder of the  75/319/EEC 
manufacturing  authorization .has  permanently  and  continuously  at  his  disposal  the  Art. 21 
services of at least one qualified person, in accordance with the conditions laid down in 
Article 49, responsible in particular for carrying out the duties specified in Article 51. 
2.  If he  personally fulfils  the  conditions  laid  down  in  Article  49,  the  holder of  the 
authorization may himself assume the responsibility referred to in paragraph 1. 
Article 49 
l. Member· States shall ensure that the qualified person referred to  in  Article 48 fulfils  75/319/EEC 
the minimum conditions of  qualification set out in paragraphs 2 and 3.  Art. 23 
(adapted) 
2. A qualified person shall be in possession of  a diploma, certificate or other evidence of 
formal qualifications awarded on completion of  a university course of  study, or a course 
recognized as equivalent by the Member State concerned, extending over a period of at 
least four years of theoretical  and  practical  study  in  one  of the ·  foflowing  scientific 
disciplines:  pharmacy,  medicine,  veterinary  medicine,  chemistry,  pharmaceutical 
chemistry and technology, biology. 
However, the minimum duration of  the university course may be three and a half years 
where  the  course  is  followed  by  a  period  of theoretical  and  practical  training  of a 
minimum duration of  one year and including a training period of at least six months in a 
pharmacy open to the public, corroborated by an examination at university level. 
Where  two  university  courses  or two  courses  recognized  by  the  State  as  equivalent 
co-exist in a.Member State and where one of  these extends over four years and the other 
over three years, the three-year course leading to a diploma, 'Certificate or other evidence 
of formal qualifications awarded on completion of a university course or its recogryzed 
equivalent shall be considered to fulfil the condition of  duration referred to in the second  -
subparagraph  in  so  far  as  the  diplomas,  certificates  or  other  evidence  of formal 
qualifications awarded on completion of both courses are  recognized  as  equivalent by 
the State in question. 
46 The  course  shall  include  theoretical  and  practical  study  bearing  upon  at  least  the  75/319/EEC 
following basic subjects:  Art. 23 
(adapted) 
Applied physics 
General and inorganic chemistry 
Organic chemistry 
Analytical chemistry 
Pharmaceutical chemistry, including analysis of  medicinal products 
General and applied biochemistry (medical)  · 
Physiology 
Microbiology 
Pharmacology 
Pharmaceutical technology 
Toxicology  . 
Pharmacognosy  (study  of the  composition  and  effects  of the  natural  active 
substances of  plant and animal origin). 
.  . 
Studies  in  these subjects should be so balanced as  to  enable the person  concerned to 
fulfil the obligations specified in Article 51. 
In  so  far  as  certain  diplomas,  certificates  or other evidence  of formal  qualifications 
mentioned in the first subparagraph do not fi1dfil the criteria laid down in this paragraph, 
the competent authority of the  Member State  shall  ensure that the  person  concerned 
provides evidence of  adequate knowledge ofthe subjects involved. 
3. The qualified person shall have acquired practical experience over at least two years, 
in one or more undertakings which are author:ized to manufacture medicinal products, in 
the  activities of qualitative analysis of medicinal  products, of quantitative analysis of 
active  substances  and of the  testing  and  checking necessary  to  ensure  the  quality  of 
medicinal products. 
The duration of practical experience may be reduced by one year where a  university 
course lasts for at least five years and by a year and a half where the course lasts for at 
least six years. 
47 Article SO 
I. A person engaging in  the activities of the person referred to  in  Article 48 from  the  75/319/EEC 
time of the application of Directive 75/319/EEC, in a Member State without complying  Art. 24 
with the provisions of  Article 49 shall be eligible to continue to engage in those activities  (adapted) 
in the State concerned.  · 
2.  The  holder  of a  diploma,  certificate  or  other  evidence  of formal  qualifications 
awarded on completion of  a university course - or a course recognized as equivalent by 
the Member State concerned - in  a scientific discipline allowing him to  engage in  the 
activities of  the person referred to in Article 48 in accordance with the laws of  that 'State 
may - if he began his course prior to 21  May  1975 - be considered as  qualified to carry 
out in  that State the duties of the person referred to  in  .Artic_le  48  provided that he has 
previously engaged in the following activities for at least two years before 21  May  1985 
following  notification  of this  directive  in  one  or  more  undertakings  authorized  to 
manufacture:  production  supervision  and/or  qualitative  and  quantitative  analysis  of 
acti~e substances, and the necessary testing and checking under the direct authority of 
the person referred to in Article 48 to ensure the quality of  the medicinal products. 
If the  person concerned has  acquired the  practical  experience  referred  to  in  the  first 
subparagraph  before  21  May  1965,  a  further  one  year's  practical  experience  in 
accordance with the conditions referred to in the first subparagraph will be required to be 
completed immediately before he engages in such activities. 
48 ·Article 51 
I. Member States shall take all appropriate measures to ensure that  the qualified person 
referred to  in  Article  48,  without prejudice to his  relationship with  the  holder of the 
manufacturing authorization, is responsible, in the context of  the procedures referred to 
in Article 52, for securing: 
(a)  in  the  case  of  medicinal  products  manufactured  within  the  Member  States 
concerned,  that  each  batch  of medicinal  products  has  been  manufactured  and 
checked  in  compliance  with  the  Jaws  in  force  in  that  Member  State  and  in 
accordance with the requirements of  the marketing authorization; 
(b)  in the case of medicinal products coming from  third countries, that each production 
batch has undergone in  the  importing Member State a full  qualitative analysis,  a 
quantitative analysis of at least all  the active constituents and all  the other tests or 
checks necessary to ensure the quality of  medicinal products in accordance with the 
requirements of  the marketing authorization. 
The batches of medicinal products which have  undergone such  controls in  a Member 
State shall be exempt from  the controls if they are marketed in another Member State, 
accompanied by the control reports signed by the qualified person. 
75/319/EEC 
Art. 22 (I), 1st and 2nd 
subparagraphs 
(adapted) 
2.  In the case of medicinal products imported from  a third country, where appropriate  75/319/EEC 
arrangements have been made by the Community with the exporting country to ensure  Art. 22 (I), 3rd 
that the manufacturer of  the medicinal product applies standards of  good manufacturing  subparagraph 
practice at least equivalent to those laid down by the Community, and to ensure that the  (as amended by 
controls referred to under point (b) of the first subparagraph of paragraph  1 have been  93/39/EEC Art. 3 (2)) 
carried  out· in  the  exporting  country,  the  qualified  person  may  be  relieved  of 
responsibility for carrying out those controls.  · 
3.  In all cases and particularly where the medicinal products are released for sale, the  75/319/EEC 
qualified  person  must certify  in' a  register or equivalent document  provided  for  that  Art. 22 (2) 
purpose,  that  each  production  batch  satisfies  the  provisions  of this  Article;  the  said  (adapted) 
register or equivalent document must be kept up to date as operations are carried out and· 
must remain  at  the  disposal  of the  agents  of the  competent authority  for  the  period 
specified in the provisions of the Member State concerned and in any event for at least 
five years. 
Article 52 
Member States shall ensure that the duties of qualified persons referred to  in Article 48  75/319/EEC 
are fulfilled, either by means of appropriate administrative measures or by making such  Art. 25 
persons subject to a professional code of conduct. 
Member States may provide for the temporary suspension of such a person  upon  the 
commencement of administrative or disciplinary procedures against him  for  failure  to 
fulfil his obligations. 
Article 53 
The provisions of  this Title shall apply to homeopathic medicinal products. 
49 
92173/EEC 
Art. 3 
(adapted) (4) 
TITLEV 
LABELLING AND PACKAGE LEAFLET 
Article 54 
The following particulars shall appear on the outer packaging of medicinal products or, 
where there is no outer packaging, on the immediate packaging: 
(a)  the name of  the medicinal product followed by the common name where the product 
contains  only  one  active  substance  and  if its  name  is  a  brand  name;  where  a 
medicinal  product  is  available  in  several  phiU11laceutical  forms  and/or  several 
strengths,  the  pharmaceutical  form  and/or  the  strength  (baby,  child  or  adult  as 
appropriate) must be included in the name of  the medicinal product; 
(b)  a statement of the active substances expressed qualitatively and quantitatively per 
dosage Uilit or according to the form of  administration for a given volume or weight, 
using their common names; 
(c)  the pharmaceutical form  ~d  the contents by weight,  by volume or by number of 
doses of  the product; 
(d)  a list of  those excipients known to have a recognized action or effect and included in 
the  guidelines  published  pursuant  to  Article  65.  However,  if the  product·  is 
injectable, or a topical or eye preparation, all excipients must be stated; 
(e)  the method and, if  necessary, the route of  administration; 
(t)  a special warning that the medicinal product must be stored out of  reach of  children; 
(g)  a spedal warning, if  this is necessary for the medicinal product; 
(h)  the expiry date in clear terms (month/year); 
(i)  special storage precautions, if  any; 
G)  special precautions for disposal of unused medicinal products  or waste  materials 
· from medicinal prQducts, if  appropriate; 
(k)  the name and address of the holder of the authorization for placing the medicinal 
product on the market; 
(I)  the number of  the authorization for placing the medicinal product on the market; 
(m) the manufacturer's batch number; 
(n)  in the case of  self-medication, instructions on the use ofthe medicinal products. 
50 
92/27/EEC 
Art. 2 (I), points (a) to 
(n) 
(adapted) Article 55 
I. The particulars laid down in Articles 54 and 62 shall appear on immediate packagings  92/27/EEC 
other than those referred to in paragraphs 2 and 3.  Art. 3 
2.  The following particulars at least shall appear on immediate packagings ·which take 
the form of blister packs and are placed in an outer packaging that complies with the 
requirements laid down in Articles 54 and 62. 
the name of  the medicinal product as laid down in Article 54 (a), 
·the name of  the holder of  the authorization for placing the product on the market, 
the expiry date, 
the batch number. 
3. The following particulars at least shall appear on small immediate packaging units on 
which the particulars laid down in Articles 54 and 62 cannot be displayed: 
the name of the medicinal product and,  if necessary, the strength and the route of 
administration, 
the method of  administration, 
the expiry date, 
the batch number, 
the contents by weight, by volume or by unit. 
Article 56 
The particulars  referr~d to  in  Articles  54,  55  and  62  shall  be  easily  legible,  clearly 192127/EEC 
comprehensible and indelible.  ·  Art. 4 (I) 
Article 57 
Notwithstanding Article  60,  Member States may require the  use  of certain  forms  of  92/27/EEC 
labelling of  the medicinal product making it possible to ascertain:  Art. 5 (2) 
(adapted) 
the price of  the medicinal product, 
the reimbursement conditions of  social security organizations, 
the legal status for supply to the patient, in accordance with Titl~ VI, 
identification and authenticity. 
51 Article 58 
The inclusion in the packaging of all medicinal products of a package leaflet shall be 
obligatory unless all the infonnation required by Articles 59 and 62 is directly conveyed 
on the outer packaging or on the. immediate packaging 
Article 59 
92/27/EEC 
Art. 6 
(adapted) 
l. The package leaflet shall be drawn up in accordance with the summary of  the product  92/27/EEC 
characteri~tics; it shall include, in the following order:  Art. 7 (1) 
(adapted) 
(a)  for the identification of  the medicinal product: 
the  name  of the  medicinal  product,  followed  by  the  common  name  if the 
product contains only one active  substance and  if its  name  is  a brand  name; 
where a medicinal product is available in several phannaceutical fonns and/or 
several  strengths,  the  phannaceutical fonn  and/or  the  strength  (for exaniple, 
baby, child, adult) must be included in the name of  the medicinal product, 
a full  statement of the active substance and excipitmts expressed qualitatively 
and a  statement of the  active  substance  expressed  quantitatively,  using  their 
common names, in the case of  each presentation of  the medicinal product, 
the phannaceutical fonn and the contents by weight, by volume or by number of 
doses of  the product, in the case of  each presentation of  the product, 
the  phannaco-therapeutic  group,  or  type  of  activity  in  tenns  easily 
comprehensible for the patient, 
the  name  and  address  of the  holder  of the  authorization  for  placing  the 
medicinal product on the market and of  the manufacturer; 
(b)  the therapeutic indications; 
52 .. 
(c)  a list of  information which is necessary before taking the medicinal product: 
- contra-indications, 
- appropriate precautions for use, 
- forms  of interaction  with  other  medicinal  products  and  other  forms  of 
interaction (for example, alcohol,  tobacco,  foodstuffs)  which  may affect the 
action ofthe medicinal product, 
- special warnings; 
this list must: 
- take  into  account  the  particular  condition  of certain  categories  of users 
(e.g. children,  pregnant  or bre.astfeeding  women,  the  elderly,  persons  with 
specific pathological conditions), 
- mention, if appropriate, potential effects on the ability to drive vehicles or to 
·  operate machinery, 
detail  those  excipients,  knowledge  of which  is  important  for  the  safe  and 
effective use of  the medicinal product and included in the guidelines published 
pursuant to Article 65; 
(d)  the necessary and usual instructions for proper use, in particular: 
- the dosage, 
- the method and, if  necessary, route of  administration, 
- the frequency of  administration, specifying if  necessary, the appropriate time at 
which the medicinal product may or must be administered, 
and, as appropriate, depending on the nature of  the product: 
- the duration of  treatment, where it should be limited, 
- the action to be taken in the case of an overdose (e.g., symptoms, emergency 
procedures), 
•- the course of  action to take when one or more doses have not been taken, 
- indication, if  necessary, of  the risk of  withdrawal effects; 
53 
92127/EEC 
Art. 7 (I) 
(adapted) (e)  a description of the undesirable effects which can occur under normal use of the  . 92127/EEC 
medicinal product and, if necessary, the action  to be taken  in  such a  case;  the  Art. 7 (1) 
patient should be expressly invited to communicate any undesirable effect which is  (adapted) 
not mentioned in the leaflet to his doctor or to his pharmacist; 
(f)  a reference to the expiry date indicated on the label, with: 
- a warning again~t using the product after this date, 
- where appropriate, special storage precautions, 
- if  necessary, a warning against certain visible signs of  deterioration; 
(g)  the date on which the package leaflet was last revised. 
2. Notwithstanding paragraph  1 (b), the authority  competent may decide that certain  92127/EEC 
therapeutic  indications  shall  not  be  mentioned  in  the  package  leaflet,  where  the  Art. 7 (2) 
dissemination of  such information might have serious disadvantages for the patient.  (adapted) 
Article 60 
Member States may not prohibit or impede the placing on the  market of medicinal 
products within their territory on grounds connected with labelling or the package leaflet 
where these comply with the requirements of  this Title. 
Article 61 
92127/EEC 
Art. 5 (1) and Art. 9 
(adapted) 
l. One or more specimens or mock-ups  of the outer packaging  and  the  immediate  92127/EEC 
packaging of a  medicinal  product,  together  with  the  draft package  leaflet,  shan  be  Art. 10 (1) to (4) 
submitted to the authorities competent for authorizing marketing when the marketing  (adapted) 
authorization is requested. 
2. The competent authority shall refuse the marketing authorization if  the labelling or the 
package leaflet do riot comply with the provisions of this Title or if they are.  not in 
accordance with the particulars listed in the summary of  product characteristics. 
3. All proposed changes to an aspect of the labelling or the package leaflet covered by 
this  Title  and  not  connected  with  the  summary  of product  characteristics  shan· be 
submitted to the  authorities  competent  for  authorizing  marketing.  If the  competent 
authorities  have  not  opposed  a · proposed  change  within  90  days  following  the 
introduction of  the request, the applicant may put the change into effect. 
4. The fact that the competent authority do not refuse a marketing authorization pursuant 
to paragraph 2 or a change to the labelling or the package leaflet pursuant to paragraph 3 
does  not  alter  the  general  legal  liability  of the  manufacturer or as  appropriate  the 
marketing authorization holder. 
54 Article 62 
The  outer  packaging  and  the  package  leaflet  may  include  symbols .  or pictograms 
designed to clarify certain information mentioned in  Articles 54 and 59 (1) and other 
information compatible with the summary of the product characteristics which is useful 
for health education, to the exclusion of  any element of  a promotional nature. 
Article 63 
92127/EEC 
Art. 2 (2) and 
Art. 7 (3) 
(adapted) 
I. The particulars for labelling listed in Articles 54, 59 and 62 shall appear in the official  92127/EEC 
language or languages of  the Member State where the product is placed on the market.  Art. 4 (2) 
(adapted) 
The first subparagraph shall not prevent these particulars from being indicated in several 
languages, provided that the same particulars appear in all the languages used. 
2. The package leaflet must be written in  clear and understandable terms for the users  92/27/EEC 
and be clearly legible in the official language or languages of the Member State where  Art. 8 
the medicinal product is placed on the market.  (adapted) 
The frrst  subparagraph  shall  not prevent the  package leaflet being printed in  several 
languages, provided that the same information is given in all the languages used. 
3.  The  competent  authorities  may  exempt  labels  and  package  leaflets  for  specific  92127/EEC 
medicinal products from the obligation that c~rtain particulars shall appear and that the  Art. IO (5) 
leaflet must be  in  the official language or languages of the  Member State where the 
product is placed on the market,· when the product is not intended to be delivered to the 
patient for self-administration. 
Article 64 
Where the provisions of this Title are not complied with, and a notice served on the  92/27/EEC 
person  concerned  has  remained  without  effect,  the  competent  authorities  of the  Art. II (I) 
Member States  may suspend  the  marketing authorization,  until  the  labelling  and  the  (adapted) 
package leaflet of  the medicinal product in question have been made to comply with the 
requirements of  this Title. 
Article 65 
As necessary, the Commission shall publish guidelines concerning in particular:  92127/EEC 
Art. 12 
the  formulation  of certain  special  warnings  for  certain  categories  of medicinal  (adapted) 
products, 
the particular information needs relating to self-medication, 
the legibility of  particulars on the labelling and package leaflet, 
methods for the identification and authentication of  medicinal products, 
the list of  excipients which must feature on the labelling of  medicinal products and 
the way these excipients must be indicated. 
These guidelines shall be adopted in  the  form  of a Directive,  in  accordance with the 
procedure laid down in Article 122. 
55 .1. The outer packaging and the container of  medicinal products containing radionuclides  89/343/EEC 
shall be labelled in accordance with the regulations for the safe transport of radioactive  Art. 5 
materials laid down by the International Atomic Energy Agency. Moreover, the labelling  (adapted) 
shall comply with the provisions set out in paragraphs 2 and 3. 
2.  Ute label on the shielding shall include the particulars mentioned in Article 54. In 
addition, the labelling on the shielding shall explain in full, the codings used on the vial 
and  shall  indicate,  where  necessary,  for  a  given  time  and  date,  the  amount  of 
radioactivity per dose or per vial and the number of  capsules, or, for liquids, the number 
of  millilitres in the container; 
3. The vial shall be labelled with the following information: 
the name or code of  the medicinal product, including the name or chemical symbol 
of  the radionuclide, 
the batch identification and expiry date, 
the international symbol for radioactivity, 
the name of  the manufacturer, 
the amount of  radioactivity as specified in paragraph 2. 
Article 67 
The competent authority shall ensure that a detailed instruction leaflet is enclosed with  89/343/EEC 
the  packaging of radiopharmaeeuticals,  radionuclide  generators,  radionuclide  kits  or  Art. 6 (1) 
radionuclide precursors. The text of this leaflet shall be established in accordance with  (adapted) 
the provisions of Article 59. In addition, the leaflet shall include any precautions to  be 
taken  by  the  user  and  the  patient  during  the  preparation  and  administration  of the 
medicinal  product and  special  precautions  for  the  disposal  of the  packaging  and  its 
unused contents. 
56 Article 68 
The homeopathic medicinal products shall be identified by a reference on their labels, in  92/73/EEC 
clear and legible fonn, to their homeopathic nature.  ·Art. 2 (2) 
(adapted)  . 
Article 69 
1.  In addition to the clear mention of the words "homeopathic medicinal product", the  92/73/EEC 
labelling and, where appropriate, the package insert for the medicinal products referred  Art. 7 (2) and (3) 
to in Article 14 (1} shall bear the following, and no other, infonnation:  (adapted) 
the scientific name of  the stock or stocks followed by the degree of  dilution, making 
use of  the symbols of  the phannacopoeia used in accordance with Article I (5), 
name  and  address  of the  registration  holder  and,  where  appropriate, . of the 
manufacturer, 
method of  administration and, if  necessary, route, 
expiry date, in clear tenns (month, year), 
phannaceutical fonn, 
contents of  the sales presentation, 
special storage precautions, if  any, 
a special warning if  necessary for the medicinal product, 
manufacturer's batch number, 
registration number, 
"homeopathic medicinal product without approved therapeutic indications", 
a warning advising the user to consult a doctor if the symptoms persist during the 
use of  the medicinal product. 
2. Notwithstanding paragraph 1, Member States may require the use of  certain types of 
labelling in order to show: 
the pri~  of  the medicinal product, 
the conditions for refunds by social security bodies. 
51 TITLE VI 
CLASSIFICATION OF MEDICINAL PRODUCTS 
Article 70 
1. When a marketing authorization is granted, the competent authorities shall specify the  92/26/EEC 
classification of  the medicinal product into:  Art. 2 
a medicinal product subject to medical prescription, 
a medicinal product not subject to medical prescription. 
To this end, the criteria laid down in Article 71 (I) shall apply. 
2. The competent authorities may fiX  sub-categories for medicinal products which are 
available on medical prescription  only.  In  that case,  they shall refer to the  following 
classification: 
(a)  medicinal products on renewable or non-renewable medical prescription; 
(b)  medicinal products subject to special medical prescription; 
(c)  medicinal products on restricted medical prescription, reserved  for  use  in  certain 
specialized areas. 
Article 71 
1. Medicinal products shall be subject to medical prescription where they:  92/26/EEC 
Art. 3 
are likely to present a danger either directly or indirectly, even when used correctly,  (adapted) 
if  utilized without medical supervision, or 
are frequently and to a very wide extent used incorrectly, and !lS a result are likely to 
present a direct or indirect danger to human health, or 
contain substances or preparations thereof, the activity and/or adverse reactions of 
which require further investigation, or 
are normally prescribed by a doctor to be administered parenterally. 
58 2.  Where Member States provide for the sub-category of medicinal products subject to  92/26/EEC 
special medical prescription, they shall take account of  the following factors:  Art. 3 
(adapted) 
the medicinal product contains, in a non-exempt quantity, a substance .classified as a 
narcotic  or  a  psychotropic  substance  within  the  meaning  of the  international 
conventions in force, such as the United Nations Conventions of  1961 and 1971, or 
the medicinal product is  likely, if incorrectly used, to present a substantial risk of 
medicinal abuse, to lead to addiction or be misused for illegal purposes, or 
the  medicinal  product  contains  a  substance  which,  by  reason  of its  novelty  or 
properties, could be considered as belonging to the group envisaged in  the second 
indent as a precautionary measure. 
3.  Where Member States provide for the sub-category of medicinal products subject to 
restricted prescription, they shall take account of  the following factors: 
the medicinal product, because of its pharmaceutical characteristics or novelty or in 
the interests of public health, is reserved for treatments which can only be followed 
in a hospital environment,  · 
the  medicinal  product  is  used  in  the  treatment  of conditions  which ·must  be 
diagnosed  in  a  hospital  environment  or in  institutions  with  adequate  diagnostic 
facilities, although administration and follow-up may be carried out elsewhere, or 
the  medicinal  product  is  intended  for  outpatients  but  its  use  may  produce  very 
serious  adverse  reactions  requiring  a  prescription  drawn  up  as  required  by  a 
specialist and special supervision throughout the treatment. 
4. A competent authority may waive applic:ation of  paragraphs I, 2 and 3 having regard 
to: 
(a)  the maximum single dose, the maximum daily dose, the strength, the pharmaceutical 
form, certain types of  packaging; and/or 
(b)  other circumstances of  use which it has specified. 
5.  If a competent authority does not designate medicinal products into sub-categories 
referred to in Article 70 (2), it shall nevertheless take into account the criteria referred to 
in paragraphs 2 and 3 of  this Article in determining whether any  medicinal product shall 
be classified as a prescription-only medicine. 
59 Article 72 
Medicinal  produc~ not subject to  prescription shall be  those  which  do  not meet the  192/26/EEC 
criteria listed in Article 71.  _  Art. 4 
·  Article 73 
The competent authorities shall draw up a list of  the medicinal products subject, on their  92/26/EEC 
territory, to medical prescription, specifying, if necessary, the category of classification.  Art. 5 (I) 
They shall update this list annually. 
Article 74 
On the occasion of  the five-yearly renewal of  the marketing authorization or when new  92/26/EEC 
facts  are  brought  to  their  notice,  the  competent  authorities  shall  examine  and,  as  Art. 5 (2) 
appropriate,  amend the classification of a medicinal product,  by  applying  the  criteria 
listed in Article 71. 
Article 75 
' 
Each  year,. Member  States  shall  communicate  to  the  Commission  and to  the  other 192/26/EEC 
Member States, the changes that have been made to the list referred to in Article 73.  Art. 6 (2) 
60 TITLE VII 
WHOLESALE DISTRIBUTION OF 
MEDICINAL PRODUCTS 
Article 76 
.Without prejudice to Article 6, Member States shall take all appropriate action to ensure  92/25/EEC 
that  only medicinal  products  in  respect of which  a marketing authorization  has  been  Art. 2 
granted in accordance with Community law are distributed on their territory. 
· Article 77 
I.  Member  States  shall  take  all  appropriate  measures  to  ensure  that  the  wholesale  92/25/EEC 
distribution of medicinal  products  is  subject to  the  possession of an  authorization  ~o  Art. 3 
engage in activity as a wholesaler in medicinal products, stating the place for which itis  (adapted) 
valid. 
2.  Where persons entitled to  supply medicinal products to the  public may also, under 
national. law,  engage  in  wholesale  business,  such  persons  shall  be  subject  to  the 
authorization provided for in paragraph I. 
3.  Possession of a manufacturing authorization shall include authorization to distribute 
by wholesale the  medicinal  products covered  by  that authorization.  Possession of an 
authorization to engage in activity as a wholesaler in medicinal products shall not giv.e 
dispensation from the obligation to possess a manufacturing authorization and to comply 
with  the  conditions  set  out  in  that  respect,  even  where  the  manufacturing  or import 
business is secondary. 
4. At the request of the Commission or any Member State, Member States shall supply 
all  appropriate  information  concerning  the  individual  authorizations which  they  have 
granted under paragraph I. 
5. Checks on the persons authorized to engage in the activity of  wholesaler in medicinal 
products  and  the  inspection  of  their  premises,  shall  be  carried  out  under  the 
responsibility of  the Member State which granted the authorization. 
6.  The Member State which granted the authorization referred to in  paragraph  I  shall 
suspend or revoke that authorization if  the conditions of  authorization cease to be met. It 
shall forthwith inform the other Member States and the Commission thereof. 
7.  Should a Member State consider that, in respect of  a person holding an authorization 
granted by another  Member State  under the  terms of paragraph  I, the  conditions of 
authorization are not, or are no longer met, it shall forthwith  inf~rm the Commission and 
the other Member State involved. The latter shall take the measures necessary and shall 
inform  the  Commission  and  the  first  Member  State  of the  decisions  taken  and  the 
reasons for those decisions. 
61 Article 78 
Member States shall ensure that the  time  taken  for  the  procedure for  examining the  92/25/EEC 
application for the distribution authorization does not exceed 90 days from the day on  Art. 4 (I) 
which the comj,etent authority of  the Member State <;oncerned receives the application.  (adapted) 
The competent authority may,' if need be, require the applicant to supply all  necessary 
infonnation concerning the conditions of authorization.  Where the authority exercises 
this option, the period laid down  in  the  first ·paragraph  shall  be  suspended until  the 
requisite additional data have been supplied. 
Article 79 
In  order to obtain the distribution  authorization,  applicants  must  fulfil  the  following 
minimum requirements: 
(a)  they must have suitable and adequate premises, installations and equipment, so as to 
ensure proper conservation and distribution of  the medicinal products; 
(b)  they must have staff, and in particular, a qualified person designated as responsible, 
meeting  the  conditions  provided  for ,  by  the  legislation  of· the  Member  State 
concerned; 
(c)  they must undertake to fulfil the obligations incumbent on them under the terms of 
Article 80. 
Article 80 
Holders  of  the  distribution  authorization  must  fulfil  the · following  minimum 
requireptents: · 
(a)  they  must  make  the  premises,  installations  and  equipment  referred  to  in 
Article 79 (a) acc.essible at all times to the persons responsible for inspecting them; 
(b)  they must obtain their supplies of medicinal products only from  persons who are 
themselves in possession of the distribution authorization or who are exempt from 
obtaining such authorization under the terms of  Article 77 (3); 
(c)  they  must  supply  medicinal  products  only  to  persons  who  are  themselves  in 
possession of the  distribution  authorization  or who are  authorized  or entitled  to 
supply medicinal products to the public in the Member State concerned; 
(d)  they must have an emergency plan which ensures effective implementation of any 
recall  from  the  market  ordered  by  the  competent  authorities  or carried  out  in 
cooperation  with  the  manufacturer  or  marketing  authorization  holder  for  the 
medicinal product concerned; 
62 
92/25/EEC 
Art. 5 
(adapted) 
92/25/EEC 
Art. 6 
(adapted) (e)  they  must  keep  records  either  in  the  form  of purchase/sales  invoices,  or  on 
computer, or in  any other form,  giving for any transaction  in  medicinal  products 
received or dispatched at least the following information: 
date, 
name of  the medicinal product, 
quantity received or supplied, 
name and address of  the supplier or consignee, as appropriate; 
(t)  they  must  keep  the  records  referred  to  under  (e)  available  to  .the  competent 
authorities, for inspection purposes, for a period of  five years; 
(g)  they must comply with the principles and guidelines of  good distribution practice for 
medicinal products, as laid down in Article 84. 
Article 81 
92/25/EEC 
Art  .. 6 
(adapted) 
With regard to the supply of medicinal products to pharmacists and persons authorized  92/25/EEC 
or entitled to supply medicinal prodUcts to the public, Member States shall not impose  Art. 7 
upon  the  holder of a  distribution  authorization  which  has  been  granted  by ·another  (adapted) 
Member State, any obligation, in  particular public service obligations,  more stringent 
than those they impose on persons whom they have themselves authorized to engage in 
equivalent activities. 
The said obligations  should,  moreover,  be justified,  in  keeping  with  the  Treaty,  on 
grounds of public health protection and be proportionate in relation to the objective of 
such protection. 
Article 82 
For all  supplies  of medicinal  products  to  a  person  authorized  or entitled  to  supply  92/25/EEC 
medicinal  products  to  the  public  in  the  Member  State  concerned,  the  authorized  Art. 8 
wholesaler must enclose a document that makes it possible to ascertain: 
the date, 
the name and pharmaceutical form of  the medicinal product, 
the quantity supplied,. 
the name and address of  the supplier and consignor. 
Member States shall take all appropriate measures to ensure that persons authorized or 
entitled to supply medicinal products to the public are able to provide information that 
makes it possible to trace the distribution path of  every medicinal product. 
63 Article 83 
The  provisions  of this  Title  shall  not  prevent  the  application  of more  stringent  92/25/EEC 
requirements laid down by Member States in respect of  the wholesale distribution of:  Art. 9 
(adapted) 
narcotic or psychotropic substances within their territory, 
medicinal products derived from blood, 
immunological medicinal products, 
radiopharmaceuticals. 
Article 84 
The Commission shall publish guidelines on good distribution practice. To this end,  it  92/25/EEC 
shall consult the Committee for Proprietary Medicinal Products and the Pharmaceutical  Art. 1  0 
Committee established by Council Decision 751320/EECl.  (adapted) 
Article 85 
Member States shall,· in  special  cases,  authorize  the  direct  distribution  of medicinal  92/28/EEC 
products to the public, by the industry for promotional purposes.  Art. 3 (  6), 2nd sentence 
(adapted) 
OJ L 147, 9.6.197S, p. 23. 
64 TITLE VIII 
ADVERTISING 
Article 86 
1.  For the purposes of this Title, "advertising of medicinal products" shall include any  92/28/EEC 
form  of door-to-door  information,  canvassing  activity  or  inducement  designed  to  Art. I (3) and (4) 
promote the prescription, supply,  sale  or consumption of medicinal  products;  it  shall 
include in particular: 
the advertising of  medicinal products to the general public, 
advertising of  medicinal products to persons qualified to prescribe or supply them, 
visits by medical sales representatives to persons qualified to  prescribe medicinal 
products, 
the supply of  samples, 
the provision of inducements to prescribe or supply medicinal products by the gift, 
offer or promise of  any benefit or bonus, whether in money or in kind, except when 
their intrinsic value fs minimal, 
sponsorship of promotional meetings attended by persons qualified to prescribe or 
supply medicinal products, 
sponsorship of scientific congresses attended by persons  qualified to prescribe  or 
supply  medicinal  products  and  in  particular  payment  of their  travelling  and 
accommodation expenses in connection therewith. 
2. The following are not covered by this Title: 
the  labelling  and  the  accompanying  package  leaflets,  which  are  subject  to  the 
provisions of  Title V; 
correspondence,  possibly  accompanied  by  material  of a  non-promotional  nature, 
needed to answer a specific question about a particular medicinal product; 
factual, informative announcements and reference material relating, for example, to 
pack changes, adverse-reaction warnings as part of general drug precautions, trade 
catalogues and price lists, provided they include no product claims; 
statements relating to human health or diseases, provided there is no reference, even 
indirect, to medicinal products. 
65 (S) 
Article 87 
I. Member States shall prohibit any  advertising of a medicinal  product  in  respect of  92/28/EEC 
which" a marketing authorization has not been granted in  accordance with  Community  Art. 2 
law. 
2. All parts of the advertising of a medicinal product must comply with the particulars 
listed in the summary of  product characteristics. 
3.  The advertising of  a medicinal product: 
shall  encourage  the  rational  use  of the  medicinal  product,  by  presenting  it 
objectively and without exaggerating its properties, 
shall not be misleading. 
Article 88 
1.  Member  States  shall  prohibit  the  advertising  to  the  general  public  of medicinal  92/28/EEC 
products which:  Art. 3 (l) to (6), 1st 
are available on medical prescription only, in accordance with Title VI, 
contain psychotropic or narcotic substances, such as the United Nations Conventions 
of 1961 and 1971,  · 
may  not  be  advertised  to  the  general  public  in  accordance  with  the  second 
subparagraph of  paragraph 2. 
2. Medicinal products may be advertised to the general public which, by virtue of  their 
composition and purpose, are intended and designed for use without the inver¥ention of 
a medical practitioner for diagnostic purposes or for the prescription or  monitoring of 
treatment, with the advice of  the pharmacist, if  necessary. 
Member  States  shall  prohibit the  mentioning  in  advertising  to  the  general  public of 
therapeutic indications such as: 
tuberculosis, 
sexually transmitted diseases, 
other serious infectious diseases, 
cancer and other tumoral diseases, 
chronic insomnia, 
diabetes and other metabolic illnesses. 
66 
sentence 
(adapted) 3. Member States shall be able to ban, on their territory, advertising to the general public  92/28/EEC 
of  medicinal products the cost of  which may be reimbursed.  Art. 3 (I) to (6) 
1st sentence 
4.  The prohibition referred to in  paragraph  1 shall not apply to vaccination campaigns  (adapted) 
carried out by the industry and approved by the competent authorities of the Member 
States. 
5. The prohibition referred to in paragraph 1 shall apply without prejudice to Article 14 
of  Directive 89/552/EEC. 
6. Member States shall prohibit the direct distribution of  medicinal products to the public 
by the industry for promotional purposes. 
Article 89 
(b)  include the following minimum information: 
the  name  of the  medicinal  product,  as  well  as  the  common  name  if the 
medicinal product contains only one active substance, 
the information necessary for correct use of  the medicinal product, 
an express, legible invitation to read carefully the  instructions on the package 
leafle~ or on the outer packaging, as the case may be. 
2. Member States may decide that the advertising of  a medicinal product to the general 
public  may,  notwithstanding  paragraph  1,  include  only  the  name  of the  medicinal 
product if  it is intended solely as a reminder. 
67 Article 90 
The advertising of a  medicinal  product to  the  general  public  shall  not  contain  any  92/28/EEC 
material which:  Art. 5 
(adapted) 
(a)  gives  the  impression  that  a  medical  consultation  or  surgical  operation  is 
unnecessary,  in  particular by  offering a  diagnosis  or by  suggesting  treatment  by 
mail; 
(b)  suggests that the effects of taking the medicine are guaranteed, are unaccompanied 
by adverse reactions or are better than, or equivalent to, those of another treatment 
or medicinal product; 
(c)  suggests that the health of  the subject can be enhanced by taking the medicine; 
(d) suggests that the health of  the subject could be affected by not taking the medicine; 
this  prohibition  shall  not  apply  to  the  vaccination  campaigns  referred  to  in 
Article 88 (4); 
(e)  is directed exclusively or principally at children; 
(f)  refers to a recommendation by scientists, health professionals or persons who are 
neither of the foregoing but who,  because of their celebrity, could encourage the 
consumption of  medicinal products; 
(g)  suggests  that  the  medicinal  product  is  a  foodstuff,  cosmetic  or other consumer 
product; 
(h)  suggests that the safety or efficacy of  the medicinal product is due to the fact that it 
is natural; 
(i)  could, by a description or detailed representation of  a case history, lead to erroneous 
self-diagnosis; 
G)  refers, in improper, alarming or misleading terms, to claims of recovery; 
(k)  uses, in improper, alarming or misleading terms, pictorial representations of  changes 
in  the human  body caused by disease  or injury,  or of the action  of a  medicinal 
· product on the human body or parts thereof;  · 
(I)  mentions that the medicinal product has been granted a marketing authorization. 
68 Article 91 
I. Any advertising of a  medicinal product to persons qualified to  prescribe or supply  92/28/EEC 
such products shall include:  Art. 6 
essential infonnation compatible with the summary of  product characteristics; 
the supply classification of  the medicinal product. 
Member  States  may  also  require  such  advertising  to  include  the  selling  price  or 
indicative price of the various presentations and the conditions for reimbursement by 
social security bodies. 
2.  Member States may decide that the advertising of a  medicinal  product to  persons 
qualified to prescribe or supply such products may, notwithstanding paragraph I, include 
only the name of  the medicinal product, if  it is intended solely as a reminder. 
Article 92 
.1. Any documentation relating to a medicinal product which is transmitted as part of  the  92/28/EEC 
promotion of  that product to persons qualified to prescribe or supply it shall include, as a  Art. 7 
minimum, the particulars listed in Article 91  (1) and shall state the date on which it was 
drawn up or last revised. 
2. All the infonnation contained in the documentation referred to in paragraph I shall be 
accurate, up-tO-date, verifiable and sufficiently complete to enable the recipient to fonn 
his or her own opinion of  the therapeutic value of  the medicinal  product concerned. 
3. Quotations as well as tables and other illustrative matter taken from medical journals 
or other scientific works for use in the documentation referred to in paragraph I shall be 
faithfully reproduced and the precise sources indicated. 
69 Article 93 
1.  Medical .  sales  representatives  shall  be  given  adequate  training  by  the  firm  which  92/28/EEC 
employs  them  and shall  have  sufficient  scientific  knowledge  to  be  able  to  provide  Art. 8 
information which is precise and as complete as possible about the medicinal products 
which they promote. 
2. During each visit, medical sales representatives shall give the person's visited, or have 
available for theni, summaries of the product characteristics of  each medicinal product 
they present together, if the legislation of the Member State so permits, with details of 
the price and conditions for reimbursement referred to in Article 91  (I). 
3.  Medical sales representatives  shall  transmit to  the scientific  service  referred  to  in 
Article 98 (I) any information about the use of the medicinal products they advertise, 
with particular reference to any adverse reactions reported to them by the persons they 
visit. 
Article 94 
1.  Where tnedicinal products are being promoted to  persons qualified  to  prescribe or  92128/EEC 
supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered  Art. 9 
or promised to such persons unless they are inexpensive and relevant to the practice of  (adapted) 
medicine or pharmacy. 
2. Hospitality at sales promotion shall always be rea5onable in level and secondary to the 
main  purpose  of the  meeting  and  must  not  be  extended  to  other  than  health 
professionals. 
3. Persons qualified to prescribe or supply medicinal products shall not solicit or accept 
any inducement prohibited under paragraph 1 or contrary to paragraph 2. 
4. Existing measures or trade practices in Member States relating to prices, margins and 
discounts shall not be affected by paragraphs 1, 2 and 3. 
Article 95 
. The provisions of Article 94 (I) shall not prevent hospitality being offered, directly or  92/28/EEC 
indirectly, at events for purely professional and scientific purposes; such hospitality shall  Art. 10 
always be reasonable in level and remain subordinate to the main scientific objective of 
the meeting; it must not be extended to persons other than health professionals. 
70 Article 96 
I. Free samples shall be provided on  an  exceptional basis only to  persons qualified to  92/28/EEC 
prescribe them and on the following conditions:  Art. II 
(adapted) 
(a)  the number of samples for each medicinal product each year on  prescription shall 
be limited; 
(b)  any supply of samples shall be  in  response to  a written request, signed and dated, 
from the prescribing agent;  · 
(c)  those  supplying  samples  shall  maintain  an  adequate  system  of control  and 
accountability; 
(d)  each sample shall be identical with the smallest presentation on the market; 
(e)  each sample shall be marked "free medical sample- not for sale" or shall show some 
other wording having the same meaning; 
(f)  each  sample  shall  be  accompanied  by  a  copy  of the  summary  of product 
characteristics; 
(g)  no  samples of  medicinal  products  containing psychotropic  or narcotic  substances 
within  the  meaning  of international  conventions,  such  as  the  United  Nations 
Conventions of 1961 and 1971, may be supplied. 
2.  Member States may also place further restrictions on the distribution of samples of 
certain medicinal products. 
Article 97 
1. Member States shall ensure that there are adequate and effective methods to monitor  92/28/EEC 
the advertising of medicinal products. Such methods, which may be based on a system  Art. 12 (1 ) and (2) 
of prior vetting,  shall  in  any  event  include  legal  provisions  under which  persons  or. 
organizations regarded under national law as having a legitimate interest in  prohibiting 
any  advertisement  inconsistent ·with  this  Title,  may  take  legal  action  against  such 
advertisement, or bring such advertisement before an administrative authority competent 
either to decide on complaints or to initiate appropriate legal proceedings. 
71 2.  Under the legal provisions referred to  in  paragraph  I, Member States shall  confer  92/28/EEC 
upon the courts or administrative authorities powers enabling them, in cases where they  Art.  I2 (I} and (2} 
deem such measures to be necessary, taking into account all the interests involved, and  (adapted) 
in particular the pub~ic interest: 
to order the cessation of, or to institute appropriate legal proceedings for an order for 
the cessation of, misleading advertising, 
or 
· if misleading advertising has not yet been published but publication is imminent, to 
or~er the prohibition of, or to institute appropriate legal proceedings for an order for 
the prohibition of, such publication, 
even without proof of  actual loss or damage or of intention or negligence on the part of 
.the advertiser: 
3  ..  Member  States  shall  make  provision  for  the  measures  referred  to  in  the  second 
subparagraph to be taken under an accelerated procedure, either with  interim effect or 
with defmitive effect. · 
It shall be for each Member State to decide which of  the two options set out in the first 
subparagraph to select..  · 
4.  Member .  States  may  confer  upon  the  courts  or  administrative  authorities  powers 
enabling  them,  with  a  view  to  eliminating  the  continuing  effects  of misleading 
advertising the cessation of  which has been ordered by a final decision:  · 
' 
to require publication of that decision  in  full  or in  part and in  such  form  as  they 
deem adequate, 
to require in addition the publication of  a corrective statement. 
5.  Paragraphs  I to 4 shall not exclude the voluntary control of advertising of medicinal  92/28/EEC 
products by self-regulatory bodies and recourse to  such bodies,  if proceedings before  Art. I2 (4) 
such bodies are possible in addition to the judicial or administrative proceedings referred  (adapted) 
to in paragraph I. 
72 Article 98 
1. The marketing authorization holder shall establish, within his undertaking, a scientific  92/28/EEC 
service in  charge of information about the medicinal products which he  places on the  Art.  13 
market.  ·  (adapted) 
2. The marketing authorization holder shall: 
keep  available  for,  or communicate  to,  the  authorities  or  bodies  responsible  for 
monitoring  advertising  of medicinal  products,  a  sample  of all  advertisements 
emanating from his undertaking together with a statement indicating the persons to 
whom  it  is  addressed,  the  method  of  dissemination  and  the  date  of  first 
disse!lJ ination, 
ensure that advertising of medicinal  products  by  his  undertaking conforms to the 
requirements of  this Title, 
verify that medical sales representatives employed  by his  undertaking have  been 
adequately trained and fulfill.the obligations imposed upon them by Article 93  (2) 
~d  (3), 
supply the authorities or bodies responsible for monitoring advertising of  medicinal 
products  with  the  information  and  assistance  they  require  to  carry  out  their 
responsibilities, 
ensure  that  the  decisions  taken  by  the  authorities  or  bodies  responsible  for 
monitoring advertising of medicinal products are  immediately and fully  complied 
with. 
Article 99 
Member States shall take the appropriate measures to ensure that the provisions of this  92128/EEC 
Title are applied and shall determine in particular what penalties shall be imposed should  Art.  14 
the provisions adopted in the execution of  Title be infringed.  (adapted) 
Article 100 
Advertising of the  homeopathic medicinal  products  referred  to  in  Article  13  (2)  and  92173/EEC 
Article  14  (I) shall  be  subject to the provisions  of this  Title  with  the  exception  of  Art. 6 (3) 
Article 87 (1 ). 
However, only the information specified in Article 69 (I) may be used in the advertising 
of  such medicinal products. 
Moreover,  each  Member  State  may  prohibit  in  its  territory  any  advertising  of the 
homeopathic medicinal products referred to in Article 13 (2) and Article 14 (I). 
73 TITLE IX 
PHARMACOVIGILANCE 
Article 101 
The Member States shall take all appropriate measures to encourage doctors and other  75/319/EEC 
health  care  professionals  to  report  suspected  adverse  reactions  to  the  competent  Art. 29e 
authorities.  (as amended by 
93/39/EEC Art. 3 (3)) . 
The  Member  States  may  impose  specific  requirements  on  medical  practitioners,  in  (adapted) 
respect  of the  reporting  of suspected  serious  or  unexpected  adverse  reactions,  in 
particular where such reporting is a condition of  the marketing authorization. 
Article 102 
In  order  to  ensure  the  adoption  of appropriate  regulatory  decisions  concerning  the  75/319/EEC 
medicinal  products  authorized  within  the  Community,  having  regard  to  information  Art. 29a 
obtained about adverse reactions to medicinal products under normal conditions of use,  (as amended by 
the Member States shall establish a pharmacovigilance system. This system shall be used  93/39/EEC Art. 3 (3)) 
to collect information useful in the .surveillance of medicinal products, with  particular 
reference  to  adverse  reactions  in  human  beings,  and  to  evaluate  such  information 
scientifically. 
_Such information shall be collated with data on consumption of  medicinal products. 
This system shall also collate  information  on  frequently  observed misuse and  serious 
abuse of  medicinal products. 
74 Article 103 
The  marketing  authorization  holder  shall  have  permanently  and  continuously  at  his  75/319/EEC 
disposal an appropriately qualified person responsible for pharmacovigilance.  Art. 29c 
That qualified person shall be responsible for the following: 
(a)  the establi~hment and maintenance of  a system which ensures that information about 
all suspected adverse reactions which are reported to the personnel of  the company, 
and to medical representatives, is collected and collated at a single point within the 
Community; 
(b)  the preparation for the competent authorities of  the reports referred to in Article I 04, 
in  such  form  as  may  be  laid  down  by  those  authorities,  in  accordance  with  the 
relevant national or Community guidelines; 
(c)  ensuring  that  any  request  from  the  competent  authorities  for  the  provision  of 
additional information necessary for the evaluation of  the benefits and risks afforded 
by a medicinal product is  answered fully and promptly,  including the provision of 
information  about the  volume of sales  or prescriptions  of the  medicinal  product 
concerned. 
Article 104 
I. The  marketing  authorization  holder  shall  be  required  to  record  and  to  report  all 
suspected serious adverse reactions which are brought to his attention by a health care 
professional to the competent authorities immediately, and in any case within 15 days of 
their receipt at the latest. 
2. The marketing authorization holder shall be required to maintain detailed records of 
all  other  suspected  adverse  reactions  which  are  reported  to  him  by  a  health  care 
professional. 
Unless  other  requirements  have  been  laid  down  as  a  condition  of the  granting  of 
authorization, these records shall be submitted to the competent authorities immediately 
upon  request  or  at  least  every  six  months  during  the  first  two  years  following 
authorization, and once a year for the following three years. Thereafter, th~ records shall 
be submitted  at  five-yearly  intervals  together with  the  application  for renewal of the 
authorization, or immediately upon request.  These recor:ds  shall· be  accompanied by  a 
scientific evaluation. 
75 
(as amended by 
93/39/EEC Art. 3 (3)) 
(adapted) 
75/319/EEC 
Art. 29d 
(as amended by 
93/39/EEC Art. 3 (3)) 
(adapted) Article 105 
The Member States shall ensure that reports of suspected serious adverse reactions are  75/319/EEC 
immediately brought to the attention of the Agency and the  marketing  authorization  Art. 29f 
hold~r, and in any case within 15 days of  their notification, at the latest.  (as amended by 
93/39/EEC Art. 3 (3)) 
(adapted) 
Article 106 
In order to facilitate the exchange of information about pharmacovigilance within the 
Community,  the  Commission,  in  consultation  with  the  Agency,  Member  States  and 
interested parties, shall draw up guidance on the collection, verification and presentation 
of  adverse reaction reports. 
This guidance shall take account of international harmonization work carried out with 
regard to-terminology and classification in the field ofpharmacovigilance. 
Article 107 
75/319/EEC 
Art. 29g 
(as amended by 
93/39/EEC Art. 3 (3)) 
Where,  as  a  result  of the  evaluation  of adverse  reaction  reports,  a  Member  State  75/319/EEC 
considers that a marketing authorization should be varied, suspended or withdrawn,  it  Art. 29h 
shall forthwith inform the Agency and the marketing authorization holder.  (as amended by 
93/39/EEC Art. 3 (3)) 
In case of urgency. the competent authority concerned may suspend the marketing of a  (adapted) 
medicinal  product,  provided  the  Agency  is  informed ·at  the  latest  on  the  following 
working day. 
Article 108 
Any amendments which may be necessary to update provisions of  Articles 101  to 107 to  75/319/EEC 
take account of  scientific and technical progress shill I be adopted in accordance with the  Art. 29i 
procedure laid down in Article 122.  (as amended by 
93/39/EEC Art. 3 (3)) 
(adapted) 
76 TITLE X 
SPECIAL PROVISIONS ON MEDICINAL PRODUCTS DERIVED FROM 
HUMAN BLOOD AND PLASMA 
Article I09 
1.  In respect of the use of human blood or human plasma as a starting material for the  89/381/EEC 
manufacture of medicinal products, Member States shall take the necessary measures to  Art. 3 (1), (2} and (3) 
prevent the  transmission of infectious  diseases.  In  so  far  as  this  is  covered  by  the  (~dapted) 
amendments referred to in Article 121, as well as the application of the monographs of 
the  European  Pharmacopoeia  regarding  blood  and ·plasma,  these  measures  shall 
comprise  those  recommended  by  the  Council  of Europe  and  the  .  World  Health 
Organization, particularly with reference to the selection and testing ofblood and plasma 
donors. 
2.  Member States shall take the  necessary measures to  ensure .that human  blood and 
human plasma donors and donation centres are always clearly· identifiable. 
3. All  the safety guarantees referred to  in  paragraphs  1 and 2  must also  be given  by 
importers of  human blood or human plasma from third countries. 
Article II  0. 
Member  States  shall  take  the  necessary  measures  to  promote  Community  89/381/EEC 
self-sufficiency in human blood or human plasma. For this purpose, they shall encourage  Art. 3 (4) 
the  voluntary  unpaid  donation  of blood  and  plasma  and  shall  take  the  necessary  (adapted) 
measures to develop the production and use of products derived from human blood or 
human  plasma  coming  from  voluntary  unpaid  donations.  They  shall  notify  the. 
Commission of  such measures. 
77 TITLE XI 
SUPERVISION AND SANCTIONS 
Article 111 
I. The competent authority of the Member State concerned shall ensure, by means of  75/3I9/EEC 
repeated  inspections,  that  the  legal  requirements  governing  medicinal  products  are  Art. 26, I st paragraph 
complied with.  (as amended by 
89/34I/EEC Art. 3 (6)) 
Such inspections shall be carried out by officials representing the competent authority  75/319/EEC 
who shall be empowered to:  Art. 26 (2) 
(adapted) 
(a)  inspect manufacturing or commercial establishments and any laboratories entrusted 
by· the  holder of the  manufacturing  authorization  with  the  task  of carrying  out 
checks pursuant to Article 20; 
(b)  take samples; 
(c)  examine  any  documents  relating to the  object  of the  inspection,  subject  to  the 
provisions  in  force  in  the  Member  States  on  2I  May  I975  and  which  place 
restrictions  on  these  powers  with  regard ·to  the  descriptions  of the· method  of 
preparation. 
2.  Member  States  shall  take  all  appropriate  steps  to  ensure  that  the  manufacturing 
processes used in the manufacture of  immunological products are properly validated and 
attain batch-to-batch consistency. 
3.  After every  inspection as  referred to  in  paragraph  I, the  officials representing the 
competent  authority  shall  report  on  whether  the  manufacturer  complies  with  the 
principles and guidelines of good manufacturing practice laid down  in  Article 47. The 
content of  such reports shall be communicated to the manufacturer who has to undergo 
the inspection. 
Article 112 
89/342/EEC 
Art. 4 (I) 
75/319/EEC 
Art. 26, 3rd paragraph 
(as amended by 
89/34I/EEC Art. 3 (6)) 
(adapted) 
Member States shall take all appropriate measures to ensure that the person responsible  65/65/EEC 
for  marketing  a  medicinal  product  and,  where  appropriate,  the  holder  of  the  Art. 8 
manufacturing authorization, furnish proof of the controls carried out on the medicinal  + 
product  and/or  the  ingredients  and  of the  controls  carried  out  at  an  intermediate  75/319/EEC 
stage  of the  manufacturing  process,  in  accordance  with  the  methods  laid  down  in  Art. 27 
Article 8 (3) (h).  (adapted) 
78 Article 113 
"For the purpose of implementing Article 112, Member States may require manufacturers 
of immunological products to submit to a competent authority copies of all the control 
reports signed by the qualified person in accordance with Article 51. 
Article 114 
I. Where it considers it necessary in the interests of public health, a Member State may 
require the holder of an authorization for marketing: 
live vaccines, 
immunological medicinal products used in the primary immunization of  infants or of 
other groups at risk, 
immunological medicinal products used in public health immunization programmes, 
new  immunological  medicinal  products  or  immunological  medicinal  products 
manufactured using  new  or altered  kinds  of technology  or new  for  a  particular 
manufacturer,  during  a  transitional  period  normally  specified  in  the  marketing 
authorization, 
to  submit  samples  from  each  batch  of the  bulk  and/or  the  medicinal  product  for 
examination by a  State  laboratory or a  laboratory  designated  for that purpose  before 
release on to the market unless, in the case of a batch manufactured in another Member 
State, the competent authority of that Member State has previously examined the b~tch 
in question and declared it to be in conformity with the approved specifications. Member 
States shall ensure that any such examiniation is completed within 60 days of  the receipt 
ofthe samples. 
2.  Where, in the interests of public health, the laws of a Member State so  provide, the 
competent  authorities  may  require  the  marketing  authorization  holder  for  medicinal 
products  derived from  human  blood or human  plasma to  submit samples  from  each 
batch of the bulk and/or the medicinal product for testing by a  State  laboratory or a 
laboratory designated for that purpose before being released into free circulation, unless 
the competent authorities of another Member State have previously examined the batch 
in  question  and  declared  it  to  be  in  conformity  with  the  approved  specifications. 
Member States shall ensure that any such examination is  completed within 60 days of 
the receipt of  the samples. 
79 
89/342/EEC 
Art. 4 (2) 
+ 
89/381/EEC 
Art. 4 (2) 
89/342/EEC 
Art. 4 (3) 
(adapted) 
89/381/EEC 
Art. 4 (3) 
(adapted) Article 115 
Member States shall take all necessary measures to ensure that the manufacturing and  89/381/EEC 
, purifying processes used in the preparation of medicinal products derived from  human  Art. 4 (I) 
blood or human plasma are  properly validated,  attain  batch-to-batch  consistency  and 
guarantee,  insofar  as  the  state  of technology  permits,  the  absence  of specific  viral 
contamination. To this end manufacturers shall notify the competent authorities of the 
method  used  to  reduce  or eliminate  pathogenic  viruses  liable  to  be  transmitted  by 
medicinal  products  derived  from  human  blood  or  human  plasma.  The  competent 
authority may submit samples of  the bulk and/or the medicinal product for testing by a 
State  laboratory  or  a  laboratory  designated  for  that  purpose,  either  during  the 
examination of the application pursuant to Article  19, or after a marketing authorization 
has been granted. 
Article 116 
The competent authorities of  the Member States shall suspend or revoke an authorization  65/65/EEC 
to place a medicinal product on the market where that product proves to be harmful in  Art. II, 1st paragraph 
the normal conditions of use, or where its therapeutic efficacy is  lacking, or where  its  (as amended by 
qualitative  and  quantitative  composition  is  not  as  declared.  Therapeutic  efficacy  is  89/341/EEC Art.  1 (1)) 
lacking  when  it  is  established  that  therapeutic  results  cannot  be  obtained  with  the 
medicinal product. 
An authorization shall also be suspended or revoked where the particulars supporting the  65/65/EEC 
application as provided for in Articles 8,  10  (1) and  11  are incorrect or have not been.  Art. 11, 2nd paragraph 
amended in accordance with Article 23.  (as amended by 
83/570/EEC Art. 1 (6)) 
80 Article 117 
I. Notwithstanding the measures provided for in  Article 116, Member States shall take 
all  appropriate measures  to  ensure that the supply of the medicinal  product shall  be 
prohibited and the medicinal product withdrawn from the market if: 
(a)  the medicinal product proves to be harmful under normal conditions of  use, or 
(b)  it is lacking in therapeutic efficacy, or 
(c)  its qualitative and quantitative composition is not as declared, or 
(d)  the controls on the medicinal product and/or on the ingredients and the controls at an 
intermediate stage of  the manufacturing process have not been carried out or if  some 
other  requirement  or  obligation  relating  to  the  grant  of  the  manufacturing 
authorization has not been fulfilled. 
2.  The  competent  authority  may  limit  the  prohibition  to  supply  the  product,  or  its 
withdrawal from the market, to tho~e batches which are the subject of  dispute. 
Article 118 
75/319/EEC 
Art. 28 
(adapted) 
I. The competent authority shall suspend or revoke the marketing authorization  for a  75/319/EEC 
category of  preparations or all preparations where any one of  the requirements laid down  Art. 29 
in Article 41  is no longer met.  (adapted) 
2. ·In  addition to the measures specified  in  Article  117,  the  competent authority may 
suspend manufacture or imports of medicinal products coming from third countries, or 
suspend or revoke the manufacturing authorization for a category of preparations or all 
preparations where Articles 42, 46, 51  and 112 are not complied with. 
Article 119 
The provisions of  this Title shall apply to homeopathic medicinal products. 
81 
92173/EEC 
Art. 4 (I) 
(adapted) (6) 
TITLE XII 
STANDING COMMITTEE 
Article 120 
• 
1. A Standing Committee on Medicinal Products for Human Use on the Adaptation to  75/318/EEC 
Technical Progress of  the Directives on the Removal ofTechni~al Barriers to trade in the  Art. 2b 
Medicinal Products Sector, hereinafter called "the Standing Committee", is  hereby set  (adapted) 
up; it shall consist of  representatives of the Member States with a representative of the 
Commission as chairman. 
2. The Standing Co.mmittee shall adopt its own rules of  procedure. 
Article 121 
Any changes which are necessary in order to adapt Annex I to take account of  scientific  75/318/EEC 
and technical progress shall be adopted in accordance with the procedure laid down in  Art. 2a, I st paragraph 
Article 122.  (as amended by 
87/19/EEC Art.  I (I)) 
(adapted) 
82 Article 122 
Where the procedure laid down in this Article is to be followed, the Commission shall be  75/319/EEC 
assisted by the Standing Committee.  Art. 37a 
(as amended by 
The representative of  the Commission shall submit to the Standing Committee a draft of  93/39/EEC Art. 3 (4)) 
the measures to be taken. The Standing Committee shall deliver its opinion on the draft  (adapted) 
within a time limit which the Chairman may lay down according to the urgency of the 
matter. The opinion shall be delivered by the majority laid down in Article 205 (2) of  the 
Treaty in the case of  decisions which the Council is required to adopt on a proposal from 
the  Commission.  The  votes  of the  representatives  of the  Member  States  within  the 
Standing  Committee  shall  be  weighted  in  the  manner  set  out  in  that  Article.  The 
Chairman shall not vote. 
The Commission shall adopt the measures envisaged if they are in accordance with the 
opinion of  the Standing Committee. 
If the  measures  envisaged  are  not  in  accordance  with  the  opinion  of the  Standing 
Committee, or if  no opinion is delivered, the Commission shall, without delay, submit to 
the Council a proposal relating to the measures to be taken. The Council shall act by a 
qualified majority. 
If on the expiry of a period of  three months from the date of referral to the Council, the 
Council has not acted, the proposed measures shall be adopted by the Commission. 
Article 123 
Where the procedure laid down in this Article is to be followed, the Commission shall be 
assisted by the Standing Committee. 
The representative of  the Commission shall submit to the Standing Committee a draft of 
the measures to be taken. The Standing Committee shall deliver its opinion on the draft 
within a time limit which the Chairman may lay down according to the urgency of the 
matter. The opinion shall be delivered by the majority laid down in Article 205 (2) of  the 
Treaty in the case of  decisions which the C-ouncil is required to adopt on a proposal from 
the  Commission.  The votes of the  representatives  of the  Member  States  within  the 
Standing  Committee  shall  be  weighted  in  the  manner  set  out  in  that Article.  The 
Chairman shall not vote. 
The Commission shall adopt the measures envisaged if they are in  accordance with the 
opinion of  the Standing Committee. 
If the  measures  envisaged  are  not in  accordance  with  the  opinion  of the  Standing 
Committee, or if  no opinion is delivered, the Commission shall, without delay, submit to 
the Council a proposal relating to the measures to be taken. The Council shall act by a 
qualified majority. 
If  on the expiry of a period of  three months from the date of referral to the Council, the 
Council has not acted, the proposed measures shall be adopted by the Commission, save 
where the Council has decided against the said measures by a simple majority. · 
83 
75/319/EEC 
Art. 37b 
(as amended by 
93/39/EEC Art. 3 (4)) 
(adapted) TITLE XIII 
GENERAL PROVISIONS 
Article 124 
Member  States  shall  take  all  appropriate  measures  to  ensure  that  the  competent  75/319/EEC 
authorities concerned communicate to each other such information as  is  appropriate to  Art. 30, 1st paragraph 
guarantee  that  the  requirements  for  the  manufacturing  a~thorizations or  marketing  (adapted) 
authorizations are fulfilled. 
Upon reasoned request, Member States shall forthwith communicate the reports referred  75/319/EEC 
to  in  Article  111  (3) to the  competent authorities of another Member State.  If,  after  Art. 30, 2nd paragraph 
considering the reports, the Member State receiving the reports considers that it cannot  (as amended by 
accept the  conclusions reached by the  competent authorities  of the  Member State  in  89/341/EEC Art. 3 (8)) 
which the report was established, it Shall inform the competent authorities concerned of 
its reasons and may request further information. The Member States concerned shall use 
their best endeavours to reach agreement. If necessary, in the case of serious differences 
of  opinion, the Commission shall be informed by one of  the Member States concerned. 
Article 125 
1.  Each Member State shall take all the appropriate measures to ensure that decisions  75/319/EEC 
authorizing  marketing,  refusing  or revoking  a  marketing  authorization,  cancelling  a  Art. 33 (1) 
decision  refusing  or  revoking  a  marketing  authorization,  prohibiting  supply,  or  (adapted) 
withdrawing  a  product  from  the  market,  together  with  the  reasons  on  which  such 
decisions are based, are brought to the attention of  the Agency forthwith. 
2.  The  marketing authorization  holder shall  be  obliged to  notify  the  Member  States  75/319/EEC 
concerned forthwith of  any action.taken by him to suspend the marketing of a medicinal  Art. 33 (2) to (4) 
product or to withdraw a medicinal product from the market, together with the reasons  (as amended by 
for  such  action  if the  latter  concerns  the  efficacy  of the  medicinal  product  or the  89/341/EEC Art. 3 (9)) 
protection of public health. Member States shall ensure that this information is  brought  (adapted) 
to the attention of  the Agency. 
3. Member States shall ensure that appropriate information about action taken pursuant 
to paragraphs 1 and 2 which may affect the protection of  public health in third countries 
is forthwith brought to the attention of  the World Health Organization, with a copy to the 
Agency. 
4.  The Commission shall publish annually a list of the medicinal products which  are 
prohibited in the Community. 
84 Article 126 
Member  States  shall  communicate  to  each  other  all  the  information  necessary  to  92/73/EEC 
guarantee the quality and safety of homeopathic medicinal products manufactured and  Art. 5 
marketed  within  the  Community,  and  in  particular  the  information  referred  to  in 
Articles 124 and 125. 
Article 127 
Every decision referred to in this Directive which is taken by the competent authority of  65/65/EEEC 
a Member State shall state in detail the reasons on which it is based.  Art. 12 
(adapted) 
Such decision shall be notified to the party concerned, together with information as  to 
the redress available to him under the laws in  force  and of the time-limit allowed for 
access to such redress. 
Marketing  authorizations,  and  decisions  to  revoke  such  authorizations,  shall  be 
published by each Member State in the appropriate official publication. 
85 
+ 
75/319/EEC 
Art. 31 
(adapted) 
+ 
92/25/EEC 
Art. 4 (2) 
(adapted) 
+ 
92/27/EEC 
Art. 11 (2) 
(adapted) 
+ 
92/28/EEC 
Art. 12 (3) 
(adapted) Article 128 
An authorization  to market a  medicinal  product  shall  not  be  refused,  suspended  or 165/65/EEC 
revoked except on the grounds set out in this Directive.  Art. 21 
No  decision  concerning  suspension  of manufacture  or of importation  of medicinal  75/319/EEC 
products coming from  third countries,  prohibition of supply or withdrawal  from  the  Art. 32 
market of  a medicinal product may be taken except on the ground set out in Articles 117  (adapted) 
and 118.  · 
Article 129 
I. At the request of the manufacturer, the exporter or the authorities of an importing 
third country, Member States .shall certify that a manufacturer of  medicinal products is in 
possession  of  the  manufacturing  authorization.  When  issuing  such  certificates 
Member. States shall comply with the following conditions: 
(a)  they shall have regard to the prevailing administrative arrangements of the World 
Health Organization; 
(b)  for medicinal products intended for export which are already authorized on their 
territory, they shall supply the summary of  the product characteristics as approved in 
accordance with Article 21. 
2.  When the manufacturer is  not in  possession of a marketing authorization he shall 
provide  the  authorities  responsible  for  establishing  the  certificate  referred  to. in 
paragraph I, with a declaration explaining why no marketing authorization is available. 
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75/319/EEC 
Art. 28a 
(as amended by 
89/341/EEC Art. 3 (7)) 
(adapted) TITLE XIV 
FINAL PROVISIONS 
Articlel30 
Directives  65/65/EEC,  . 75/318/EEC,  75/319/EEC,  89/342/EEC,  89/343/EEC, 
89/381/EEC, 92125/EEC, 92126/EEC, 92/27/EEC, 92128/EEC and 92/73/EEC, amended 
by the Directives referred to in Annex II, Part A, are repealed, without prejudice to the 
obligations of  the Member States concerning the time-limits for implementation set out 
in Annex II, Part B.· 
References to the repealed Directives shall be construed as "references to this Directive 
and shall be read in accordance with the correlation table in Annex III. 
Article 131 
This Directive shall enter into force on 1 January 2000. 
Article 132 
This Directive is addressed to the Member States. 
Done at Brussels, 
For the European Parliament  For the Council 
The President  The President 
87 ANNEX I 
ANALYTICAL, PHARMACOTOXICOLOGICAL 
AND CLINICAL STANDARDS AND PROTOCOLS IN 
RESPECT OF THE TESTING OF 
MEDICINAL PRODUCTS 
INTRODUCTION  75/318/EEC 
Annex 
The particulars and documents accompanying an application for marketing authorization  (as amended by 
pursuant to Articles 8 and 10 (1) shall be presented in four parts, in accordance with the  91/507/EEC Art. 1) 
requirements set out in this Annex and taking account of the guidance published by the  (adapted) 
Commission  in  The rules governing medicinal products in  the European Community, 
Volume 2: Notice to applicants for marketing authorizations for medicinal products for 
human use in the Member States of  the European Community. 
In assembling the dossier for application for  marketing authorization, applicants shall 
take into account the Community guidelines relating to the quality, safety and efficacy of 
medicinal  products  published  by  the  Commission  in  The  rules  governing medicinal 
products in the European Community, Volume 3 and its supplements: Guidelines on the 
quality, safety and efficacy of  medicinal products for human use. 
All information which is relevant to .the evaluation of the medicinal product concerned 
shall be included in the application, whether favourable or unfavourable to the product. 
In  particular,  all  relevant  details  shall  be  given  of any  incomplete  or  abandoned 
pharmacotoxicological  or  clinical  test  or  trial  relating  to  the  medicinal  product. 
Moreover, in order to monitor the benefit/risk assessment after marketing authorization 
has been granted, any change to the data in the dossier, any new information not in the 
original  application  and  all  pharmacovigilance  reports,  shall  be  submitted  to  the 
competent authorities. 
The general sections of  this Annex give the requirements for all categories of medicinal 
products; they are supplemented by sections containing additional special requirements 
for radiopharmaceuticals and for biological medicinal products, such as  immunological 
medicinal  products  derived  from  human  blood  or  pl~ma. The  additional  special 
requirements for biological medicinal products are also applicable to medicinal products 
obtained through processes mentioned in the first indent of Part A and the first indent of 
Part B of  the Annex to Regulation (EEC) No 2309/93 .. 
Member States shall also ensure that all tests on animals are conducted in  accordance 
with Council Directive 86/609/EEC of24 November 1986 on the approximation of  laws, 
regulation and· administrative provisions of the Member States regarding the .  protection 
of  animals for experimental and other scientific purposes  1 . 
OJ L 3S8, 18.12.1986, p. I. 
88 PART I 
SUMMARY OF THE DOSSIER 
A. Administrative data 
The medicinal product which is the subject of  the application shall be identified by name 
and name of  the active substance(s), together with the pharmaceutical form, the method 
of  administration, the strength and th.e final presentation, including packaging. 
The name and address  of the  applicant shall  be  given,  together with  the  name  and 
address  of the  manufacturers  and  the  sites  involved  in  the  different  stages  of the 
manufacture (including the manufacturer of  the finished product and the manufacturer(s) 
of  the active substance(s)), and where relevant the name and address of  the importer. 
The applicant  shall  identify  the  number of volumes of documentation  submitted  in 
support of  the application and indicate what samples, if  any, are also provided. 
Annexed to the administrative data shall be copies of  the manufacturing authorization as 
defmed in Article 40, together with a list of countries in which authorization has been 
granted, copies of  all the summaries of  product characteristics in accordance with Article 
II as approved by Member States and a list of countries in which an application has 
been submitted. 
B. Summary of product characteristics 
The applicant shall propose a summary of  the product characteristics, in accordance with 
Article II. 
In addition the applicant sliall provide samples or mock-ups of  the packaging, labels and 
package leaflets for the medicinal product concerned. 
89 
75/318/EEC 
Annex 
(as amended by 
911507/EEC Art. 1) 
(adapted) C. Expett reports 
In  ~ccordance with Article  12  (2),  expert reports must be  provided on  the chemical, 
phannaceutical and biological documentation, the phannacotoxicological documentation 
and the clinical documentation respectively. 
The expert report shall consist of a critical evaluation of the quality of the medicinal 
product and the investigations carried out on animals and human beings and bring out all 
the data relevant for evaluation. It shall be worded so as to enable the reader to obtain a 
good understanding of the properties, quality, the proposed specifications and control 
methods,  the safety, the efficacy,  the  advantages and disadvantages of the  medicinal 
product. 
All important data shall be summarized in  an appendix to the expert report, whenever 
possible including rep,ort formats in tabular or in graphic form. The expert report and the 
summaries shall contain precise cross references to the  information  contained  in  the 
main documentation. 
.  ) 
Each expert report shall be prepared by a suitably qualified and experienced person. It 
shall  be signed  and  dated  by  the  expert,  and attached  to  the  report  shall  be  brief 
information about the educatiQnal background, training and professional experience of 
the expert. The professional relationship of  the expert to the applicant shaU be declared. 
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(adapted) PART2 
CHEMICAL,  PHARMACEUTICAL  AND  BIOLOGICAL  TESTING  OF 
MEDICINAL PRODUCTS 
All the test procedures shall correspond to the state of  scientific progress at the time and 
shall be validated procedures; results of  the validation studies shall be provided. 
All  the  test procedure(s) shall  be  described  in  sufficiently  precise  detail  so  as  to  be 
reproducible in control tests, carried out at the request of the competent authority; any 
special  apparatus  and  equipment which  may  be  used  shall  be  described  in  adequate 
detail, possibly accompanied by a diagram. The formulae of  the laboratory reagents shall 
be  supplemented,  if necessary,  by  the  manufacturing  method.  In  the  case  of test 
procedures  included  in  the  European  Pharmacopoeia  or  the  pharmacopoeia  of a 
Member  State,  this  description  may  be  replaced  by  a  detailed  reference  to  the 
pharmacopoeia in question. 
A. Qualitative and quantitative particulars of the constituents 
The  particulars  and  documents  which  must  accompany applications  for  marketing 
authorization, pursuant to  point 3 of Article 8 (3) (c) shall be submitted in accordance 
with the following requirements. 
I. Qualitative particulars 
1.1. "Qualitative particulars" of all the constituents of the medicinal product shall mean 
the designation or description of: 
the active substance(s), 
the  constituent(s)  of the  excipients,  whatever  their  nature  or the  quantity  used, 
including  colouring  matter,  preservatives,  adjuvants,  stabilizers,  thickeners, 
emulsifiers, flavouring and aromatic substances, etc., 
the constituents, intended to be ingested or otherwise administered.to the patient, of 
the  outer covering· of the medicinal products  - capsules,  gelatine  capsules,  rectal 
capsules, etc. 
·These particulars shall be  supplemented by any relevant data concerning the container 
and,  where  appropriate,  its  manner of closure,  together with  details  of devices  with 
which the medicinal product will be used or administered and which will be delivered 
with the medicinal product. 
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(adapted) 1.2. In the context of  a radiopharmaceutical kit, which is to be radiolabelled after supply 
by the manufacturer, the active substance is considered to be that part of  the formulation 
which  is  intended  to  C1lfTY  or bind  the  radionuclide.  Details  of the  source  of the 
radionuclide shall be stated. In addition, any compounds essential for the radiolabelling 
shall be stated. 
In a· generator, both mother and qaughter radionuclides are to be considered as active 
substances. 
2.  The  ''usual terminology",  to  be used  in  describing  the  constituents  of medicinal 
products, shall mean, notwithstanding the application of  the other provisions in Article 8 
(3) (c): 
in respect of substances which appear in the European Pharmacopoeia or, failing 
this, in the national pharmacopoeia of  one of  the Member States, the main title at the 
head of  the monograph in question, with reference to the pharmacopoeia concerned, 
in respect of  other substances, the international non-proprietary name recommended 
by the  World Health Organization,  which may  be  accompanied  by  another non-
proprietary name, or, failing these, the exact scientific designation; substances not 
having an international non-proprietary name or an exact scientific designation shall 
be  described  by  a  statement  of  how  and  from  what  they  were  prepared, 
supplemented, where appropriate, by any other relevant details, 
in  respect of colouring matter,  designation by the  "E" code assigned to them  in 
Council Directive 78/25/EEC of 12  December  1977 on the approximation of the 
rules of the Member States concerning the colouring matters authorized for use in 
medicinal products  I. 
3. Quantitative particulars 
3.1. In order to give ''quantitative particulars" of the active substances of the medicinal 
products, it is necessary, depending on the pharmaceutical form  concerned, to specify 
the mass, or the number of  units of  biological activity, either per dosage-unit or per unit 
of  mass or volume, of  each active substance. 
Units  of biological  activity  shall  be  used  for  substances  which  cannot  be  defmed 
chemically. Where an International Unit of biological activity has been defined by the 
World Health Organization, this shall be used.  Where no International Unit has  been 
defmed, the units of biological activity shall be expressed in  such a way as to provide 
unambiguous information on the activity of  the substances. 
Whenever possible, biological activity per units of  mass shall be indicated. 
OJ L II, 14.1.1978, p. 18. Directive as last amended by the Act of Accession of Spain and Portugal. 
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(adapted) This information shall be supplemented: 
in respect of injectable preparations, by the mass or units of biological activity of 
each active substance in the unit container, taking into account the usable volume of 
the product, after reconstitution, where appropriate, 
in respect of  medicinal products to be administered by drops, by the mass or units of 
biological  activity  of each  active  substance  contained  in  the  number  of drops 
corresponding to  I ml or I g of  the preparation, 
in  respect  of syrups,  emulsions,  granular  preparations  and  other  pharmaceutical 
forms to be administered in  measured quantities, by the mass or units of biological 
activity of  each active substance_ per measured quantity. 
3.2.  Active  substances  present  in  the  form  of compounds  or  derivatives  shall  be 
designated quantitatively by their total mass, and if  necessary or relevant, by the mass of 
the active entity or entities of  the molecule. 
3.3. For medicinal products containing an  active substance which  is  the subject of an 
application  for  marketing  authorization  in  any  Member  State  for  the  first  time,  the 
quantitative  statement  of an  active  substance  which  is  a  salt or  hydrate  shall  be 
systematically  expressed  in  terms  of the  mass  of the  active  entity  or entities  in  the 
molecule.  All subsequently authorized medicinal products in the Member States shall 
have their quantitative composition stated in the same way for the same active substance. 
3.4.  For  immunological  medicinal  products,  the  quantitative  particulars  shall  be 
expressed  by  units  of biological  activity,  except  for  well  defined  immunoligical 
medicinal  products  for  which  the  concentration  may  be  expressed  by  mass/unit  of 
volume. 
3.5. The requirement to'express the content of active substances in terms ofthe mass of 
active  entities,  as  in  point  3.3.  above,  may  not  apply  to  radiopharmaceuticals.  For 
radionuclides,  radioactivity  shall  be  expressed  in  becquerels  at  a  given  date  and,  if 
necessary, time with reference to time zone. The type of  radiation shall be indicated. 
4. Development pharmaceutics 
4.I.  An  explanation  should  be  provided  with  regard  to  the  choice  of composition, 
constituents arid  container and the  intended function  of the  excipients  in  the  finished 
product.  This  explanation  shall  be  supported  by  scientific  data  on  development 
pharmaceutics.  The  overage during manufacture,  with justification thereof,  should be 
stated. 
4.2.  For  radiopharmaceuticals,  this  should  include  a  consideration  of 
chemical/radiochemical purity and its relationship to biodistribution. 
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I. The  description  of the  manufacturing  method  accompanying. the  application  for  91/507  /EEC Art. I) 
marketing authorization pursuant to point 4 of  Article 8 (3) (d), shall be drafted in such a  (adapted) 
way as to give an adequate synopsis of  the nature of  the operations employed. 
For this purpose it shall include at least: 
mentjon of  the various stages of  manufacture, so that an assessment can be made of 
whether the processes employed in producing the pharmaceutical form  might have 
produced an adverse change in the constituents, 
in the case of continuous manufacture, full  details concerning precautions taken to 
ensure the homogeneity of  the finished product, 
the  actual  manufacturing  formula,  with  the  quantitative  particulars  of all  the 
substances used, the quantities of excipients, however, being given  in  approximate 
terms in  so far as the pharmaceutical form .makes this necessary; mention shall oe 
made  of any  substances  that may  disappear  in  the  course  of. manufacture;  any 
overage shall be indicated and justified, 
:- a statement of the stages of manufacture at which sampling is  carried out for  in-
process control tests, where other data in the documents supporting the application 
show such tests to be necessary for the quality control of  the finished product, 
experimental studies validating the manufacturing process, where a non-standard 
method of  manufacture is used or where it is critical for the product, 
u 
for sterile medicinal products, details of the  sterilization processes and/or aseptic 
procedures used. 
2. For radiopharmaceutical kits, the description of the manufacturing method shall also 
include  details  of the  manufacture  of the  kit  and  details  of its  recommended  final 
processing to produce the radioactive medicinal product. 
For radionuclides, the nuclear reactions involved shall be discussed. 
C. Controls of  starting materials 
I. For the purposes of  this section, "starting materials" shall mean all the constituents of 
the medicinal product and,  if necessary,  of its container,  as  referred  to  in  Section A, 
point  I~ above. 
94 In the case of: 
an  active  substance  not  described  in  the  European  Pharmacopoeia  or  in  the 
pharmacopoeia of  a Member State, or 
an  active  substance  described  in  the  European  Pharmacopoeia  or  in  the 
pharmacopoeia of a  Member  State  when  prepared  by  a  method  liable  to  leave 
impurities  not  mentioned  in  the  pharmacopoeial  monograph  and  for  which  the 
monograph is inappropriate to adequately control its quality, 
which is  manufactured by a person different from  the applicant, the latter may arrange 
for  the  detailed  description  of the  manufacturing  method,  quality  control  during 
manufacture and process validation to be supplied directly to the competent authorities 
by the manufacturer of  the active substance. In this case, the manufacturer shall however 
provide the  applicant with all the  data which may be necessary for the  latter to take 
responsibility for the medicinal product. The manufacturer shall confrrrn in  writing to 
the  applicant  that  he  shall  ensure  batch  to  batch  consistency  and  not  modify  the 
manufacturing process or specifications without informing the applicant. Documents and 
particulars  supporting  the  application  for  such  a  change  shall  be  supplied  to  the 
competent authorities. 
The  particulars  and  documents  accompanying  the  application  for  marketing 
authorization pursuant to Article 8 (3) (h) and (i) and 10 (1), shall include the results of 
the tests,  including batch analyses particularly for active substances, relating to quality 
control of all the constituents used.  These shall  be  submitted  in  accordance with  the 
following provisions. 
1.1. Starting materials listed in pharmacopoeias 
The monographs of the European Pharmacopoeia shall be applicable to all substances 
appearing in it. 
·In  respect of other substances, each Member State may require observance of its  own 
national pharmacopoeia with regard to products manufactured in its territory. 
Constituents  fulfilling  the  requirements  of the  European  Pharmacopoeia  or  the 
pharmacopoeia of  one of  the Member States shall be deemed to coni ply sufficiently with 
Article 8 (3) (h).  In this case the description of the analytical methods may be replaced 
by a detailed reference to the pharmacopoeia in question. 
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(adapted) However, ; where  a  starting  material  in  the  European  Pharmacopoeia  or  in  the 
pharmacopoeia of a  Member State  has  been  prepared  by  a  method  liable  to  leave 
impurities not controlled in the pharmacopoeia monograph, these impurities and their 
maximum  tolerance  limits  must be declared  and  a  suitable  test  procedure  must  be 
described. 
Colouring matter shall, in all cases, satisfy the requirements of  Directive 78/25/EEC. 
The routine tests carried out on each batch or-starting materials must be as stated in the 
application  for  marketing  authorization.  If tests  other  than  those  mentioned  in  the 
pharmacopoeia are  used,  proof must be  supplied that the  starting materials  meet the 
quality requirements of  that pharmacopoeia. 
In  cases  where  a  specification  contained  in  a  monograph  of  the  European 
Pharmacopoeia  or  in  the  national  phannacopoeia  of a  Member  State  might  be 
insufficient to ensure the quality of  the substance, the competent authorities may request 
more appropriate specifications from the marketing authorization holder. 
The competent authorities shall infonn the authorities responsible for the pharmacopoeia 
·in  question.  The marketing authorization  holder shall  provide the  authorities  of that 
pharmacopoeia  with  the  details  of  the  alleged  insufficiency  and  the  additional 
specifications applied. 
In cases where a starting material is described neither in the European Pharmacopoeia 
nor In the pharmacopoeia of  a Member State, compliance with the monograph of a third 
country pharmacopoeia can be accepted; in such cases, the applicant shall submit a copy 
of  the monograph accompanied where necessary by the validation of  the test procedures 
contained in the monograph and by a translation where appropriate. 
1.2. Starting materials n'ot in a pharmacopoeia 
Constituents which are not given in any pharmacopoeia shall be described in the form of 
a monograph under the following headings: · 
(a)  The name of  the substance, meeting the requirements of Section A, point 2, shall be 
supplemented by any trade or scientific synonyms; 
(b)  the  definition of the  substance,  set down  in  a fonn  similar  to  that  used  in  the 
European  Pharmacopoeia,  shall  be  accompanied  by  any  necessary  explanatory 
· evidence, especially concerning the molecular structure where appropriate; it  must 
be accompanied by an appropriate description of the method of synthesis.  Where 
substances can only be described by their manufacturing method, the description 
should be sufficiently detailed to characterize a substance which is constant both in 
its composition and in its effects; 
(c)  methods of identification may be described in  the form of complete techniques as 
used for production of the substance, and in  the fonn of tests which  ought to be 
carried out as a routine matter; 
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I (d)  purity tests shall be described in relation to the sum total of predictable impurities, 
especially those which may have a harmful effect, and, if necessary, those which, 
having regard to the  combination of substances to which  the  application  refers, 
might adversely affect the stability of the medicinal product or distort analytical 
results; 
(e)  with regard to complex substances of plant or animal/human origin, a  distinction 
must be made between the  case  where  multiple pharmacological effects  render 
chemical, physical or biological control of the principal constituents necessary, and 
the case of substances containing one or more groups of principles having similar 
activity, in respect of  which an overall method of  assay may be accepted; 
(f)  when materials of  animal/human origin are used, measures to ensure freedom from 
potentially pathogenic agents shall be described; 
(g)  for radionuclides, the nature of the radionuclide, the identity of the isotope, likely 
impurities, the carrier, the use and the specific activity shall be given; 
(h)  any special precautions that may be necessary during storage of  the starting material 
and, if  necessary, the maximum period of  storage before retesting shall be given. 
1.3. Physico-chemical characteristics liable to effect bio-avai/ability 
The following items of information concerning active substances, whether or not listed 
in the pharmacopoeias, shall be provided as part of  the general description of the active . 
substances if  the bio-availability of  the medicinal product depends on them: 
crystalline form and solubility coefficients, 
particle size, where appropriate after pulverization, 
state of  solvation, 
oiVwater coefficient of  partition  I . 
The first three indents are not applicable to substances used solely in solution. 
2.  For biological medicinal products, such as  immunological medicinal  products and 
medicinal  products  derived  from  human  blood  or plasma,  the  requirements  of this 
paragraph shall apply. 
The competent authorities may also request the pK and pH values if  they think this infonnation is essential. 
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For the; purposes of this paragraph, starting materials shall mean any substance used in  7  5/318/EEC 
the ll):anufacture of  the medicinal product; this includes the constituents of  the medicinal  Annex 
prrAiuct, and, if necessary, of its container, as referred to in paragraph A, point I above,  {as amended by 
as well as source materials such as  microorganisms,  tissues of either plant or animal  911507/EEC Art. l) 
origin, cells or fluids {including blood) of  human or animal origin, and biotechnological  (adapted) 
cell  constructs.  The  origin  and  history  of starting  materials  shall  be  described  and 
documented. 
The  description  of the  starting  material  shall  include  the  manufacturing  strategy, 
purification/inactivation  procedures  with  their  validation  and  all  in-process  control 
procedures designed to ensure the quality, safety and batch to batch consistency of the 
finished product. 
2.1. When cell banks are used, the cell characteristics shall be shown to have remained 
unchanged at the passage level used for the production and beyond. 
2.2.  Seed  materials,  cell  banks,  pools  of serum  or  plasma  and  other  materials  of 
biological  origin  and,  whenever possible,  the  source  materials  from  which  they  are 
derived shall be tested for adventitious agents. 
If  the  presence  of  potentially  pathogenic  adventitious  agents  is  inevitable,  the 
correspondant  material  shall  be  used  only  when  further  proc~ssing  ensures  their 
elimination and/or inactivation, and this shall be validated. 
2.3. Whenever possible, vaccine production shall be based on a seed lot system and on 
established cell banks; for serums, defmed pools of  starting materials shall be used. 
For bacterial  and  viral  vaccines,  the  characteristics  of the  infectious  agent  shall  be 
· demonstrated on the seed. In addition, for live vaccines, the stability of the attenuation 
characteristics  shall  be  demonstrated  on  the  seed; · if this  proof is  not  suffteient,  the 
attenuation characteristics shall also be demonstrated at the production stage. 
2.4. For immunological medicinal products, the specifications and control methods for 
the source materials shall  be  described  in  as  much detail. as  possible.  The description 
shall include particulars concerning collection, pretreatment and storage. 
2.5. For medicinal products derived from  human blood or plasma, the origin and the 
criteria and procedures for collection, transportation and storage of the source material 
shall be described and documented. 
Pefined pools of  source material shall be used. 
3. For radiopharmaceuticals, starting materials include irradiation target materials. 
98 D. Control tests carried out at intermediate stages of  the manufacturing process 
I.  The  particulars  and  documents  accompanying  an  application  for  marketing 
authorization, pursuant to Article 8 (3) (h) and (i) and Article  IO,  paragraph  I of this 
Directive,  shall  include  particulars  relating  to  the product control  tests  that  may  be 
carried  out  at  an  intermediate  stage  of the  manufacturing  process,  with  a  view  to 
ensuring the consistency of  the technical characteristics and the production process. 
These tests are essential for checking the conformity of the medicinal product with the 
formula when, exceptionally, an applicant proposes an analytical method for testing the 
finished product which does not include the assay of all the active substances (or of all 
the excipient constituents subject to the same requirements as the active substances). 
The  same  applies  where  the  quality  control  of the  finished  product depends  on  in-
process control tests, particularly if the medicinal product is  essentially defined by its 
method or preparation. 
2.  For biological  medicinal  products,· such  as  immunological medicinal products and 
medicinal products derived from human blood or plasma, the procedures and the criteria-
of  acceptability  published  as  recommendations  of  the  WHO  (Requirements  for 
Biological Substances) shall  serve  as  guidelines  for  all  controls of production stages 
which are not specified in the European Pharmacopoeia, or falling this, in the national 
pharmacopoeia of  a Member State. 
For inactivated or detoxified vaccines, effective inactivation or detoxification shall be 
verified  during each  production run,  unless this  control  is  dependent upon  a test  for 
which the availability of susceptible animals  is  limited.  In  this  case,  the test shall be 
carried out until  consistency of production and correlation with appropriate in process 
controls  have  been  established  and  thereafter compensated  by  appropriate  in-process 
controls. 
3.  For modified or adsorbed immunological medicinal  products, the products shall  be 
qualitatively and quantitatively characterized at an intermediate stage, as  late as possible 
in the manufacturing process. 
E. Control tests on the finished product 
I. For the control of the fmished product, a batch of a medicinal product comprises all 
the units of a pharmaceutical form  which  are  made from  the  same initial quantity of 
·material  and  have  undergone  the  same  series  of manufacturing  and/or  sterilization 
operations or, in the case of a continuous production process, all the units manufactured 
in a given period of  time. 
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routinely on each batch of fmished  product. The frequency of the tests which  are  not  Annex 
carried out routinely shall be stated. Release limits shall be indicated.  (as amended by 
91/507/EEC Art. I) 
The  particulars  and  documents  accompanying  the  application  for  marketing  (adapted) 
authorization pursuant to Article 8 (3) (h) and (i) and Article  10 (I) of this Directive, 
shall include particulars relating to control tests on the finished product at release. They 
shall be submitted in accordance with the following requirements. 
The provisions of  the monographs for pharmaceutical forms, immunosera, vaccines and 
radiopharmaceutical preparations of the European Pharmacopoeia or failing that, of a 
Member State,  shall  be  applicable to  all  products defined therein.  Fot all  controls of 
biological medicinal products such as immunological medicinal products and medicinal 
products derived from human blood or plasma which are not specified in  the European 
Pharmacopoeia or failing this, in the pharmacopoeia of a Member State, the procedures 
and  the  criteria  of  acceptability  published  as  recommendations  in  the  WHO 
(Requirements for Biological Substances) shall serve as guidelines. 
If test  procedures and limits  other  than  those  mentioned  in  the  monographs  of the 
European Pharmacopoeia, or failing this, in  the national pharmacopoeia of a Member 
State,  are  used,  proof shall  be  supplied .  that the  finished  product would,  if tested  in 
accordance  with  those  monographs,  meet  the  quality  requirements  of  that 
pharmacopoeia for ~e  pharmaceutical form concerned. 
1.1. General characteristics of  the finished product 
Certain tests of the general characteristics of a product shall always be included among 
the tests on the  finished product.  These tests  shall,  wherever applicable,  relate to the 
control  of average  masses  and  maximum  deviations,  to  mechanical,  physical  or 
microbiological  tests,  organoleptic  characteristics,  physical  characteristics  such  as 
density,  pH,  refractive  index,  etc.  For  each  of these  characteristics,  standards  and 
tolerance limits shall be specified by the applicant in each particular case. 
The conditions of the tests, where aJlpropriate, the equipment/apparatus employed and 
the standards shall be  described  in  precise details whenever they are  not given  in  the 
European Pharmacopoeia or the pharmacopoeia of the Member States; the same shall 
apply in cases where the methods prescribed by such pharmacopoeias are not applicable. 
Furthermore,  solid  pharmaceutical  forms  having  to  be  administered  orally  shall  be 
subjected to in vitro studies on the liberation and dissolution rate of the a~tive substance 
or substances; these studies shall also be carried out where administration is by another 
means  if the  competent  authorities  of the  Member  State  conc~rned consider  this 
necessary. 
100 1.2. Identification and  assay of  active substa~e(s) 
Identification  and  assay of the  active  substance(s)  shall  be  carried  out either  in  an 
average representative sample from the production batch or in a number of dosage-units 
analysed individually. 
Unless there is appropriate justification, the maximum acceptable deviation in the active 
substance  content of the  fmished  product  shall  not  exceed  ±  "5%  at  the ·time  of 
manufacture. 
On the basis of the stability tests, tbe manufacturer must propose and justify maximum 
acceptable tolerance limits in the active substance content of  the finished product up to 
the end of  the proposed shelf-life. 
In  certain exceptional cases of particularly complex mixtures,  where. assay of active 
substances which are very numerous or present in very low amounts would necessitate 
an intricate investigation difficult to carry out in respect of each production batch, the 
assay of one or more active substances in  the fmished product may be omitted, on the 
express condition that such assays are made at intermediate stages in  the production 
process. This relaxation may not be extended to the characterization of the substances 
concerned. This simplified technique shall be supplemented by a method of  quantitative 
evaluation, enabling the competent authority to have the conformity of the medicinal 
product with its specification verified after it has been placed on the market. 
An  in  vivo  or in  vitro  biological  assay  shall  be  obligatory  when  physico-chemical 
methods cannot provide adequate information on the quality of the product.  Such an 
assay  shall,  whenever  possible,  include  reference  materials  and  statistical  analysis 
allowing calculation of  confidence limits. Where these tests cannot be carried out on the 
finished product, they may be performed at an intermediate stage, as late as possible in 
the manufacturing process. 
Where the particulars given in section B show that a significant overage of an  active 
substance is  employed in the manufacture of the medicinal product, the description of 
the control tests 01:1  the finished product shall include, where appropril:lte,  the chemical 
and,  if necessary,  the  toxico-pharmacological  investigation  of the  changes  that  this 
substance  has  undergone,  and  possibly  the  characterization  and/or  assay  of the 
degradation products. 
1.3. Identification and  assay of  excipient constituents 
In so far as is necessary, the excipient(s) shall be subject at least to identification tests. 
The test procedure proposed for identifying colouring matters must enable a verification 
to be made that such matters appear in the list annexed to Directive 78125/EEC. 
An upper and lower limit test shall be obligatory in respect of  preserving agents and an 
upper limit test for any other excipient constituent liable  to affect adversely organic 
functions; an upper and lower limit test shall be obligatory in respect of  the excipient if it 
is liable to affect the  bio-availability of an active substance,  unless  bio-availability is 
guaranteed by other appropriate tests. 
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Apart from the pharmacotoxicological tests submitted with the application for marketing  (as amended by 
authorization,  particulars  of  safety  tests,  such  as  sterility,  bacterial  endotoxin,  911507/EEC Art.  I} 
pyrogenicity and local tolerance in animals shall be included in the analytical particulars  (adapted) 
wherever such tests must be undertaken as  a matter of routine in  order to verify the 
quality of  the product 
2. For all controls of biological medicinal products, such as immunological medicinal 
products and medicinal products derived from  human blood or plasma, which are not 
specified in the European Pharmacopoeia, or failing this, in the national pharmacopoeia 
of a  Member  State,  the  procedures  and  the  criteria  of acceptability  published  as 
recommendations  in  the  World  Health  Organization  (Requirements  for  Biological 
Substances) shall serve as guidelines. 
3.  For radiopharmaceuticals,  radionuclidic  purity,  radiochemical  purity  and  specific 
activity shall be described. For content of  radioactivity, the deviation from that stated on 
the label should not exceed± 10%. 
For generators, details on the testing for mother and daughter radionuclides are required. 
For generator-eluates, tests for mother radionuclides and for other components of the 
generator system spall be provided. 
For kits, the specifications of  the fmished product shall include tests on perfonnance of 
products after radiolabelling. Appropriate controls on radiochemical and radionuclidic 
purity  of the  radiolabelled  compound  shall  be  included.  Any  material  essential  for 
radiolabelling shall be identified and assayed. 
F. Stability tests 
1.  The  particulars  and  documents  accompanying  the  application  for  marketing 
authorization pursuant to Article 8 (3) (g) and (h) shall be submitted in accordance with 
the following requirements. 
A  description  shall  be  given  of the  investigations  by  which  the  shelf life,  the 
recommended  storage conditions  and  the  specifications  at  the  end  of the  shelf-life 
proposed by the applicant have been detennined. 
Where a  finished product is  liable to give rise to degradation products, the applicant 
must declare these and indicate characterization methods and test procedures. 
The conclusions shall contain the results of analyses, justifying the proposed shelf life 
under the recommended storage conditions and the specifications of  the finished product 
at the end of  the shelf-life under these recommended storage conditions. 
102 The maximum acceptable level of degradation products at the end of shelf-life shall be  75/318/EEC 
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A study of the interaction between product and container shall be submitted wherever  911507 /EEC Art. I) 
the  risk  of such  interaction  is  regarded  as  possible,  especially  where  injectable  (adapted) 
preparations or aerosols for internal use are concerned. 
2. Where for biological medicinal products, such as immunological medicinal products 
and medicinal products derived from human blood or plasma, stability tests cannot be 
carried out on the finished products, it is acceptable to carry out stability indicating tests 
at an intermediate stage of  production as late as possible in the manufacturing process. In 
addition, there should be an evaluation ofthe stability of  the finished product using other 
secondary tests, 
3.  For radiophannaceuticals,  information  on stability  shall  be  given  for  radionuclide 
generators,  radionuclide  kits  and  radiolabelled  products.  The  stability  during  use  of 
radiophannaceuticals in multi-dose vials shall be documented. 
103 PART3 
TOXICOLOGICAL AND PHARMACOLOGICAL TESTS 
I. Introduction 
1.  The  particulars  and  documents  accompanying  the  application  for  marketing 
authorization pursuant to Articles 8 (3) (i) and 10 {I) shall be given in accordance with 
the requirements below. 
Member States shall ensure that the safety tests are carried out in  conformity with the 
provisions  relating  to  good  laboratory  practice  laid  down  by  Council  Directives 
87/18/EECI and 88/320/EEC2. 
The toxicological and pharmacological tests must show: 
· (a)  the potential toxicity of the product and any dangerous or undesirable toxic effects 
that may occur under the proposed conditions of use in human beings; these should 
be evaluated in relation to the pathological condition concerned; 
(b)  the pharmacological properties of the product, in  both qualitative and quantitative 
relationship to the proposed use in human beings. All results must be reliable and of 
general applicability. Whenever appropriate, mathematical and statistical procedures 
shall be used in designing the experimental methods and in evaluating the results. 
Additionally, it is necessary for clinicians to be given information about the therapeutic 
potential of  the product. 
2.  Where  a  medicinal  product  is  intended  for  topical  use,  reabsorption  must  be 
investigated, due account also being taken of  the possible use of the product on broken 
skin and absorption through other relevant surfaces. Only if it  is  proved that systemic 
absorption under these conditions is negligible may repeated dose systemic toxicity tests, 
foetal toxicity tests and studies of  reproductive function be omitted. 
If,  however, reabsorption is demonstrated during therapeutic experimentation, toxicity 
tests shall be carried out on animals, including where necessary, foetal toxicity tests. 
In all cases, tests of  local tolerance after repeated application shall_ be carried out with 
particular care  and include  histological  examinations;  the  possibility  of sensitization 
shall be investigated and any carcinogenic potential investigated in the cases referred to 
in Section II E of  this Part. 
I 
2 
OJ LIS, 17.1.1987, p. 29. 
OJ L 14S, 11.6.1988, p. 3S; .Direc:tive as amended by Direc:tive 90/18/EEC (OJ L II, 13.1.1990, p. 37). 
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(adapted) 3.  For biological  medicinal  products  such  as  immunological  medicinal  products  and 
medicinal products derived from human blood or plasma, the requirements of this Part 
may have to be adapted for individual products; therefore the testing programme carried 
. out shall be justified by the applicant. 
In establishing the testing programme, the following shall be taken into consideration: 
all tests requiring repeated administration of the product shall  be  designed to take 
account of  the possible induction of, and interference by, antibodies; 
examination of reproductive  function,  of embryo/foetal  and  perinatal  toxicity,  of 
mutagenic  potential  and  of carcinogenic  potential  shall  be  considered.  Where 
components other than the active substance(s) are  incriminated, validation of their 
removal may replace the study. 
4.  For radiopharmaceuticals,  it  is  appreciated ,that  toxicity  may  be  associated  with  a 
radiation dose. In diagnosis, this is a consequence of the use of  radiopharmaceuticals; in 
therapy,  it  is  the  wanted  property.  The  evaluation  of  safety  and  efficacy  of 
radiopharmaceuticals shall, therefore, address requirements for medicinal products and 
radiation  dosimetry  aspects.  Organ/tissue  exposure  to  radiation  shall  be  documented. 
Absorbed  radiation  dose  estimates  shall  be  calculated  according  to  a  specified, 
'internationally recognized system by a particular route of  administration. 
5.  The toxicology and pharmacokinetics of an excipient used for the first  time  in  the 
pharmaceutical field shall be investigated. 
6. Where there is a possibility of  significant degradation during storage of  the medicinal 
product, the toxicology of  degradation products must be considered. 
11. Performance of tests 
A. Toxicity 
I. Single dose toxicity 
An acute test is  a qualitative and quantitative study of the toxic reactions which  may 
result from a single administration of  the active substance or substances contained in the 
medicinal  product,  in  the  proportions  and  physico-chemical  state  in  which  they  are 
present in the actual product. 
The acute toxicity test must be carried out in two or more mammalian species of  known 
strain  unless  a  single  species  can  be  justified.  At  least  two  different  routes  of 
administration  shall  normally  be  used,  one  being  identical  with  or  similar  to  that 
proposed  for  use  in  human  beings  and  the  other ensuring  systemic  exposure  to  the 
substance. 
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(adapted) This study v:t'ill  cover the signs observed, including  local reactions.  The period during  75/318/EEC  · 
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to reveal tissue or organ damage or recovery, usually for a period of 14 days but not less  (as amended by 
than 1 days, but without exposing the animals to prolonged suffering. Animals dying  91/507  /EEC Art. l) 
dw"ing  the observation period should be subject to autopsy as also should all  animals  (adapted) 
surviving to the end of  the observation period. Histopathological examinations should be 
considered  on  any  organ  showing  macroscopic  changes  at autopsy.  The  maximum 
amount of  information should be obtained from the animals used in the study. 
The single dose toxicity tests should be conducted in  such  a way that signs of acute 
toxicity are revealed and the mode of death assessed as far as  reasonably possible.  In 
suitable species, a quantitative evaluation of  the approximate lethal dose and information 
on the dose effect relationship should be obtained, but a high  level of precision  is  not 
required. 
These studies may give some indication of  the likely effects of  acute overdosage in man 
and may be useful for the design of toxicity studies requiring repeated dosing on the 
suitable animal species. 
In the case of  active substances in combination, the study must be carried out in such a 
way as to check whether or not there is enhancement of  toxicity or if novel toxic effects 
occur. 
2. Repeated dose toxicity (sub-acute or chronic toxicity), 
Repeated dose toxicity tests are  intended to reveal any physiological and/or anatomo-
pathological  changes  induced  by  repeated  administration  of the  active  substance  or 
combination  of active  substances  under  examination,  and  to  determine  how  these 
changes are related to dosage. 
Generally, it is desirable that two tests be performed: one short-term, lasting two to four 
weeks, the other long-term. The duration of  the latter shall depend on the conditions of 
clinical use. Its purpose shall be to determine by experiment the non-toxic dose range of 
the product and normally it shall last three to six months. 
In respect of medicinal products to be administered once only to humans, a single test 
lasting two to four weeks shall be performed. 
If however,  having  regard  to  the  proposed  duration  of use  in ·human  beings,  the 
investigator sees fit to carry out experiments of greater or lesser duration than indicated 
above, he must give adequate reasons for doing so. 
Reasons should.also be given forthe dosages chosen. 
106 Repeated dose  toxicity tests  shall  be  carried out on  two species of mammals one of 
which must be  a  non-rodent.  The choice of route(s) of administration employed shall 
depend on the intended therapeutic use and the possibilities of  systemic absorption. The 
method and frequency of  dosage shall be clearly stated. 
The maximum dose should be chosen so as to bring harmful effects to light. The lower 
doses will then enable the animal's tolerance of  the product to be determined. 
Wherever  possible,  and  always  in  experiments  on  small  rodents,  the  design  of the 
experiment and the control procedures must be suited to the scale of the problem being 
tackled and enable fiducial limits to be determined. 
The evaluation of the toxic effects shall be based on observation of behaviour, growth, 
haematological  and  biochemical  tests,  especially  those  relating  to  the  excretory 
mechanism, and also on autopsy reports and accompanying histological data. The choice 
and range of  each group of  tests will depend on the species of animal used and the state 
of  scientific knowledge at the time. 
In the case of new combinations of known substances that have  been  investigated  in 
accordance with the provisions of this Directive, the chronic long-term tests may, except 
where acute and sub-acute toxicity tests have demonstrated potentiation or novel toxic 
effects, be suitably modified by the investigator who shall submit his reasons for such 
modification. 
B. Examination of  reproductive function 
If the results of other tests  reveal anything suggesting harmful effects on progeny or 
impairment  of male  or female  reproductive  function,  this  shall  be  investigated  by 
appropriate tests. 
C. Embryo/foetal and  perinatal toxicity 
This investigation comprises a demonstration of the toxic and especially the teratogenic 
effects  observed  in  the  issue  of  conception  when  the  medicinal  product  under 
investigation has been ad!llinistered to the female during pregnancy. 
Although up to the present these tests have had only a limited predictive value in regard 
to the application of the results to human beings, they are thought to provide important 
information where the results show effects such as resorptions and other anomalies  . 
.  Omission of these tests, eithc;:r because the medicinal product will not normally be used 
by women capable of  child-bearing or for other reasons, must be adequately justified. 
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conducted  in  at  least  one  species.  Where  metabolism  of a  medicinal  product  in  a  (as amended by 
particular species is  known  to be similar to  that in  man,  it  is  desirable to include this  91/507/EEC Art.  I) 
species. Also, it is desirable that one of the species is the same as  in the repeated dose  (adapted) 
~oxicity studies. 
The  details  of  the  test  (number  of  animals,  amounts  administered,  timing  of 
administration  and· criteria  for  evaluation  of results)  shall  depend  on  the  state  of 
scientific  knowledge  at the  time  when  the  application  is  lodged,  and  the  level  of 
statistical significance that the results must attain. 
D. Mutagenic potential 
The  purpose  of the  study  of mutagenic  potential  is  to  reveal  the  changes  which  a 
substance may cause in the genetic material of individuals or cells and which have the 
effect  of  making  successors  pennanently  and  hereditarily  different  from  their 
predecessors. This study is obligatory for any new substance. 
The number and types of  results and the criteria for their evaluation shall depend on the 
state of  scientific knowledge at the time ~hen  the application is lodged. 
E. Carcinogenic potential 
Tests to reveal carcinogenic effects shall nonnally be required: 
(a)  in respect of substances having a close chemical analogy with known carcinogenic 
or cocarcinogenic compounds; 
(b)  in  respect of substances which  have  given  rise  to  suspicious  changes  during  the 
long-tenn toxicological tests; 
(c)  in respect of  substances which have given rise to suspicious results in the mutagenic-
potential tests or in other short-tenn carcinogenicity tests. 
Such  tests may also  be  required  in  respect of substances to  be included  in  medicinal 
products likely to be administered regularly over a prolonged period of  a patient's life. 
The state of scientific knowledge  at the  time when  the application  is  lodged  shall  be 
taken into account when detennining the details of  the tests. 
108 F. Pharmacodynamics 
This heading covers the variations caused by the medicinal product in  the functions of 
the  physiological  systems,  whether  these  functions  are  nonnal  or  experimentally 
modified. 
This study shall follow two distinct lines of  approach. 
Firstly,  the  actions  on  which  the  recommended application  in  therapeutic  practice  is 
based shall be adequately described. The results shall be expressed in quantitative tenns 
using, (for example, dose-effect curves, time-effect curves etc.), and wherever possible, 
compared with data relating to  a substance whose activity  is  known.  Where a  higher 
therapeutic  potency  is  being  claimed  for  a  substance,  the  difference  shall  be 
demonstrated and shown to be statistically significant  . 
.Secondly,  the investigator shall provide a general pharmacological characterization of 
the substance, with special reference to adverse reactions. In general, the main functions 
of  the physiological systems should be investigated. The depth of  this investigation must 
be increased as the doses liable to produce adverse reactions approach those producing 
the main effect for which the substance is being proposed. 
The experimental techniques, unless they are standard procedures, must be described in 
such detail as to allow them to be reproduced, and the investigator must establish their 
validity. The experimental results shall be set out clearly and, when relevant to the test, 
their statistical significance quoted. 
Unless  good  reasons  are  given  to  the  contrary,  any  quantitative  modification  of 
responses resulting from repeated administration of  the substance shall be investigated. 
Tests on combinations of active substances may be prompted either by pharmacological 
premisses or by indications of  therapeutic effect. 
In the first case, the pharmacodynamic study shall demonstrate those interactions which 
might make the combination of  value in therapeutic use. 
In the second case, where scientific justification for the combination is sought through 
therapeutic  experimentation,  the  investigation  shall  detennine  whether  the  effects 
expected from the combination can be demonstrated in animals, and the importance of 
any collateral effects shall at least be investigated. 
If  a combination includes a novel active substance, the latter must previously have been 
studied in depth. 
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Pharmacokinetics  means  the  study  of the  fate  of the  active  substance  within  the 
organism, and covers the study of the  absorption,  distribution,  biotransformation  and 
excretion of  the substance. 
The  study of these  different phases  may  be  carried  out  both  by  means  of physical, 
chemical  or biological  methods,  and by  observation  of the  actual  pharmacodynamic 
activity of  the substance itself. 
Information on distribution and elimination (i.e. biotransformation and excretion) shall 
be necessary in all cases where such data are indispensable to determine the dosage for 
humans, and in respect of  chemotherapeutic substances (antibiotics, etc.) and substances 
whose  use  depends on  their non-pharmacodynamic effects (e.g.  numerous  diagnostic 
agents, etc.). 
Pharmacokinetic investigation of  pharmacologically active substances is necessary. 
In the case of new combinations of known substances which have been investigated in 
accordance with the provisions of this  Directive, pharmacokinetic studies may  not be 
required, if  the toxicity tests and therapeutic experimentation justify their omission. 
H. Laca/ tolerance 
The purpose of local tolerance studies is to ascertain whether medicinal products (both 
active substances and excipients) are tolerated at sites in the body which may come into 
contact with the medicinal product as a result of its administration in clinical use.  The 
testing strategy shall be such  that any mechanical effects of administration  or purely 
physico-chemical  actions  of the  product can  be  distinguished  from  toxicological  or 
pharmacodynamic ones. 
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CLINICAL DOCUMENTATION  (as amended by 
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The particulars and documents accompanying applications for marketing authorizations  (adapted) 
pursuant to Articles 8 (3) {i) and I 0 (I) of  this Directive shall be submitted in accordance 
with the provisions below. 
A clinical trial is any systematic study of  medicinal products in  human subjects whether 
in  patients or non-patient volunteers in  order to discover or verify the effects of and/or 
identify any adverse reaction to investigational products, and/or study their absorption, 
distribution, metabolism and excretion in order to ascertain the efficacy and safety of  the 
products. 
Evaluation of  the application for marketing authorization shall be based on clinical trials 
including clinical pharmacological trials designed to determine the efficacy and safety of 
the product under normal conditions of use, having regard to the therapeutic indications 
for use in human beings. Therapeutic advantages must outweigh potential risks. 
A. General requirements 
The clinical  particulars to  be  provided pursuant to Articles  8 (3) (i) and  10  (I) must 
enable a sufficiently well-founded and scientifically valid opinion to be formed  as to 
whether the medicinal product satisfies the criteria governing the granting of  a marketing 
authorization. Consequently. an  essential requirement is  that the results of all  clinical 
. trials should be communicated, both favourable and unfavourable. 
Clinical trials must always be preceded by adequate pharmacological and toxicological 
tests, carried out on animals in accordance with the requirements of  Part 3 of  this Annex. 
The  investigator  must  acquaint  himself  with  the  conclusions  drawn  from  the 
pharmacological and toxicological studies and hence the applicant must provide him at 
least with the investigator's brochure, consisting of all the relevant information known 
prior to  the onset of a clinical trial including chemical, pharmaceutical and biological 
data,  toxicological,  pharmacokinetic  and  pharmacodynamic  data  in  animals  and  the 
results  of earlier  clinical  trials,  with  adequate  data  to  justify  the  nature,  scale  and 
duration of the proposed trial; the  complete pharmacological and  toxicological  reports 
shall  be  provided  on  request.  For materials  of human  or animal  origin,  all  available . 
means shall be employed to ensure safety from transmission of  infectious agents prior to 
the commencement of  the trial. 
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91/507/EEC Art. I) 
1.1.  All  phases of clinical  investigation,  including  bioavailabilityand bioequivalence  (adapted) 
studies, shall be designed, implemented and reported in  accordance with good clinical 
practice. 
1.2. All clinical trials shall be carried out in accordance with the ethical principles laid 
down in the current revision of  the Declaration of  Helsinki. In principle, the freely given 
informed consent of  each trial subject shall be obtained and documented. 
The  trial  protocol  {including  statistical  design),  the  technical  application  and 
documentation shall be submitted by the sponsoJ;"  and/or investigator for an  opinion to 
the  relevant ethics  committee.  The  trials  shall  not  begin  before  the  opinion  of this 
committee has been received in writing. 
1.3.  Pre-established, systematic written  procedures for the organization,  conduct, data 
collection, documentation and verification of  clinical trials shall be required. 
1.4.  In  the case of radiopharmaceuticals, clinical trials shall  be  carried out under the 
responsibility of  a medical doctor authorized to use radionuclides for medical purposes. 
2.Archiving 
The  marketing  authorization  holder  shall  make  arrangements  for.  archiving  of 
documentation. 
(a)  The investigator shall arrange for the retention of  the patient identification codes for 
at least 15 years after the completion or discontinuation of  the trial. 
(b)  Patient files  and other source data shall be kept for the  maximum period of time 
permitted by the "hospital, institution or private practice. 
(c)  The  sponsor  or  other  owner  of the  data  shall  retain  all  other  documentation 
pertaining to the trial as  long as the product is  authorized. Th.ese  procedures shall 
include: 
the  protocol  including  the  rationale,  objectives  and  statistical  design  and 
methodology  of the  trial,  with  conditions  under  which  it  is  performed  and 
managed,  and  details  of the  investigational  product,  the  reference  medicinal 
product and/or the placebo used, 
standard operating procedures, 
all written opinions on the protocol and procedures, 
112 the investigator's brochure, 
case report forms on each trial subject, 
final report, 
audit certificate(s), if  available. 
(d)  The final report sh~ll be retained by the sponsor or subsequent owner, for five years 
after the medicinal product is no longer authorized. 
Any change of  ownership of  the data shall be documented. 
All data and documents shall be made available if  requested by relevant authorities. 
C. Presentation of results 
I.  The  particulars  of each  clinical  trial  must  contain  sufficient  detail  to  allow  an 
objective judgement to be made: 
the  protocol,  including  the  rationale,  objectives  and  statistical  design  and 
methodology of  the trial, with conditions under which it is performed and managed, 
and details ofthe investigational medicinal product used, 
audit certificate(s), if  available, 
the  list  of investigator(s),  and  each  investigator  shall  give  his  name,  address, 
appointments, qualifications and clinical duties, state where the trial was carried out 
and assemble the information in respect of each patient individually, including case 
report forms on each trial subject, 
final  report  signed  by  the  investigator  and  for  multicentre  trials,  by  all  the 
investigators or the coordinating (principal) investigator. 
2. The particulars of  clinical trials referred to above shall be forwarded to the competent 
authorities.  However,  in  agreement with  the competent authorities,  the  applicant may 
omit part of  this information. Complete documentation shall be provided forthwith upon 
request. 
3. The clinical observations shall be summarized for each trial indicating: 
(a)  the number and sex of  patients treated; 
(b)  the selection and age-distribution of the groups of patients being investigated and 
the comparative tests; 
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(d) where  controlled trials were carried out under the  above  conditions, whether the  91~507/EECArt. I) 
control group:  (adapted) 
received no treatment, 
received a placebo, 
received another medicinal product of  known effect, 
received treatment other than therapy using medicinal products; 
(e)  the frequency of  observed adverse reactions; 
(f)  details  concerning  ..  patients  who  may  be  at  increased  risk,  e.g.  elderly  people, 
children,  women  during  pregnancy  or  menstruation,  or whose  physiological  or 
pathological condition requires special consideration; 
(g)  parameters  or evaluation  criteria  of efficacy  and  the  results  in  terms  of these 
parameters; 
(h)  a statistical evaluation of  the results when this is called for by the design of  the trials 
and the variable factors involved 
4. ·The investigator shall,  in  his conclusions on the experimental evidence, express an 
opinion on the safety of the product under normal conditions of use,  its  tolerance,  its 
efficacy  and  any  useful  information  relating  to  indications  and  contra-indications, 
dosage and average duration of treatment as well as any special precautions to be taken 
during treatment and the clinical symptoms of overdosage. In reporting the results of a 
multi-centre study, the principal investigator shall, in his conclusions, express an opinion 
on  the  safety and efficacy  of the  investigational  medicinal  product  on  behalf of all 
centres. 
5. In addition, the investigator shall always indicate his observations on: 
(a)  any  signs  of habituation,  addiction  or  difficulty  in  weaning  patients  from  the 
medicinal product; 
(b)  any interactions that have been observed with other medicinal products administered 
concomitantly;  · 
(c)  the criteria determining exclusion of  certain patients from the trials; 
(d)  any deaths which occurred during the trial or within the follow-up period. 
6. Particulars concerning a new combination of medicinal substances must be  identical 
to  those  required  for  new  medicinal  products  and  must  substantiate  the  safety  and 
efficacy of  the combination. 
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must be undertak.en and reviewed.  (as amended by 
91/507/EEC Art.  I) 
If the medicinal product is  intended for long-tenn administration,  particulars shall  be  (adapted) 
given  of  any  modification  of  the  phannacological  action  following  repeated 
administration, as well as tbe establishment of  long-tenn dosage. 
D. Clinical pharmacology 
1. Pharmacodynamics 
The phannacodynamic action correlated to the efficacy shall be demonstrated including: 
the dose-response relationship and its time course, 
justification for the dosage and conditions of  administration, 
the mode of  action, if  possible. 
The phannacodynamic action not related to efficacy shall be described. 
The demonstration of phannacodynamic effects in  human beings shall  not  in  itself be 
sufficient to justify conclusions regarding any particular potential therapeutic effect. 
2. Pharmacokinetics 
The following phannacokinetic characteristics shall be described: 
absorption (rate and extent), 
distribution, 
metabolism, 
excretion. 
Clinically significant features including the implication of  the kinetic data for the dosage 
regimen especially for patients at risk, and differences between man and animal species 
used in the preclinical studies, shall be described. 
115 3. Interactions 
If the  medicinal  product  is  normally  to  be  administered  concomitantly  with  other 
medicinal products, particulars shall be given of  joint administration tests performed to 
demonstrate possible modification of  the pharmacological action. 
If  pharmacodynamiclpharmacokinetic interactions exist between the substance and other 
medical products or substances like alcohol, caffeine, tobacco or nicotine, likely to be 
taken simultaneously, or if such interactions are  likely, they should be described and 
discussed; particularly from the point of view of clinical relevance and the relationship 
to  the  statement  concerning  interactions  in  the  summary  of product  characteristics 
presented in accordance with Article ll point 5.6. 
E. Bioavailability/bioequivalence 
The assessment of bioavailability must be undertaken in all cases where it is necessary, 
e.g. where the therapeutic dose is near the toxic dose or where the previous tests have 
revealed  anomalies  which  may .be  related  to  pharmacodynamic  properties,  such  as 
.variable absorption. 
In  addition, an assessment of bioavailability shall  be  undertaken  where  necessary  to 
demonstrate bioequivalence for the medicinal products referred to in Article 10 (I) (a). 
F. C.linical efficacy and safety 
I. In general, clinical trials shall be done as "controlled clinical trials" and if possible, 
randomized; any other design shall be justified. The treatment of  the control groups will 
vary from  ca5e to case and also will depend on ethical considerations; thus it may,. in 
some instances, be more pertinent to compare the efficacy of a new medicinal product 
with that of an established medicinal product of proven therapeutic value  rather than 
with the effect of  a placebo.  · 
As far as possible, and particularly in trials where the effect of the product cannot be 
objectively  measured,  steps  shall  be  taken  to  avoid  bias,  including  methods  of 
randomization and blinding. 
2. The protocol of  the trial must include a thorough description of  the statistical methods 
to be employed, the number and reasons for inclusion of  patients (including calculations 
of the power of the trial), the level of significance to be used and a description of the 
statistical  unit.  Measures taken  to  avoid bias,  particularly  methods of randomization, 
shall be documented.  Inclusion of a  large  number of subjects  in  a  trial  must not be 
:regarded as an adequate substitute for a properly controlled trial. 
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(adapted) 3. Clinical statements concerning the efficacy or safety of a medicinal product under  7  5/318/EEC 
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valid evidence.  '  (as amended by 
91/507/EEC Art.  I) 
4.  The value of data on the efficacy and safety of a medicinal product under normal  (adapted) 
conditions  of use  will  be  very  greatly  enhanced  if such  data  come  from  several 
competent investigators working independently. 
5. For vaccines and serums, the immunological status and age of  the trial population and 
the local epidemiology are of  critical importance and shall be monitored during ~e  trial 
and fully described. 
For live attenuated vaccines, clinical trials shall  be so designed as  to reveal  potential 
transmission of the  immunizing agent from  vaccinated to  non-.vaccinated  subjects.  If 
transmission is possible, the genotypic and phenotypic stability of the immunizing agent 
shall be studied. 
For vaccines  and  immunological  medicinal  products,  follow-up  studies  shall  include 
appropriate immunological tests, and where applicable, antibody assays. 
6. The pertinence of the different trials to the assessment of safety and the validity of 
methods of  evaluation shall be discussed in the expert report. 
7.  All  adverse  events  including  abnormal  laboratory  values  shall  be  presented 
indiviaually and discussed, e_specially: 
in terms of  overall adverse experience and 
as a function of  the nature, seriousness arid causality of  effects. 
8. A critical assessment of  relative safety, taking into account adverse reactions, shall be 
made in relation to: 
the disease to be treated, 
other therapeutic approaches, 
particular characteristics in sub-groups of  patients, 
preclinical data on toxicology and pharmacology. 
9.  Recommendations  shall  be made  for  the  conditions  of use,  with  the  intention  of 
reducing the incidence of  adverse reactions. 
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When, in respect of particular therapeutic indications, the applicant can show that he  is 
unable  to  provide  comprehensive  data  on  the  efficacy  and  safety  under  normal 
conditions of  use, because: 
the  indications  for which the product in  question  is  intended  are  encountered so 
rarely that the applicant cannot reasonably be  expected to  provide comprehensive 
evidence, or 
in  the present state of scientific knowledge, comprehensive information cannot be 
provided, or 
it would be contrary to generally accepted principles of medical  ethics  to  collect 
such information, 
marketing authorization may be granted on the following conditions: 
(a)  the applicant completes on identified programme of studies within  a time  period 
. specified by the competent authority, the results of which shall form the basis of a 
reassessment of  the benefit/risk profile,  · 
(b)  the medicinal product in question may be supplied on medical prescription only and 
may in certain cases be administered only under strict medical supervision, possibly 
in a hospital and for a radiopharmaceutical, by an authorized person, 
(c)  the  package  leaflet and  any  medical  information  shall  draw  the  attention  of the 
medical  practitioner  to  the  fact  that  the  particulars  available  concerning  the 
medicinal product in question are as yet inadequate in certain specified respects. 
H. Post-marketing experience 
1. If  the medicinal product is already authorized in other countries, information shall be 
given  in  respect of adverse  drug  reactions of the  medicinal  product  concerned  and 
medicinal products containing the same active substance(s), in relation to the usage rates 
if possible. Information from worldwide studies relevant to the safety of the medicinal 
product shall be included. 
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(adapted) For this purpose, an adverse drug reaction is a reaction which is noxious and upintended 
and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of 
disease or for the modification of  physiological function. 
2.  In  the  case of vaccines  already authorized  in  other countries,  information  on  the 
monitoring ofvacc~nated  subjects to evaluate the prevalence of  the disease in question as 
compared to nonvaccinated subjects shall be submitted, when available. 
3.  For immunological  medicinal  products,  response  in  periods  of increased  antigen 
exposure shall be identified. 
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Council Directive 89/341/EEC (OJ L 142,25. 5. 1989, p. 11) 
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Council Directive 92128/EEC (OJ L 113, 30. 4.  1992, p.  13) 
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Directive 78/420/EEC 
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